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Abstract 
 
Introduction: The protective efficacy of the BCG vaccine against pulmonary 
tuberculosis varies across the globe and is lower in countries near the equator. 
Previous studies have shown disparate immunogenicity profiles after infant 
BCG vaccination in The United Kingdom, Malawi, The Gambia and Indonesia. 
Pre-exposure to environmental mycobacteria and maternal or infant co-
infections are one of the mechanisms that could explain these variations. 
Exact molecular mechanisms that drive sustained differences in BCG 
immunogenicity are not known.   
 
Methods and Hypothesis: In this study we aimed to investigate molecular 
mechanisms that drive differences in BCG immunogenicity. We hypothesised 
that differential DNA methylation or dynamic phenotypes of antigen presenting 
cells contribute to underlying differences in BCG immunogenicity. We used 
samples from South African, Ugandan and UK BCG vaccinated infants to 
investigate their BCG-induced immune responses. In South Africa we 
compared DNA methylation profiles between high and low BCG responders. 
In the UK and Uganda, we compared BCG specific immune responses and 
DNA methylation profiles between both countries. Lastly, in Uganda, we 
investigated longitudinal changes in dendritic cell phenotypes. 
 
Results: We found that differential DNA methylation of immune pathways 
such as T cell activation, or potassium and calcium channel Signalling is 
associated with variation in BCG immunogenicity in South African infants. The 
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comparison of immune responses between UK and Ugandan infants revealed 
that Ugandan infants have a strong inflammatory response to BCG, but levels 
of TH1 and TH2 cytokines are similar.  The analysis of DNA methylation 
between these countries revealed that genes of B cell activation pathway are 
more methylated in Uganda, whereas genes of TGFb regulatory pathways are 
more methylated in the UK. The analysis of antigen presenting cells revealed 
that key dendritic cell populations are absent at birth and develop within the 
first year of life. We also highlight that cytomegalovirus (CMV), Epstein-Barr 
virus (EBV) and maternal latent tuberculosis infection (LTBI) have profound 
effects on dendritic cell phenotypes. 
 
Implications: These results point towards a role for DNA methylation in the 
regulation of BCG immune responses, however, in vitro studies focusing on 
highlighted gene candidates and pathways should be conducted. Small 
differences in immunogenicity profiles after BCG vaccination in the UK and 
Uganda suggest that BCG efficacy in these countries should be similar, an 
area requiring a further investigation. The absence of dendritic cells at birth 
should be investigated and the kinetics of their development within the first 
week of life examined. Special attention should be paid to the development of 
vaccines or treatments for CMV, EBV and LTBI, as these pathogens modulate 
DC phenotypes.   
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1. Introduction 
1.1. Tuberculosis and the BCG vaccine: remaining challenges 
1.1.1. An overview of tuberculosis 
 
Tuberculosis (TB) is an airborne infectious disease caused by bacillus 
Mycobacterium tuberculosis (Mtb), identified by Robert Koch in 18821, and 
preventable with Bacillus Calmette–Guérin (BCG) vaccine. It is mainly a disease of 
the lung as 70% of cases are pulmonary; however, Mtb can spread to other organs 
such as meninges, lymph nodes and bones resulting in an extrapulmonary disease2. 
 
1.1.1.1. The burden of tuberculosis 
 
TB is the ninth leading cause of death worldwide and the primary cause due to a 
single infectious agent. In 2016 alone, there were 1.7 million deaths worldwide and 
an estimated 10.4 million  new cases. The global incidence of TB is 140/100,000 
persons and remains highest in countries of Sub-Saharan Africa (Central African 
Republic, South Africa, Lesotho, Mozambique) and South-East Asia (The Philippines, 
Democratic People's Republic of Korea)3 (figure 1).  
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Figure 1. Global incidence of tuberculosis in 2016 per country. Source: Global Tuberculosis 
Report 2017, World Health Organization, Geneva, Switzerland3. 
 
1.1.1.2. The heterogeneity of tuberculosis infection and risk 
factors 
 
TB is a complex disease and can manifest itself in the form of an active or latent 
infection. Individuals exposed to Mtb can become infected and rapidly progress to the 
active form of the disease. They could remain latently infected and might progress to 
active TB later in life. Exposed individuals could also be rapidly cleared of Mtb bacilli, 
resulting in a lack of adaptive immune responses, or the infection could be contained 
locally without detectable systemic responses (figure 2). 
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Figure 2. The heterogeneity of TB infection. Source: The Immune response in tuberculosis. 
Anne O'Garra et al.4 
 
Typical symptoms of active TB include but are not limited to fever, weight loss, night 
sweats, cough (often with blood), lung cavities and densities5. Recent estimates 
suggest that 23% of the world’s population is infected with latent TB, amounting to a 
total of 1.7 billion people6. Latently infected individuals have no clinical evidence of 
TB disease, and epidemiological studies suggest that 5-10% of them will develop the 
active form of TB7. The risk of progressing to the active form of TB is increased in 
childhood8. It also depends on numerous risk factors including HIV infection, diabetes, 
alcohol and drug use, poverty, malnutrition and overcrowding, limited or no access to 
health services, smoking and imprisonment3. These factors reduce overall well-being 
and are detrimental to health and the immune system. A weakened immune system 
is no longer able to control the latent TB infection, resulting in Mtb dissemination, and 
an active form of TB disease. 
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1.1.1.3. The landscape of TB diagnosis and treatment 
 
A complex disease manifestation makes the diagnosis of TB difficult. The host’s 
reactivity to Mtb antigens can be measured by the tuberculin skin test (TST), 
otherwise known as the Mantoux test. The patient is challenged intradermally with 
purified protein derivative (PPD), an extract of Mtb. Development of a hypersensitivity 
reaction indicates that a patient has an immune response to Mtb antigens.  PPD 
antigens are present in Mtb, as well as in BCG and environmental mycobacteria; 
therefore the disadvantage of TST is its inability to distinguish between latent TB, 
active TB, BCG vaccination, or pre-exposure to environmental mycobacteria9. More 
recent assays were developed that measure the immune response to early secretory 
antigen target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10), two Mtb proteins 
that are not present in the BCG vaccine, and have a limited presence in the 
environment10. The reactivity to these antigens is examined by the production of 
interferon g (IFNg) in an IFNg release assay (IGRA), measured either by enzyme-
linked immunoassay (ELISA) (Qiagen), or enzyme-linked immunospot (ELISPOT) 
(TSPOT.TBTM) assay. These assays can distinguish between Mtb infection and BCG 
vaccination or exposure to environmental mycobacteria but are unable to identify 
whether the disease is active or latent. Other diagnostic methods include culture-
based methods, where patient sputum is cultured in a laboratory facility and examined 
for the presence of Mtb bacilli11. This diagnostic method is considered a reference 
standard; however Mtb is a slow growing mycobacterium, and the culture diagnosis 
can take up to 12 weeks. The culture-based techniques require category III 
containment facilities and highly trained laboratory staff, both of which are scarce in 
low-income countries where the TB burden is high. Another method is a direct 
microscopic examination of bacilli of sputum smear through the use of Ziehl-Neelsen 
staining. This is an inexpensive and rapid method, however, has poor sensitivity and 
is unable to distinguish between different species of mycobacteria11.  Lastly, the 
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Xpert® MTB/RIF assay is a rapid molecular test for TB diagnosis that can provide 
results within two hours. It has a superior performance to microscopic smear 
examination, and studies report a sensitivity of 86.8% and specificity of 93.1%12. 
Xpert® MTB/RIF assay is particularly useful in the detection of multi-drug resistant TB 
(MDR-TB) (defined as resistance to rifampicin and isoniazid); however, it is the most 
costly diagnostic tool. 
 
Once diagnosed, TB is a complicated disease to treat. Mtb is a slow-growing 
mycobacterium and requires a prolonged antibiotic treatment. The standard World 
Health Organization (WHO) recommended drug regimen in patients infected with 
drug-susceptible Mtb lasts for six months and contains two months of isoniazid, 
rifampicin, pyrazinamide and ethambutol treatment, followed by four months of 
isoniazid and rifampicin given on a daily basis13. The treatment of MDR-TB is 
extraordinarily complex and can last up to 12 months, with multiple oral and injectable 
drugs that induce severe side effects14.  
 
1.1.1.4. Tuberculosis in the United Kingdom and Uganda 
 
According to recent WHO estimates there were 6500 TB cases in the UK in 2016, 
with an average annual incidence rate of 9.9/100,000 persons3. The incidence of TB 
in the non-UK-born population (49.4/100,000) is 15 times higher than the UK-born 
population, and 74% of TB cases are born abroad. The number of new cases has 
been declining at a sustained level of 10% since 2012, but slowed down to 1% in 
201615. To address the incidence of TB and combat the disease, the UK has 
implemented ten critical areas for action in the Collaborative TB Strategy for England 
2015-2020 guideline. These recommendations include reducing active TB in new 
migrants through pre-entry screening programmes, preventing TB reactivations 
through LTBI testing, reducing delay and maintaining the quality of diagnostics, and 
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ensuring an integrated approach with a focus on social determinants15. BCG is not 
recommended nationally and used only in areas where TB incidence is ≥40 patients 
per 100,000 persons15.  
 
Uganda is a Sub-Saharan African country with a high TB burden. WHO estimates 
suggest that in 2016 there were 83,000 new TB cases and the average incidence rate 
was 201/100,000 persons. Importantly,  42% of new TB cases were in HIV-positive 
individuals3. An estimated 49% of individuals are latently infected with TB16. 
Intermittent access to anti-TB drugs, challenges in drug delivery to remote and mobile 
communities, poor health-seeking behaviours and drug adherence, as well as 
inadequate funding of TB treatments,  are some reasons that explain the high TB 
incidence in Uganda17.  
 
1.1.1.5. The role of the WHO and UN in fighting tuberculosis 
 
Eradicating TB and putting a stop to the TB epidemic requires a mobilised effort of 
international stakeholders. Multiple non-governmental organisations (NGO), as well 
as international agencies such WHO and United Nations (UN), are contributing to this 
global effort. WHO announced the End TB Strategy for 2016-2035, with the primary 
aim of reducing TB deaths by 90% and TB incidence by 80% by 2030, in comparison 
with 201518. UN has published 17 sustainable development goals (SDG), including a 
goal to ensure healthy lives and promote well-being for all at all ages19. Both 
strategies outline many aims and objectives to end the TB epidemic. Some are TB 
specific (increase treatment coverage and success rate, reduce proportion of people 
that experience catastrophic costs due to TB, improve coverage of LTBI treatment) 
and some address risk factors specific for TB (reduce prevalence of HIV and diabetes, 
reduce alcohol and drug use, achieve universal healthcare coverage, decrease 
proportion of population living below poverty line and in slums). Importantly, both 
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strategies emphasise the need to develop new and improved vaccines that are 
effective against pulmonary TB, especially in countries where the burden is high. 
 
1.1.2. TB vaccines in use and development 
 
BCG was introduced in 1921 and is the only licensed vaccine for tuberculosis. It 
consists of an attenuated strain of Mycobacterium bovis, the etiological agent of TB 
in cattle. Despite its widespread use, the efficacy of BCG against pulmonary TB 
varies, and BCG can disseminate in HIV-infected and immunocompromised 
individuals causing a disease called BCGosis. As a consequence, BCG is not 
recommended for these populations, resulting in a large number of neonates 
susceptible to TB20.  Because of BCG limitations, novel vaccine candidates are under 
development. These fall into three main categories: priming, boosting and therapeutic 
vaccines. Priming vaccines are pre-exposure preventive vaccines and are typically 
administered before the first exposure to Mtb, often to neonates. These vaccines 
often contain antigens from stages of replication and metabolism of Mtb20. H1 and H4 
vaccines, both in phase IIa clinical trials are  examples of  priming pre-exposure 
vaccines currently in development (figure 3)21. Boosting vaccines are preventive 
vaccines administered after previous BCG vaccination. They target adolescents or 
adults previously immunised with BCG or known LTBI status and often include fusion 
proteins, a combination of antigens from both active and latent stages of the infection. 
Examples of these vaccines include H56 (phase IIa, dormancy antigen H1 and 
Rv2660c), M72 (phase IIb, antigens Rv1196 and Rv0125) and ID93 (phase IIa; 
antigens Rv2608, Rv3619, Rv3620, Rv1813 ). Lastly, therapeutic vaccines are being 
developed to improve the outcome of active TB treatment. The development of 
therapeutic vaccines is particularly vital in MDR-TB and extensively drug-resistant TB 
(XDR-TB), where treatment success is less than 50%. Therapeutic vaccines aim to 
enhance the immune response to TB antigens, hoping to clear the infection quicker. 
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M. Vaccae (phase III) and RUTI (phase IIb) are examples of such vaccines (figure 
3)20.  
 
 
Figure 3. Clinical and preclinical TB vaccine pipeline. Source: Global Report on Tuberculosis 
Vaccines 201821 
 
The most advanced candidate vaccine in clinical trials is M. Vaccae. It is a heat-
inactivated whole-cell vaccine derived from Mycobacterium vaccae. The efficacy trial 
started in 2013, aiming to enrol 10,000 individuals; however, there is no further 
information available20. The second most advanced vaccine is the recombinant BCG 
vaccine, VPM1002. Early clinical studies have shown a superior safety and efficacy 
profile to the BCG vaccine. VPM1002 is currently undergoing phase IIb trials in HIV 
exposed and unexposed infants and entering phase III efficacy trial in India22.  
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Recently, a BCG-boosting vaccine candidate, a recombinant strain of Modified 
Vaccinia Virus Ankara that expresses Mtb antigen 85A (MVA85A) was tested in a 
phase IIb trial in BCG vaccinated South African infants. Despite inducing a moderate 
IFNg producing and Ag85-specific CD4 T cell responses, the efficacy of the vaccine 
was 17.3% against tuberculosis disease and -3.8% against Mtb infection23. TB 
vaccine design remains challenging as there are no reliable correlates of protection, 
the progress of the disease is slow, disease endpoints are not well defined, and 
incidence is low, increasing the need for large and costly clinical trials. Possible 
explanations for MVA85A failure include targeting infants vs adults. The vaccine has 
previously shown much greater immunogenicity in adults, who are the primary source 
of TB transmission. Another possible explanation could be the route of delivery. 
MVA85A was received intradermally and induced a systemic immune response. 
However, pulmonary TB is the predominant manifestation of the disease, and 
perhaps new TB vaccines should be delivered via a mucosal route to induce local 
pulmonary immune responses. 
 
Novel approaches to design TB vaccines are being explored. Mucosal vaccines aim 
to produce both humoral and cellular immune responses, both locally at mucosal 
surfaces and systemically24. As Mtb enters the body through mucosal surfaces of the 
airways, it is clear that mucosal vaccines that induce strong mucosal responses could 
be effective in TB prevention. Mucosal vaccines are easy to deliver, and are not 
associated with pain or fear of needles25. There are currently ten mucosal vaccines 
in development, out of which eight are delivered intranasally, one orally, and one 
nasally24.  
 
The field of TB vaccine development has expanded rapidly in the past decade, thanks 
to European Union (EU)-funded international consortia led by Tuberculosis Vaccine 
Initiative (TBVI) and a coordinated effort of multiple stakeholders. Importantly, the 
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development of new TB vaccines is impaired without a thorough knowledge of how 
the current vaccine BCG works, why does it sometimes fail to work, and what are the 
protective immune responses it induces.  
 
1.1.2.1. The immune response to the BCG vaccine 
 
The immune response to the BCG vaccine is complex and overarches both innate 
and adaptive immune responses, both of which will be described here.  
 
1.1.2.1.1. The innate immune response to the BCG vaccine 
 
When administered intradermally, BCG induces a local inflammatory response.  
Pathogen-associated molecular patterns (PAMPs) (lipoproteins, glycoproteins such 
as mannosylated lipoarabinomannan (ManLAM) or phosphatidylinositol mannoside 
(PIM)) are recognised by pathogen recognition receptors (PRRs) including toll-like 
receptor (TLR) 2 & 4, complement receptors and mannose receptors of monocytes, 
neutrophils and dendritic cells26,27. TLR2 engagement, imperative for BCG 
recognition28, signals via myeloid differentiation primary response gene 88 (MYD88) 
and upregulates NF-κB leading to an increased production of: cytokines (interleukin 
1 (IL1), IL6, tumour necrosis factor α (TNFα)), chemokines (CXCL8, CCL2), 
costimulatory receptors (CD80 & CD86) and adhesion molecules (E-selectin)29. In 
macrophages, prolonged stimulation of TLR2 negatively affects major 
histocompatibility complex (MHC) class I antigen processing and downregulates the 
expression of MHC class II, reducing antigen presentation to T cells, and impairing 
the adaptive immune response30. Similarly, opsonisation of BCG with factor H, a 
regulatory protein of  complement that inhibits the alternative complement pathway, 
has been shown to increase levels of pro-inflammatory cytokines IL6 and TNFa31. An 
acute and robust proinflammatory response activates macrophages and results in 
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quick and efficient killing of BCG via production of reactive oxygen species (ROS) 
and reactive nitrogen species (RNS). The efficient killing limits the time to process 
BCG antigens and present them to T cells, potentially impairing the adaptive immune 
responses and subsequent efficacy of the BCG vaccine32.  Therefore, a balanced 
inflammatory response is essential to effectively kill BCG while assuring the induction 
of an adaptive immune response sufficient to protect against future TB disease. 
Studies suggest that BCG persists for up to 4 weeks and the cellular filtrate from 
suction blisters reveal that CD3 lymphocytes, CD14 monocytes and CD15 neutrophils 
are predominant at the site of inoculation33.  
 
Neutrophils compose up to 60% of white blood cells and secrete large amounts of 
cytokines and chemokines to prime phagocytosis34. Upon contact with BCG, 
neutrophils produce chemokines IL8, CCL2, CCL3; and cytokines such as IL1a, IL1b 
and Transforming Growth Factor b (TGFb). BCG exposure in neutrophils also induces 
their surface markers such as CD11b, CD18, and FcgRs II and III35. BCG-containing 
neutrophils have a delayed apoptosis36, suggesting that BCG may use them as a 
vehicle to disseminate to lymph nodes into the proximity of T cells and dendritic cells 
(DCs). Interestingly, the interaction of BCG infected neutrophils with dendritic cells 
has shown to drive DC maturation and induce BCG antigen presentation in DCs for 
T cell priming37.  Neutrophils have also proved to stimulate T cell activation in lymph 
nodes thereby activating adaptive immune responses38. They have also been shown 
to play a role in regulating the BCG infection by secreting large amounts of IL1039, 
and high frequencies of neutrophils are observed at sites of infection in the lungs of 
patients with TB40 . Lastly, the role of neutrophils is highlighted in gene expression 
studies where neutrophil signatures are prominent in TB disease41.  
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Dendritic cells are major antigen presenting cells (APCs) and act as a bridge between 
innate and adaptive immune responses. Dendritic cell receptors that recognise BCG 
are TLR2 & 4, TLR942, CR3 (CD11b/CD18), CR4 (CD11c/CD18), DEC-205 (CD205), 
and dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN, CD209)32.  DC-
SIGN is the most important phagocytic receptor as antibody neutralisation of DC-
SIGN reduces BCG interaction with DCs by 80%43. Once phagocytic receptors 
recognise BCG PAMPs, they are internalised and presented on the surface of DCs 
in the context of MHC-II to CD4 T cells. In vitro studies suggest that the exposure of 
DCs to BCG PAMPs upregulates DC specific maturation markers in vitro: MHC-II, 
CD40, CD80, CD8644 CD83, HLA-DR45 and increases the secretion of IL12, which in 
vivo drives TH1 responses and induces IFNγ production in T cells45.  
 
1.1.2.1.2. The adaptive immune response to the BCG vaccine 
 
BCG engages multiple arms of adaptive immune responses (figure 4). BCG-
containing DCs in vivo traffic to draining lymph nodes where they present BCG 
antigens to CD4 T cells in the MHC II context. The presence of TH1 polarising 
cytokines such as IL12 and IL18 and antigen presentation activates CD4 T cells and 
makes them traffic to the site of infection, where they secrete  IFNg, which stimulates 
macrophages to phagocytose BCG. Indeed, the secretion of IFNg and CD4 TH1 
immune response is paramount for the effective killing of BCG46. A TH1 immune 
response is observed following BCG immunisation in adults and infants47.  Mice 
studies suggest that CD4 T cells are the principal effector cells induced by BCG in 
the lung48. 
 
Human in vitro and in vivo studies suggest that BCG induces a robust antigen-specific 
CD8 response with increased secretion of IFNg and cytotoxic proteins, cell 
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proliferation and degranulation32,49. In the periphery, CD8 T cells have shown to 
induce apoptosis of BCG infected cells via the FasL-Fas interaction, resulting in 
apoptosis of Fas-expressing cells50. This allows other immune cells to phagocytose 
apoptotic bodies and further drive the adaptive immune response. In contrast, in 
lungs, this mechanism limits the excessive tissue damage and pulmonary failure32. In 
addition to CD8 responses to BCG antigens presented in an MHC I context, there is 
evidence of CD1 restricted CD8 T cells after BCG immunisation in human51 and 
guinea pigs52. These cells recognise mycobacterial lipid and have been suggested to 
play a role in maintaining the latent stage of the disease in the periphery or, prevent 
TB dissemination32.  
 
The production of IL17A and IL2253 characterises CD4 TH17 T cells. They play a dual 
role in protection and pathology. BCG vaccination induces CD4 TH17 cells to produce 
IL17A in lungs, which recruits neutrophils and granulocytes, resulting in an excessive 
immunopathology54. However, IL17A was shown to be important in maintaining CD4 
IFNg responses in the lungs of mice55. TH17 cells have been shown to enhance 
vaccine-induced protection in mice models, following Mtb challenge56,57. A study in 
UK infants reports that BCG induces TH1 and TH17 responses in T cells isolated 
from peripheral blood58.  Further evidence shows that in BCG vaccinated mice, robust 
TH1 lung responses are dependent on IL17A and IL23 from lung resident memory 
TH17 cells55.  
 
The expression of FOXP3 and CD2559 characterises T regulatory cells (Tregs). In 
BCG vaccinated mice, Treg depletion increases BCG efficacy leading to a decrease 
in the Mtb burden60. Human studies confirm that BCG vaccinated adults who develop 
mild local skin inflammation following BCG immunisation, have increased levels of 
CD8 Tregs. This finding is in contrast to adults who develop a strong skin 
inflammation and have predominantly multifunctional CD4 T cells61. Tregs have been 
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proposed as mediators of the limited efficacy of BCG, by appearing shortly after 
exposure to environmental mycobacteria and regulating the BCG induced immune 
response32. Tregs can thus be detrimental to BCG efficacy, but could also play an 
essential role in preventing excessive immunopathology. 
 
Mtb and BCG are intracellular mycobacteria, which is perhaps why antibodies and B 
cell lymphocytes have not been extensively studied in the Mtb and BCG context. 
Recent evidence suggests that BCG vaccinated adults have an increased frequency 
of mycobacteria-specific memory B cells (MBCs) than non-vaccinated adults62; and 
that BCG induces antibody responses that peak 56 days post vaccination in adults63. 
Other studies highlight that patients with active TB or LTBI have an increased 
proportion of B cells with impaired proliferation, immunoglobulin and cytokine 
production; and that T cell activity was dependent on the presence of functionally 
competent B cells64, when compared to healthy controls.  Other studies reveal a 
functional role of antibodies in tuberculosis. Antibodies from LTBI patients induce 
more phagolysosomal maturation, inflammasome activation and drive intracellular 
killing of Mtb when compared to antibodies from active TB patients, and these 
functions were associated with differential antibody glycosylation between TB and 
LTBI patients65. This suggests that the development of TB from latent to the active 
stage could be due to defects in antibody functionality.  
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Figure 4. An overview of the adaptive arm of the BCG induced immune responses. Source: 
Immune Responses to Bacillus Calmette–Guérin Vaccination: Why Do They Fail to Protect 
against Mycobacterium tuberculosis? 32 
 
Taken together, both the innate and adaptive immune responses to BCG vaccination 
are complex, fragmented and multifaceted. While TH1 cytokines and specifically IFNg 
remain important, our understanding of BCG induced immunity must expand beyond 
TH1. Importantly, we should consider the immune response to BCG and Mtb as a 
delicate balance between the induction of BCG and Mtb killing and associated 
immunopathology vs the regulation of the immune system and prolonged antigen 
expression and activation of the adaptive arm of the immune system. Increasingly 
research highlights a growing role for multiple immune components including CD8, 
Tregs, B cells and other cells. Elements of the immune system do not work in 
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isolation, and future research should focus on trying to understand the multi-layered 
BCG immune response in a context of a system.      
 
1.1.2.2. Heterologous effects of BCG 
 
BCG is a complex vaccine, not only because of the immune responses it induces but 
also due to its varying efficacy against TB as well as protection against other 
diseases. BCG challenges the idea of the vaccine specificity as growing evidence 
suggests that BCG protects infants from pathogens other than Mtb, a concept known 
as heterologous or non-specific protection. 
 
1.1.2.2.1. Evidence for heterologous effects of BCG 
 
Multiple studies from West and East Africa and India have reported reduced all-cause 
infant mortality in BCG immunised infants, lasting up to 5 years. The efficacy of BCG 
in reducing all-cause infant mortality ranges between 6-72% in clinical trials to 2-95% 
in observational studies, giving strong evidence that BCG reduces infants’ deaths for 
reasons other than TB66.  
 
The reduction in infants’ mortality could be partially explained by a reduction of overall 
infection rates in BCG immunised infants. Evidence suggests that BCG immunisation 
significantly reduces the number of infections in infants. The strongest evidence to 
date is the analysis of BCG immunised infants in 33 countries, which reports that BCG 
vaccinated infants have a lower incidence of respiratory infections by 17-37%67 when 
compared to non-vaccinated peers.  Aside from respiratory infections, BCG 
immunised infants had lower rates of neonatal sepsis in Guinea-Bissau68 and Spain69, 
and lower rates of nematode infections in Uganda70. The heterologous effects of BCG 
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are more prominent in low-income countries where disease burden is high, as studies 
in Denmark failed to confirm that BCG reduces infants’ rate of infections71.  
 
1.1.2.2.2. Potential mechanisms of BCG-induced heterologous 
effects. 
 
Multiple mechanisms have been proposed as potential mediators of BCG induced 
heterologous protection. BCG induces a TH1 response, which may go beyond 
mycobacterial specificity. Increased cytokine responses (both TH1 and TH2), or high 
lymphocyte proliferation, or CD4 T cell proliferation were observed in The Gambia72,73, 
Uganda74, South Africa75, Guinea-Bissau76, Denmark77, Philippines78, and the United 
Kingdom79, in response to multiple antigens and pathogens. Infant immune 
responses shift from TH17 to TH1 focused within the first year of life80. BCG was 
proposed to facilitate that process and in effect, enlarge a pool of heterologous TH1 
cells. 
 
There is conflicting evidence on humoral responses to non-mycobacterial stimuli. 
BCG immunisation increased antibody levels against influenza vaccine in UK 
adults81; increased antibody levels to HBsAg and polio antigens in The Gambia73; and 
increased antibody concentrations to pneumococcal antigens in Australian infants82. 
However studies in South Africa83, The Gambia72 and Denmark84 failed to confirm 
these findings. Importantly, BCG vaccine strain, the age of immunisation and the age 
at observation all varied between studies, perhaps helping to explain the disparity in 
observed results.   
 
Aside from T cell and humoral mediated immunity, the most plausible mechanism to 
explain heterologous effects of BCG is innate immunity training. The concept refers 
to innate memory and the idea that following BCG stimulation (or other live vaccines 
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such as measles), innate cells will respond stronger and more rapidly upon secondary 
challenge with an unrelated pathogen. In mice, when macrophages were exposed to 
BCG, they demonstrated increased control of Candida albicans (C. albicans) infection 
in vitro and in vivo85. Similarly, BCG vaccination of Dutch adults increased expression 
of TLR4, CD11b and CD14 in monocytes up to one year, and increased their 
production of proinflammatory cytokines (IL1b, IL6, TNFa) in response to 
Staphylococcus aureus or C. albicans when measured up to three months later86; as 
well as increasing NK cell production of IL1b and IL6 for up to three months87. These 
findings indicate that monocytes and NK cells could mediate the reduction in all-cause 
mortality following BCG vaccination. 
 
Metabolic changes in cells facilitate the mechanisms of innate immune training. 
Treatment of monocytes with BCG or b-glucan (a component of C. albicans fungal 
cell wall and often used as a model for BCG training) shifts their metabolic pathway 
usage from oxidative phosphorylation to aerobic glycolysis, characterised by 
increased glucose consumption and lactate production, as well as increased 
phosphorylation of mammalian target of rapamycin (mTOR)88. Similarly, peripheral 
blood mononuclear cells (PBMC) from BCG vaccinated Dutch adults, have been 
shown to produce more lactate and express higher levels of glycolysis pathway 
components hexokinase-2 (HK2) and platelet phosphofructokinase (PFKP) after 
heterologous stimulation, at two weeks and three months after BCG immunisation 
when compared to pre-BCG immunisation PBMC89. Importantly, the role of glycolysis 
in innate immune training was further highlighted by inhibition of the mTOR pathway 
and subsequently reduced production of lactate, TNFa and IL6 in ex vivo BCG trained 
monocytes89.  
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Epigenetic mechanisms and specifically histone modifications are another 
mechanism that can drive innate immune training. The aforementioned increased 
production of TNFa and IL6, as well as increased expression of TLR4 after BCG 
vaccination, was associated with increased levels of trimethylation of lysine 4 at 
histone 3 (H3K4me3) marker, a histone modification associated with permissiveness 
and upregulation of protein transcription86.  Besides, b-glucan training of monocytes 
increased their levels of H3K4me3 at promoters of glycolysis and mTOR pathways, 
as well as IL6 and TNFa promoters, highlighting their role in trained innate immunity89. 
Aside from H3K4me3, BCG training has been shown to decrease levels of H3K9me3 
(an inhibitory marker of gene transcription) at promoters of these pathways and 
genes89.   
 
In summary, the heterologous effects of BCG are mediated by multiple pathways. 
Immune pathways such as TH1 polarisation and the role of antibodies are important, 
however, molecular pathways such as metabolic changes and modifications of the 
epigenetic profile are also highlighted. These studies help us to understand how BCG 
works on a molecular level. They emphasise a new mechanism such as epigenetic 
modifications that could play a role in explaining the variation in BCG efficacy. 
 
1.1.2.3. Variation in the efficacy of BCG vaccine  
 
The BCG vaccine against TB is notorious for giving rise to disparate host immune 
responses and uneven protection against pulmonary TB90. When BCG works well, it 
can induce long-lasting protection, extending up to 20 years in the UK91, 40 years in 
Norway92, and 60 years in Alaska93. A recent meta-analysis of BCG efficacy reported 
that BCG-induced protection against meningeal and miliary tuberculosis is high in 
infants (risk ratio (RR), 0.1) and children stringently tested for previous mycobacterial 
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exposure (RR, 0.08)90. However, the protection against pulmonary TB, the most 
common form of TB disease varies across the globe. The highest reported efficacy 
against pulmonary TB was observed in Indian infants in Canada (RR, 0.20)94, and 
lowest in Indian infants in India (RR, 0.62)95, and the pooled effect for neonatal BCG 
vaccination was RR 0.41 (figure 5). In older children, the efficacy of BCG vaccine is 
lower and depends on stringent testing to previous mycobacterial exposure. In 
stringently tested children, immunised at school age, the pooled efficacy of BCG 
vaccine against pulmonary TB is RR 0.26; however, this efficacy drops with an 
increased RR of 0.59 in non-stringently tested children90. The meta-analysis 
highlights three factors as primary contributors to observed heterogeneity in BCG 
efficacy studies: age at immunisation, latitude, and previous mycobacteria exposure. 
Other mechanisms have also been proposed. These include: differences in human 
genetics; exposure to ultraviolet (UV) light; levels of vitamin D; co-infections with 
helminths, malaria parasite and other pathogens; malnutrition; variation in 
mycobacteria genotypes; BCG strain used; composition of gut microbiota; disruption 
of vaccine cold chain supply; and administration of other vaccines. Some of these 
hypotheses will be addressed in the next chapter. It is possible that all of these factors 
influence BCG immunogenicity to some extent but it is unlikely that any one is 
exclusive or dominant. It is clear that to understand the lack of BCG efficacy in some 
countries we need to understand precise molecular mechanisms that drive its 
immunogenicity.    
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Figure 5. An overview of the BCG efficacy. Rate ratios and 95% confidence intervals 
for pulmonary tuberculosis, stratified by age vaccinated and stringency of 
prevaccination tuberculin testing. Abbreviations: BCG, Bacille de Calmette et Guérin; 
CCH, Cook County Hospital; CI, confidence interval; D + L, DerSimonian and Laird 
method; M-H, Mantel-Haenszel method; MRC, Medical Research Council; PY, 
person-years; RR, rate ratio; TB, tuberculosis; TB HH, tuberculous households; 
TBPT, Tuberculosis Prevention Trial. Source: Protection by BCG Vaccine Against 
Tuberculosis: A Systematic Review of Randomized Controlled Trials90 
 
1.1.2.4. Potential reasons for differences in the BCG 
immunogenicity 
1.1.2.4.1. Genetic factors and the immune response to BCG 
 
The DNA sequence serves as a template for protein transcription, instructing which 
types of proteins to produce when the human body is combating pathogens. 
Therefore, it is plausible that variations in DNA sequences between populations 
would, in turn, determine the array of proteins that are produced in response to 
vaccines, including BCG. Marchant et al96 have conducted a twin cohort study in The 
Gambia and measured the heritability of genes in response to vaccine antigens, 
including BCG specific antigens. They have found significant heritability for IL13 
responses to PPD (46%) and 65 kDa heat-shock protein (Hsp65) (50%), while IFNγ 
responses achieved a substantial heritability to PPD (41%) and Mtb (39%) antigens. 
Lower IFNγ heritability was observed in Ugandan household contact study by Tao et 
al.: 23% for CFP-10, 16% for ESAT-6 and 12% for Ag85B97. Lastly, Randhawa et al. 
report that polymorphism of TLR1 and TLR6 in South African infants is associated 
with increased production of TH1-like cytokines IL-2 and IFNγ98, further supporting 
the argument that human genetics play a role in the modulation of immune responses 
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to vaccines. All studies discuss that although we see intermediate levels of heritability 
in genes that are core to the immune system, it is unlikely that these gene variations 
can solely explain different patterns of BCG efficacy. 
 
1.1.2.4.2. Pre-exposure to environmental mycobacterium and 
the immune response to BCG and Mtb 
 
A growing body of evidence suggests that the exposure to environmental 
mycobacteria results in a cross-reactivity of immune responses among mycobacterial 
antigens99. Studies have reported IFNγ responses to non-tuberculosis mycobacterial 
antigens before BCG vaccination, both in the UK100 and Malawian101 young adults 
suggesting exposure to mycobacteria.  The role of this environmental exposure and 
its modulation of the immune response following BCG vaccination as well as 
susceptibility to TB has been studied in animal models102–108 and humans99,109. 
Proposed mechanisms include masking, which suggests that the exposure to 
mycobacteria elicits an immune response that cannot be further elevated with BCG 
administration; and blocking, implying that previous immunity acquired to 
environmental mycobacteria prevents multiplication of BCG, which subsequently fails 
to augment a sufficient immune response99.  
 
Numerous animal studies consistently inform that prior and post-exposure to non-
tuberculous mycobacteria (NTM) can affect the immune response to the BCG vaccine 
and subsequently hinder the protection against tuberculosis disease102–107. Mice in 
vivo studies confirm that various strains of NTM give rise to an immune response that 
is recalled rapidly after the BCG vaccination, suggesting their potential ability to 
augment the BCG protection102,103. Mice exposed to Mycobacterium avium (MA) 
before BCG vaccination show decreased IFNγ responses to Mycobacterium bovis 
derived PPD and increased immunoglobulin G1 (IgG1) titres against mycobacterial 
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antigens, characteristics of a TH2-like shift of the immune response105. Furthermore, 
infection with killed and systemically delivered MA post BCG vaccination resulted in 
increased TH1 and TH17 like responses and increased protection against Mtb 
infection. This was in contrast to when mice were exposed to oral, live and attenuated 
MA, which gave rise to TH2 like responses and decreased protection against Mtb 
infection104,106.   
 
Studies in cattle further support the argument that the exposure to NTM affects the 
outcome of BCG vaccination. BCG vaccine failed to protect against M. bovis in calves 
that were shown to have elevated IFNγ responses to MA PPD before BCG 
vaccination, suggesting an infection or environmental exposure to MA110. In contrast, 
one study suggests that pre-exposure to MA primes responses of the immune system 
and that the failure to detect BCG-specific responses is due to masking by immune 
responses to mycobacterial antigens present in MA107.  
 
In conclusion, most of the studies support the idea of cross-reactivity of immune 
responses across mycobacterial species. This suggests that previous mycobacterial 
exposure can affect the outcome of BCG vaccination. However, most of the studies 
are performed in animal models, and more research in humans is needed in order to 
fully explain variations in immune patterns elicited by the BCG vaccine.  
 
1.1.2.4.3. Infant co-infections and BCG immune responses 
 
Another hypothesis that could explain variations in the BCG induced immune 
response is the impact of other infections prenatal, postnatal and at the time of or 
post-vaccination. Unlike the UK (or other developed countries), countries where BCG 
efficacy is poor are nearer the equator and the prevalence of infections such as 
malaria, human immunodeficiency virus (HIV), tetanus, helminths and others is 
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high111. One could hypothesise that these infections would shape the immune system 
and affect vaccine-induced immune responses resulting in variable immunisation 
efficacies. 
   
Malaria is a dominant infectious disease caused by four species of Plasmodium: 
Plasmodium falciparum (P. falciparum), P. vivax, P. ovale and P. malariae. Its 
prevalence is common in tropical countries, close to the equator, where BCG induced 
protection against TB is low112. Research groups have investigated the potential 
outcome of postnatal malaria infection or in-utero exposure on the immunogenicity of 
BCG. Parra et al113 found that P. yoelli infected mice vaccinated with BCG had a 
reduced number of IFNγ and TNFα producing as well as reduced frequency of triple 
positive (TP) CD4 and CD8 antigen-specific T cells at 2 but not 7 and 10 weeks post-
malaria infection113. This suggests that malarial modulation of the immune response 
is transient and unlikely to affect the immunisation profile of the BCG vaccine. In 
contrast, attenuated human CD4 T-cell responses were observed in infants that 
survived placental malaria (PM) vs control group, and lower IFNγ responses were 
observed upon stimulation of PBMC with tuberculin PPD114. Lastly, Elliott et al115 
found an association of infant malaria with lower levels of IFNγ, IL-5 and IL-13; and 
maternal malaria and number of malaria episodes in infancy with lower IL-5115.  
 
Helminths are still the most common intestinal infection worldwide affecting the lowest 
income countries, where sanitation is inadequate116.  Helminth infections are known 
to reshape the immune system by causing chronic infections, inducing strong TH2 
immune responses, and activating Tregs117. These immune characteristics resemble 
aspects of the host immune response where BCG immunogenicity is low, giving 
substantial grounds to hypothesise that helminth infections could shift the BCG 
immune response to TH2, resulting in a loss of protection against TB. To test this, 
Elliott et al118 conducted a large trial looking at the effect of single-dose anthelmintic 
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treatment during pregnancy on the infant immune response to BCG. They found no 
influence of either albendazole or praziquantel treatment, two common anthelminthic 
drugs, on the immune response to BCG118. The same group investigated whether 
treatment of children with albendazole affected their immune responses119. Five years 
post-BCG immunisation, Albendazole treated children had slightly lower IFNγ, IL5 
and IL13 immune responses when whole blood was stimulated with crude (c) CFP119. 
In contrast, infants exposed in utero to helminths showed lower IFNγ120  and higher 
IL5120, IL10115 secretion upon stimulation of PBMC with PPD120 or cCFP115. Similarly, 
helminth-infected children had lower secretion of IFNγ and IL12 from PBMC 
stimulated with PPD121 and albendazole treated children had increased PPD specific 
T cell proliferation and IFNγ production122.  Lastly, mice infected with low dose 
Schistosoma mansoni (S. Mansoni) and challenged with BCG markedly increased 
TH2 and suppressed TH1 responses123. Helminth-induced suppression of TH1 
immune response to BCG was found to be driven by Tregs124 and TGFβ121, and the 
newest study shows that infection with Schistosoma haematobium increases the Treg 
subset, and Tregs decrease post-treatment, increasing BCG specific cytokine 
production125. 
    
HIV infection impairs the immune system and depletes the host of CD4 cells126, crucial 
for TB protection and effective responses following BCG127. As HIV infected and the 
disadvantaged immune system fails to control the vaccine-induced BCG infection, 
WHO’s recommendation is not to vaccinate infants with symptomatic HIV128. This 
policy is supported by data suggesting a risk of local and disseminated BCG disease 
in HIV infants129. Moreover, the immune response to BCG is severely impaired with a 
lower secretion of IL5, 13, IFNγ115 and reduced number of polyfunctional CD4 T cells 
producing IFNγ/ IL2/ TNFα130. Lastly, infants exposed to HIV in-utero but who remain 
uninfected, show a transient increase of the CD4 subset of cells with no effect on 
BCG immunisation131. 
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It is clear that co-infections can modulate the immune system and affect the outcome 
of immunisation. However, as most vaccines (incl. BCG) are given at birth or within 
the first year of life when the prevalence of infectious diseases is low, it is highly 
unlikely that the lower efficacy of the BCG vaccine can be a consequence of co-
infections alone. 
 
We now know that immune responses to BCG can vary by regions and we are familiar 
with potential reasons for these variations. Aside from investigating cytokines, we 
must look at cells and their phenotypes that respond to BCG vaccination. In addition, 
we should consider molecular mechanisms such as epigenetics that drive the 
sustained differences in immune responses across populations.   
 
1.2. Dendritic cells as an essential immune mechanism in the mediation of 
adaptive immune responses. 
 
Dendritic cells are specialised antigen-presenting cells that play a role in bridging 
innate and adaptive immunity. They comprise only 0.1% of all peripheral blood cells 
and their mapping and studying in human remains difficult132. There are three major 
types of dendritic cell: plasmacytoid DCs (pDCs), classical dendritic cells type 1 
(cDC1) and type 2 (cDC2). Inside epidermis and epithelia, resident dendritic cells are 
called Langheran cells (LCs), and monocytes are known to differentiate into 
monocyte-derived dendritic cells (MDDCs) during inflammation132. The majority of DC 
studies are conducted in mice, and recent technological advances allow for the 
translation of findings in mice to humans133.  
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1.2.1. The role of dendritic cells 
 
The central role of dendritic cells is to capture PAMPs in the periphery, internalise, 
process and present them to T cells for initiation of the adaptive arm of the immune 
response. DCs selectively express T cell co-stimulatory markers and secrete 
cytokines to precisely drive T cell differentiation into various subsets. By being able 
to steer T cell-mediated responses against pathogens and self-antigens, DCs are 
therefore master regulators of the adaptive immune system134.  
 
1.2.1.1. Presentation of antigens by dendritic cells 
 
The presentation of self and foreign antigens is the dominant role of dendritic cells. 
Foreign and self-antigens, as well as pathogen associated molecular patterns 
(PAMPs), are recognised by multiple cell surface receptors including Fc, Scavenger, 
C-type lectin family, macrophage mannose receptor, DEC205, and DC-SIGN134. The 
PAMP recognition by DC receptors initiates clathrin-dependent endocytosis or 
phagocytosis. A receptor-independent sampling of the extracellular environment is 
called micropinocytosis135 (figure 6).  
 
Clathrin-dependent endocytosis is an essential process in vesicular trafficking. After 
antigen recognition, a complex modulator protein machinery forms a clathrin-coated 
endocytic vesicle. Through actin rearrangement and multiple processes such as 
scission and uncoating, the clathrin-coated vesicle is internalised and fused with the 
endosome136 (figure 6).  In contrast, micropinocytosis is a clathrin-independent 
process that involves membrane ruffling and creation of large vacuoles that contain 
PAMPs, which are internalised and lysed by lysosomes. In DCs, micropinocytosis is 
a constitutive process that allows random sampling of extracellular fluid134. Lastly, 
phagocytosis is a receptor-mediated process that results in the creation of 
 48 
phagosomes. Immature DCs are capable of phagocytosis; however, upon activation, 
they lose their phagocytic capability137.  The main proteases found in DC phagosomes 
are cysteine proteases such as cathepsins, aspartate proteases and asparagine 
endopeptidase138; however, their proteolytic activity is reduced when compared with 
other phagocytic cells such as neutrophils139. It was proposed that DCs partially 
degrade proteins to present them in the MHCII context rather than fully, as is the case 
for neutrophils and macrophages140.  Exogenous PAMPs are processed and loaded 
onto MHCII molecules in late endosomes, whereas endogenous antigens are loaded 
onto MHCI molecules in the endoplasmic reticulum (ER). Once DCs process 
antigens, they differentiate into their mature phenotype, increase expression of CD83, 
CD80, CD86, HLA-DR and CCR7, and travel to lymph nodes to present processed 
antigens to T cells141.  
 
Exogenous antigens are internalised, processed and presented to T cells in the 
context of MHCII molecules whereas endogenous antigens are presented in an MHCI 
context. The role of MHCI presentation of antigens is to identify  modified cells such 
is highly proliferating tumour cells. Antigens loaded onto MHCI molecules are 
recognised by naïve CD8 T cells that become activated and initiate cell death.  
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Figure 6. An overview of pathways involved in antigen internalisation, processing and 
presentation. Source: Pathways of Antigen Processing135.  
 
1.2.1.2. Cross-presentation of antigens by dendritic cells 
 
In contrast to the presentation of self-antigens, cross-presentation is a process in 
which exogenous antigens (such as antigens derived from viral DNA) are presented 
in an MHCI context. The cross-presentation is a mechanism that activates naïve 
antigen-specific CD8 T cells to become cytotoxic T cells (CTLs), which by releasing 
perforin and granzyme facilitate the killing of infected cells142.  
 
The cytosolic pathway and the vacuolar pathway are two primary mechanisms 
described for cross-presentation. In the vacuolar pathway, phagocytosed exogenous 
PAMPs are degraded in the phagosome and loaded onto MHCI, to be later 
transported and presented on the cell surface. In the cytosolic pathway, exogenous 
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peptides are degraded by proteasomes and transported to the ER lumen via TAP 
transporter proteins. In the ER, degraded antigens are loaded onto MHCI and 
transported to cell surface142 (figure 7). 
 
 
Figure 7. An overview of cytosolic and vacuolar pathways used in antigen cross-
presentation by dendritic cells. Source: Cross-presentation by dendritic cells142 
 
1.2.1.3. The polarisation of T cells by dendritic cells 
 
Dendritic cells present antigens to CD4 T cells to drive activation, proliferation and 
differentiation into an effector phenotype. A proportion of the effector T cell population 
will survive for years as an effector memory population, which can be quickly 
mobilised upon secondary antigen exposure. Depending on the type of antigens, DCs 
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can mediate T cell activation and drive them towards a specific phenotype, tailored 
for an efficient eradication or control of an antigen or pathogen. Three factors 
influence the type of T cell response that will develop after DC-T cell interaction. 
Firstly, the expression of co-stimulatory markers on a DC surface that drives CD4 T 
cell activation. Secondly, the type of antigen expressed by DCs in a context of MHCII 
molecule. Thirdly, the array of cytokines that DCs or cells within the vicinity of DC-T 
cell interaction produce143. There are four major types of TH subsets: TH1, TH2, TH17 
and Tregs (figure 8) as well as TH9 and follicular helper T cells (Tfh).   
 
 
Figure 8. An overview of multiple pathways of T cell differentiation, stimuli and 
cytokines that induce them. Abbreviations: CLR, C-type lectin receptor; GM-CSF, 
granulocyte–macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; 
NK, natural killer; PAMPs, pathogen-associated molecular patterns; RA, retinoic acid; 
SEA, Schistosoma mansoni soluble egg antigen; TGF, transforming growth factor; 
Th, T helper cell; TLR, Toll-like receptor; TNF, tumor necrosis factor; Treg, regulatory 
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T cell. Source: Dendritic cells and other innate determinants of T helper cell 
polarisation143. 
 
A TH1 response is characterised by an elevated T cell production of IFNg and TNFa, 
which activate macrophages to induce nitric oxide (NO) mediated killing of pathogens.  
The differentiation of T cells to the TH1 phenotype requires a robust MHCII interaction 
with T cell receptor (TCR)144, DC-derived CXCL10 with T cell CXCR3 (in the lymph 
node)145, and ligation of mature DC molecules CD80 or CD86 to T cell CD28143. The 
TH1 response is often developed in response to viral, bacterial and protozoan 
infections, which stimulate membrane toll-like receptors (TLR) 4, TLR5, TLR12 and 
endosomal TLR3, TLR7 and TLR9146,147. TLR stimulation induces production of pro-
inflammatory cytokines and IL12-p70, a crucial cytokine that drives TH1 
differentiation143 (figure 8). TH1 cells are characterised by the expression of T-bet, 
STAT3 and STAT1 transcription factors148.   
 
A TH2 response is characterised by an increased T cell production of IL4, IL5 and 
IL13, and has evolved as a protective arm of immunity against large parasites such 
as helminths. TH2 cells are characterised by the expression of GATA3, STAT6, DEC2 
and MAF transcription factors148. TH2 responses drive antibody class switching in B 
cells to IgG1 and IgE and alternatively activate macrophages to promote tissue 
repair149. A weak MHCII/TCR interaction144, as well as binding of the Notch receptor 
ligand, Jagged to Notch 1 and Notch 2 on CD4 cells, have been shown to contribute 
to TH2 differentiation150. The TH2 response is developed in response to parasitic 
antigens such as helminths or Schistosoma mansoni soluble egg antigens (SEA). 
These antigens engage C-type lectin-like receptors (CLRs) on the surface of DCs. 
DCs drive TH2 differentiation in cooperation with other cells. Following helminth 
exposure, epithelial cells produce IL25, IL33 and thymic stromal lymphopoietin 
(TSLP), which recruits IL4 producing basophils into the lymph nodes. Thus epithelial 
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cells, basophils and the cytokines that they produce cooperate with DCs to induce 
the TH2 phenotype (figure 8).   
 
TH17 cells express RORgt, STAT3, RORa transcription factors148, and secrete large 
amounts of IL17A, IL17F, IL22, GM-CSF and TNFa, cytokines that recruit and 
activate neutrophils to the site of infection151. TH17 cells can, therefore, protect us 
from pathogens but also play a pathogenic role in many autoimmune diseases152. 
TH17 development is dependent on MHCII/TCR, CD80 or CD86/CD28 
interactions143. TH17 cells recognise mainly fungi and bacterial antigens presented 
by DCs. The recognition of fungi and bacterial antigens is mediated by DC receptor 
CLR, Dectin-1, which recognises b-glucans from fungal species such as Candida 
albicans153. This activates a signalling cascade that activates NF-kb and drives the 
production of pro-inflammatory cytokines such as IL1, IL6, IL23, all essential for TH17 
development154. TGFb is also essential for TH17 development, and IL17 and IL21 
derived from gdT cells can induce TH17 differentiation143 (figure 8).  
 
Tregs are recognised by their production of IL10 and TGFb or the expression of 
FoxP3, STAT5, FOXO1, and FOXO3 transcription factors148. Their role is to regulate 
immune responses and prevent the development of autoimmunity and 
immunopathology143. Immature or partially mature DCs induce Treg development. 
Interactions of inhibitory molecules such as CTLA4/CD80 or CD86, and programmed 
cell death 1 with programmed cell death 1 ligand (PD1/PDL1) send inhibitory signals 
to T cells promoting anergy and immunosuppression155. Chronic bacteria such as 
Bordetella pertussis and parasites drive Treg development. CD11b/CD18 receptors 
recognise antigens on the DC surface and signal via p38 mitogen-activated protein 
(MAP) kinase and suppression of interferon regulatory factors IRF1 and IRF8, which 
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inhibit IL12. This signalling cascade results in IL10 and TGFb secretion, essential for 
Treg development156 (figure 8). 
 
Tfh cells express BCL-6 and STAT3 transcription factors and produce IL-21. They 
have shown to play a role in the induction of germinal centre responses as well as 
providing help for B cell class switching148.  Lastly, TH9 cells express the PU.1 
transcription factor and produce IL9 and IL10. The role of TH9 cells has been 
documented in host defence against nematodes and promotion of allergic 
inflammation148.  
 
1.2.2. Differential phenotypes of dendritic cells 
 
DC functions are diverse and depend on the type of antigen they process and the 
environment DCs are in, including the vicinity of other cells and cytokines that they 
produce. Besides, DCs can be classified based on their origin, location and function. 
The main subsets of DCs (pDCs, cDC1, cDC2), as well as MDDCs, have unique 
functions and properties with implications for an immune response that they induce. 
These will be briefly discussed here. 
 
1.2.2.1. Classical dendritic cells 
 
Classical dendritic cells, also known as conventional or myeloid, are derived from 
CDPs, which undergo differentiation in peripheral organs or tissues. They traffic to 
lymph nodes from peripheral tissue via afferent lymphatic vessels157. cDCs can be 
divided into two subsets: cDC1, which have high expression of BCA-1, BDCA-3 and 
CD1c; and cDC2, which highly express CD141158. Both cDC1 and cDC2 subsets have  
similar antigen degradation, processing and presentation capabilities however they 
differ in TLR expression patterns and responsiveness132.  cDC1 cells express all TLRs 
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except TLR9, and they secrete an array of cytokines including IL-1β, IL-12, IL-6, 
TNFα, CXCL8/IL-8, CCL3, CCL4, and CCL5 and CXCL-10 upon TLR3 stimulation132. 
Their primary function is to prime CD4 T cells, and they are known to induce TH1, 
TH2 and TH17, however, this ability is strongly dependent on the tissue in which they 
reside. Lymph node resident DCs can induce TH1 and TH2 differentiation, skin 
resident DCs promote TH2, whereas blood DCs are poor TH2 inducers132.  
 
cDC2 cells express TLR3 and TLR10 and have low expression of TLR1-2, TLR6 and 
TLR8. They mainly respond to TLR3 ligands (poly I:C) and produce CXCL10/IP10, 
CCL5, IL12p70, IFNb and IFNl cytokines (a type III interferon with anti-viral 
properties)132. cDC2 are also known to promote TH1 immune responses and play a 
role in cross-presentation of tumour and pathogen-derived antigens to induce effector 
CD8 T cell responses159.  
 
1.2.2.2. Plasmacytoid dendritic cells 
 
Plasmacytoid dendritic cells are a unique subset of dendritic cells that can be 
broadly characterised by the production of type I interferons and expression of the 
CD123 marker (figure 9). Their general role is mediation of antiviral immune 
responses however they have much broader roles in other areas of the immune 
system157. pDCs develop in the bone marrow, circulate in the blood and arrive in T 
cell areas of the lymph nodes via high endothelial venules (HEV). pDCs also 
migrate from secondary lymphoid organs or blood into peripheral tissues160.  
A common DC progenitor (CDP) is characterised by a lack of lineage markers and 
expression of Fms-like tyrosine kinase 3 (FLT3 or CD135), macrophage colony-
stimulating factor receptor (M-CSFR or CD115 or CSF1R) and the receptor 
tyrosine kinase KIT (CD117 or SCFR)157. CDP is found in the bone marrow and 
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can give rise to both pDCs and cDCs. The development of pDCs involves 
differentiation of CDP to pDC-like common DC precursor that is negative in CCR9 
and low in MHCII expression161. These precursors later differentiate into pDCs, and 
all of these processes take place in the bone marrow157.  
pDCs play a role in both innate and adaptive immune responses. They present 
antigens in the context of MHCI and MHCII and activate T cells with co-stimulatory 
molecules CD80, CD86 and CD40. They produce type I IFNs to maintain an 
antiviral state, activate NK cells, and promote effector CD8 and TH1 responses. 
They can release an array of cytokines and chemokines to drive recruitment of 
immune cells and have been shown to play a role in regulatory responses by driving 
Tregs as well as inducing cell death and T cell suppression157. 
 
 
 
Figure 9. An overview of functions of plasmacytoid dendritic cells. Source: The multifaceted 
biology of plasmacytoid dendritic cells157 
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1.2.2.3. Monocyte-derived dendritic cells 
 
Monocyte-derived dendritic cells are a unique DC subset that arises from blood 
circulating monocytes, which respond to local inflammation. Studies in vitro confirm 
differentiation of blood or bone marrow CD14 monocytes to DC-like cells after GM-
CSF and IL4 stimulation162. These in vitro MDDCs have increased capacity to 
internalise, process and present antigens; they show increased stimulatory 
capacity in leukocyte reactions; and exposure to lipopolysaccharide (LPS) or BCG 
antigens induces HLADR, the maturation marker CD83 and T cell co-stimulatory 
markers CD80, CD86, and CD40163. In vivo mouse studies confirm that CD11b+ 
F4/80- monocytes are recruited to the site of inflammation, and about 25% of them 
migrate to T cell areas of the draining lymph node and differentiate into DC-like 
cells, expressing upregulated MHCII, CD11c, CD80 and CD86164.   
MDDCs become abundant in inflammation, and their increased levels were found 
in numerous fungal, protozoan and bacterial infections, including pulmonary Mtb165. 
They have been shown to play a role in both innate and adaptive parts of the 
immune response. MDDCs mediate iNOS dependent bacterial killing as well as 
iNOS mediated tissue toxicity in Listeria monocytogenes166 and Trypanosoma 
brucei167 infections respectively. They also phagocytose Salmonella bacteria 
during gastrointestinal infection168.  As for the adaptive immune response, MDDCs 
have been shown to modulate T cell responses. Infection models confirm that 
MDDCs have an ex vivo (and some in vivo) capacity to stimulate CD4 T cell 
proliferation165. They have been shown to polarise T cells to their TH1169, TH2170 or 
TH17171 phenotypes and have been highlighted as cells that can induce TGFb-
dependent IgA production and class-switching172.  
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1.2.3. The role of dendritic cells in Mtb infection 
 
The role of DCs in Mtb infection is complicated, and studies report contrasting results. 
Numerous studies report that DCs increase the cellular response against Mtb 
infection173. Both human174 and mouse175 DCs are able to phagocytose Mtb. At the 
onset of inflammation, DCs are highly represented176, and Mtb antigen presenting 
DCs mostly reside in airway epithelium, lung parenchyma, and visceral pleura176. 
Mucosal DCs are immature and specialise in antigen processing. TLRs recognise 
Mtb PAMPs resulting in DC maturation and trafficking to lymphoid organs where they 
prime T cells through MHCII expression and cytokine production such as IL12, 
essential for TH1 priming and effective Mtb killing173. In contrast, Mtb PAMPs 
recognised by DC-SIGN block NFkb activation resulting in a cascade of events: high 
IL10 levels, impaired DC maturation, masking of the Mtb pathogen in DCs, limited T 
cell activation, and subsequently impaired Mtb killing173,177. Mtb has evolved 
mechanisms that subvert host immune responses. A study has shown that mice Mtb 
infection delays the recruitment of DCs in the lungs impairing early immune 
responses and promoting Mtb replication178. Mtb infection has also shown to direct 
Th2 differentiation of CD4 T cells by inducing production of IL1b in dendritic cells179; 
it has also shown to promote the expansion of Tregs via the upregulation of PDL1 on 
dendritic cells180.     
 
An in vitro infection of MDDCs with Mtb drives their maturation and upregulates 
expression of MHCI, MHCII, CD40, CD54, CD58, CD80, CD83; and increases their 
production of TNFa, IL1, and IL6181,182. MDDCs have also shown to be capable of an 
effective Mtb phagocytosis181.  In contrast to MDDCs, Mtb infected macrophages 
show downregulation of MHCII and upregulation of CD40 and CD54. They were also 
unable to, unlike MDDCs, prime T cells to produce IFNg183. Mouse studies confirm 
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that DC depletion resulted in impaired CD4 responses and subsequent uncontrolled 
replication of Mtb in lungs and the spleen184. Human genetic deficiencies where DC 
functions are impaired have reported an uncontrolled BCG-osis and infection with 
Mycobacterium kansasii185.   
 
1.2.4. Dendritic cells: summary 
 
Dendritic cells vary in location, function and phenotype. They can elicit an array of 
immune responses to different stimuli. Thus, DC heterogeneity between 
populations could very well underlie  variations in BCG immunogenicity. Going 
deeper, what are the molecular mechanisms that could be driving the underlying 
immune responses? Why do we observe sustained differences in immune 
responses?  Could the newly emerging field of epigenetics explain some of these 
variations? 
 
1.3. Epigenetic modifications as a molecular mechanism to shape immune 
processes.  
 
Epigenetics is a term used to describe heritable changes in DNA expression and 
activity that do not involve alterations to the DNA sequence186. The epigenetic 
modifications are accomplished using many mechanisms, including DNA 
methylation, histone modifications, and small interfering RNA (siRNA)186. 
Understanding epigenetics and mechanisms that drive epigenetic changes may help 
to explain why cells that carry identical DNA express different functions and 
differentiate into various phenotypes. Extrapolating the concept, through an 
understanding of epigenetics might explain diversities in immune responses following 
infection or vaccination187. 
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1.3.1. Chromatin structure 
 
The distribution of genomic and eukaryotic DNA is regulated by proteins called 
histones, which modulate the formation of DNA/protein complexes, known as 
chromatin. The nucleosome, a basic unit of chromatin, consists of 146 DNA base 
pairs (bp), which are wrapped around an octamer of the four core histones (H2A, 
H2B, H3 and H4). These are tightly packed with amino-terminal tails extending from 
the globular region, making them accessible to histone modifying enzymes, allowing 
for epigenetic modifications188.  
 
There are two types of chromatin: euchromatin and heterochromatin, both 
distinguishable by structure and function. Euchromatin is a less condensed, more 
open and accessible form of chromatin, ready for gene transcription and often 
associated with activated genes. Conversely, heterochromatin is a more packed and 
condensed form of chromatin, inaccessible for gene transcription and associated with 
gene silencing and inactivation189. Many epigenetic changes modulate the structure 
of the chromatin and its ‘'readiness'' for gene transcription. Thus, euchromatin is often 
associated with hypomethylated DNA and hyperacetylated histones, whereas 
hypermethylation of DNA and hypoacetylation of histones are characteristics of 
heterochromatin structure (table 1)187,190. 
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Table 1. An overview of structural and epigenetic differences between euchromatin and heterochromatin 
 Chromatin Features Epigenetic Markers 
Type of 
Chromatin 
Structure DNA Sequence Activity DNA Methylation 
Histone 
Acetylation 
Histone 
Methylation 
Euchromatin 
Less Condensed 
Open Accessible 
Gene Rich Expressed Active Hypomethylation 
Hyperacetylation 
of H3 H4 
H3K4me2 
H3K4me3 
H3K9me1 
Heterochromatin 
Condensed 
Closed and 
Inaccessible 
Repetitive 
Elements 
Repressed Silent Hypermethylation 
Hypoacetylation 
of H3 H4 
H3K27me2 
H3K27me3 
H3K9me2 
H3K9me3 
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1.3.2. DNA Methylation 
 
DNA methylation is the most characterised epigenetic modification, essential for gene 
regulation, development and tumorigenesis. In mammalian cells, it mostly occurs at 
the 5' position of the cytosine base within the CpG dinucleotide, creating 5-
methylcytosine (5mC) (figure 10). The addition of 5’ 
methyl group to cytosine is catalysed by DNA 
methyltransferases (DNMTs), including DNMT3a, 
DNMT3b (initiators of de novo methylation in stem cells 
and cancer cells) and DNMT1 (recognises and copies 
methylation patterns of CpGs, which were initiated by de 
novo DNMTs)186. Distribution and methylation of CpGs 
were found to regulate gene silencing, transcription and 
chromosomal stability191. More specifically, CpG hypermethylation drives structural 
changes of chromatin, making hypermethylated genes inaccessible for transcription. 
Conversely, the absence of DNA methylation results in CpG dinucleotides being 
readily available to transcription factors, allowing gene transcription192.  Abnormal 
methylation patterns can be observed in human tumours, which have a unique ability 
to regulate the expression of its oncogenes, thereby outperforming the host's cancer-
fighting mechanisms187,191. 
 
1.3.3. Histone Modifications 
 
Core histones and more specifically their amino terminals undergo many epigenetic 
alterations, including most commonly acetylation and methylation, as well as 
phosphorylation, ubiquitination and sumoylation193. Histone acetyltransferase 
enzymes (HATs) and histone deacetylases (HDACs) regulate the acetylation and 
Figure 10. DNA methylation 
at 5' cytosine results in a 
formation of 5-
methylcytosine. 
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deacetylation of histones respectively. Acetylation, removes positive charges 
between DNA and histones, thereby reducing affinity and shaping chromatin into 
euchromatin structure, allowing for DNA processes such as transcription and repair 
to take place. Conversely, the deacetylation of histones by HDACs introduces positive 
charges between DNA and histones, increases affinity and shapes chromatin into 
densely packed heterochromatin, inaccessible for transcription and other DNA 
processes186. In contrast to histone acetylation, which is positively associated with 
gene transcription, the role of histone methylation is more heterogeneous. Histone 
methylation can result in methylation of various lysine residues and can vary in its 
extent, which may be mono, duo or trimethylation. The literature suggests that 
H3K4me, H3K36me and H3K79me methylation patterns are associated with 
activated gene regions190, whereas H3K9me, H3K20me and H4K27me methylation 
patterns correlate with gene silencing and inactivation (table 1)193. The degree of 
methylation  dictates gene expression. Trimethylation at H3K9me3 and H3K27me3 
correlates with gene repression and silencing, whereas monomethylation of the same 
lysine residues (H3K9me1 and H3K27me1) is associated with gene transcription and 
activation (table 1)187,194. 
 
1.3.4. Non-coding RNA, transcriptional gene silencing and microRNAs 
 
Small RNAs were discovered as a potential template molecule to mediate epigenetic 
modifications. They play a role in a process known as transcription gene silencing 
(TGS)186. Small RNAs function within Argonaute (AGO) complex that targets nascent 
transcript scaffolds, mRNA, and long non-coding RNAs (lncRNAs), which all play a 
role in the recruitment of chromatin-modifying scaffolds. These scaffolds initiate 
epigenetic mediated changes in gene expression and maintain a persistent memory 
of epigenetic silencing by forming positive feedback loops within chromatin-based 
signals. lncRNAs from enhancer regions have been shown to activate gene 
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expression by bringing together enhancer and promoter regions, and activatory 
molecules to histones195.   
 
In contrast, microRNAs (miRNAs) are non-coding RNAs that affect gene expression 
at the post-transcriptional level and target miRNAs directly. miRNAs mature and 
merge with the RNA-induced silencing complex (RISC) to inhibit mRNA mediated 
transcription. miRNAs have been shown to play a role in the regulation of multiple 
cellular and immune processes including the regulation of cytokine expression196.  
 
1.3.5. The regulation of epigenetics by infection and environmental 
factors 
 
Because of the advances in mapping human DNA, it has become apparent that genes  
do not solely explain susceptibility to diseases and epigenetic mechanisms must be 
considered. There is  growing evidence suggesting that environmental factors 
(nutritional supplements, low-dose radiation, reproductive factors, xenobiotic 
chemicals and others) present in the prenatal and postnatal period of life, modulate 
heritable changes in epigenetic markers and influence the susceptibility to a number 
of adult chronic diseases, including: cancer, diabetes, obesity, cardiovascular 
diseases; as well as behavioural disorders such as schizophrenia197. One of the most 
characterised examples of epigenetic modification following environmental exposure 
is the mouse Avy allele also known as agouti. There is substantial evidence that a 
degree of methylation of IAP, an element at the transcription site of the Avy allele, is 
associated with the phenotypic heterogeneity and disease susceptibility in mice, and 
many environmental factors modulate this methylation. A maternal diet rich in methyl-
donor supplementation such as folic acid, vitamin B12, choline and betaine, 
hypermethylates the IAP element of the agouti gene resulting in offspring with brown 
fur. Conversely,  a diet  short of these supplements hypomethylates the IAP element 
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and shifts the fur colour distribution to yellow. Additionally, yellow fur mice were much 
more susceptible to diabetes, obesity and tumorigenesis whereas brown fur mice 
were protected from these chronic diseases, highlighting the importance of epigenetic 
mechanisms in susceptibility to chronic diseases197. Human studies conducted in The 
Gambia report that season at conception and associated maternal nutrition modulate 
DNA methylation of infants198.   
 
Many studies are suggesting that an infection can alter the epigenetic landscape of 
the host and subsequently affect  future immune responses. These studies have been 
extensively reviewed by Bierne et al.199. In short, the literature supports that infection 
can alter the host's epigenetic landscape by changing DNA methylation patterns, 
introducing histone modifications (acetylation, methylation, phosphorylation etc.), and 
inducing the expression of non-coding RNA (ncRNA). An excellent example of 
epigenetic modifications has recently been highlighted by Wen et al.200. It is well 
documented that a severe innate immune response such as  septic shock is followed 
by deficiencies in subsequent immune responses in patients; however, the 
mechanism behind these deficiencies is unclear201.  The research group has found 
that in mice, following peritonitis-induced sepsis, newly formed dendritic cells have 
significantly reduced expression of IL12 , independently of immunoregulation by IL10. 
They found decreased levels of H3K4me3 and increased H3K27me2 histone 
modifications at IL12p35 and IL12p40 gene promoters, suggesting a heterochromatin 
conformation of chromatin and limited gene transcription200. In another example, an 
infection of macrophages with Mtb results in an upregulation of a chromatin-modifying 
complex Sin3a.  Sin3a, along with HDAC modify chromatin into its densely packed 
form of heterochromatin, preventing transcription of genes such as IFNγ inducible 
genes, including MHC class II202. The downregulation of MHC class II genes impairs 
the presentation of Mtb antigen, subsequently hindering host’s immune responses 
and giving the pathogen survival advantage. Aside from modifying histones, bacteria 
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have been shown to have the ability to introduce aberrant DNA methylation patterns. 
Uropathogenic Escherichia Coli (UPEC) infection of human uroepithelial cells recruits 
DNMTs, including DNMT1, resulting in de novo methylation of CpG islands of the 
CDKN2A gene, encoding for cell cycle regulatory proteins. As a result, UPEC 
counteracts host cell apoptosis of uroepithelial cells and promotes their proliferation 
to maintain pathogen persistence187,203. 
 
1.3.6. The epigenetic control of immune responses 
 
Epigenetic modifications can be modified by an infection, abnormal cell proliferation, 
vaccination and environmental factors. However, epigenetic modifications can also 
mediate multiple processes including cellular, metabolic, signalling and immune 
processes. Indeed, epigenetic modifications play an extensive role in the regulation 
of immune pathways204. 
 
1.3.6.1. The epigenetic regulation of innate immunity  
 
DNA methylation and histone modifications have been shown to play a role in the 
regulation of innate immunity. Increased methylation of CpG islands of TLR2 gene 
leads to lower levels of TLR2 expression and is associated with increased risk of 
pulmonary TB205. Similarly, decreased methylation in the TLR2 gene results in higher 
expression of TLR2 and an enhanced inflammatory response to bacterial challenges 
in cystic fibrosis patients206. Studies in Dutch adolescents have shown that BCG 
vaccination induced increased levels of H3K4me3 histone modifications of 
proinflammatory cytokines TNFa and IL6, as well as  of the TLR4 receptor.  These 
changes were associated with increased secretion of these cytokines and expression 
of TLR4 up to 3 months post BCG training87. Studies indicate that epigenetic 
mechanisms regulate macrophages and their functions. Engagement of TLRs in 
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macrophages induces a gene permissive histone acetylation of inflammatory 
genes207 and a subsequent increase of proinflammatory cytokines in response to 
LPS.  An increase in H3K4 methylation of the TNFAIP3 gene  (a facilitator of 
deubiquitination of NFkb and TRAF6)  results in  suppression of NFkb and mitogen-
activated protein kinase signalling, resulting in decreased levels of IL6208.  
  
1.3.6.2. The epigenetic regulation of cell differentiation and 
adaptive immunity 
 
The differentiation of myeloid cells, their function and phenotype are regulated by 
epigenetic modifications. The polarisation of M2 macrophages has been shown to be 
mediated by epigenetic mechanisms. Satoh et al209. explained that a useful 
polarisation of macrophages requires a conversion of H3K27me3 to H3K27me1 via 
JMJD3, a demethylation protein that is induced by TLR stimulation in 
macrophages209. Another group has shown that in mice, a loss of histone deacetylase 
family 3 (HDAC) in macrophages makes them sensitive to IL4 and skews their 
differentiation to the M2 phenotype. This suggests a role for histone acetylation in  
responsiveness to IL4 and macrophage differentiation to their M2 state210.  
 
The differentiation of monocyte-derived dendritic cells from monocytes is associated 
with a substantial loss of DNA methylation, mostly of enhancers and binding sites for 
transcription factors associated with the dendritic cell lineage. These findings were 
co-observed with dynamic expression changes of genes known to regulate DNA 
methylation: DNMT1, DNMT3, DNMT3B, and TET2211. 
 
Naïve CD4 T cells differentiate into polarised TH phenotypes, and this process is 
mediated by changes in histone modifications and DNA methylation. The 
differentiation of T cells and the mediation of their function by epigenetic mechanisms 
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have been extensively reviewed 212,213. High methylation of the IL4 gene can 
characterise TH1 T cells whereas TH2 cells have high methylation of the IFNG 
gene214. Naïve T cells are marked by high levels of H3K9me2 (gene silencer) at the 
IFNG, IL4, IL17A, TBX21, GATA3, RORC and FOXP3 genes. However, upon 
differentiation,  modification of histones at these genes changes, allowing for gene 
transcription and translation. The H3K9me2 modification is removed from the IFNG 
and TBX21 genes in TH1 cells; from the IL4 and GATA3 genes in TH2 cells; from the 
IL17A and RORC genes in TH17 cells; and from the FOXP3 gene in Treg cells212. 
The differentiation and regulation of functions of CD8 T cells have also been shown 
to be regulated by epigenetic mechanisms215. Studies have found a loss of permissive 
H3K4me3 and H3K9ac modifications which are replaced by repressive H3K27me3 
and DNA methylations at genes  the expression of which are  reduced in effector cells 
(FOXO1, KLF2, LEF1, TCF7, IL2RA, CD27, TNF, CCR7). Conversely, transcription 
factors (EOMES, TBX21, PRDM1) and effector genes (GZMA, GZMB, PRF1, IFNG, 
KLRG1) of which expression is increased in effector cells have a decrease in 
repressive and an increase in permissive epigenetic markers215.   
 
Lastly, studies have investigated the role of epigenetics in the induction of vaccine-
induced immune responses. A comparison of DNA methylation between low and high 
responders to Hepatitis B vaccine revealed numerous genes to be differentially 
methylated between two groups. A closer investigation revealed potential novel gene 
candidates: RNF39 was hypomethylated, and SULF2 was hypermethylated in 
indigent respondents to the Hepatitis B vaccine216. Another study investigated 
whether epigenetic modifications can mediate the immune response to the influenza 
vaccine.  This showed that a decrease in DNA methylation of cellular differentiation, 
signalling and antigen presentation pathways was associated with an increased 
humoral response to influenza vaccine217.  
 
 69 
The role of epigenetic modifications in immunity is vast and spans  multiple arms of 
the immune system. Epigenetic modifications also play a role in pathogen-specific 
immune responses, and new evidence suggests a link between Mtb infection and 
epigenetics. 
 
1.3.7. The role of epigenetics in Mtb infection 
 
The immune response to the Mtb  is heterogeneous and often not optimal and 
sufficient to effectively kill the pathogen. Epigenetic modifications have been 
proposed as a mechanism to explain these variations. A growing number of studies 
show how the epigenome affects the immune response to Mtb and conversely, how 
Mtb can utilise epigenetic modifications to divert the host's immune response and 
sustain its own survival. The epigenome of the host can affect the immune response 
to Mtb. Gringhuis et al.218 showed that following Mtb infection of dendritic cells, the 
methylation of NFkB is essential for its activation and increased transcription of IL10.  
 
Mtb utilises epigenetic mechanisms to regulate host immune responses. It employs 
19 kDa lipoprotein to antagonise TLR2 via deacetylation of histones of MHC2TA and 
class II transactivator gene (CIITA) promotors. The deacetylation of these genes 
results in a decreased presentation of Mtb antigens, T cell activation, and sustained 
survival of Mtb within cells219. Enhanced cellular survival protein (Eis) found in Mtb 
can inhibit ERK1/2 and JAK pathways in activated T cells. It does so by acetylation 
of DUSP16/MKP-7, both genes that are essential regulators of the ERK1/2 and JAK 
pathways. Thus Mtb can negatively inhibit T cell activation by acetylation of crucial 
ERK1/2 and JAK pathway genes220. Studies also demonstrate associations between 
TB disease or susceptibility and epigenetic modifications. Hypermethylation of the 
vitamin D receptor (VDR) gene results in increased susceptibility to TB, both in African 
and European populations221; the IL17 gene is hypermethylated in macrophages 
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isolated from active or latent TB when compared to healthy individuals222; and TB 
patients have hypermethylation of the TLR2 gene CpG islands223.  Additionally, there 
is growing evidence of a role for miRNAs in response to Mtb infection. miRNA-21 
targets IL12 mRNA and inhibits its translation224; miRNA-29 targets IFNg to suppress 
the immune response to Mtb225; and other miRNAs were able to target multiple 
inflammatory mRNAs subsequently attenuating the expression of pro-inflammatory 
cytokines and regulating the immune response to Mtb226.  
 
In summary, studies demonstrate that Mtb uses epigenetic mechanisms to interfere 
with host immune responses. It does so by decreasing antigen presentation as well 
as inhibiting critical proinflammatory cytokines. 
 
1.3.8. Transcriptomic signatures in TB vaccine trials  
 
Epigenetic mechanisms modify the readiness of genes for mRNA transcription and 
subsequent protein translation. Therefore, one could expect, that mRNA and its 
signatures play a substantial role in the TB field. Because of technical advances, 
numerous studies have explored whether we can use transcriptomics to distinguish 
between healthy controls, active TB, LTBI, patients that are at risk of progressing to 
active TB, and patients that remain latently infected. Zak et al.227 have identified a 
mRNA signature of 16 genes that prospectively identified people at risk of developing 
active TB in African adolescents227. Anderson et al.228 have developed a 51-transcript 
signature that can distinguish TB from other diseases in African children228. Cliff et 
al229 have identified dynamic phases of blood gene expression patterns that change 
throughout TB treatment229. These and other studies highlight the growing role of 
transcriptomics in the TB field. They help to progress towards identifying reliable 
correlates of BCG protection or TB risk.   
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1.4. Introduction summary  
 
The burden of TB remains high, and there is a growing threat of multi-drug resistant 
TB. Research consortia such as TBVAC2020 and international organisations like the 
European Union and United Nations highlight the need and facilitate research for the 
development of new TB vaccines. Despite a moderate number of TB vaccines in the 
pipeline BCG is still the only licensed vaccine for tuberculosis. The efficacy of BCG 
against pulmonary TB varies across geographical regions, and a comparison of 
immune responses between countries revealed distinct immune responses, 
potentially explaining the observed BCG efficacy disparities. The development of new 
TB vaccines and the improvement of BCG is impaired by a lack of reliable correlates 
of protection; limited understanding of the complex immunity that BCG induces across 
populations; and a lack of knowledge of molecular mechanisms that drive sustained 
BCG induced immune responses. Novel avenues of research must be explored to 
answer these questions. Dendritic cells have been highlighted previously to have a 
role in BCG mediated immunity; however, they have been poorly characterised 
across populations, and their contribution to BCG immunogenicity remains unclear. 
Molecular mechanisms have been largely neglected in vaccine efficacy trials, and 
epigenetic modifications have been indicated to play a role in vaccine-induced 
immune responses  including following BCG as well as in Mtb immunity. This PhD 
will contribute to a better understanding of BCG induced immunity in the UK and 
Uganda and will investigate immune (dendritic cells) and molecular (epigenetic 
modifications) mechanisms that could explain underlying BCG immunogenicity 
profiles between these two countries. 
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2. Aims, Objectives and hypotheses.  
 
BCG varies in efficacy and immunogenicity across geographical locations and 
reasons for these variations as well as the molecular mechanisms that drive them are 
still not well understood. This study will involve an examination of the immune 
responses of UK and Ugandan infants as well as an investigation into potential 
mechanisms, specifically, the involvement of dendritic cell phenotype and epigenetic 
profiles, which modulate these responses in a host. An in-depth understanding of 
immune and molecular mechanisms that determine vaccine efficacy is essential for 
the optimal design of new and improved vaccines, including BCG. The overarching 
hypothesis for this study is that DNA methylation patterns or dendritic cells 
phenotypes and composition are underlying mechanisms that can explain the 
spectrum of BCG immunogenicity and in this study, are associated with the immune 
response to the BCG vaccine. The study is split into four specific aims, each one 
addressed in a separate results chapter with the aim-specific hypothesis. 
 
1) Aim 1 is to conduct a pilot study of DNA methylation profiles and their 
relationship to BCG-induced immune responses in BCG-vaccinated South 
African infants.  
2) Aim 2 of this study is to compare  immune responses to  BCG vaccination in 
the UK and Uganda. 
3) Aim 3 is to investigate the role of dendritic cell in Uganda in the context of 
BCG vaccination.  
4) Aim 4 is to compare DNA methylation profiles between UK and Ugandan 
infants at 10 and 52 weeks after BCG vaccination.  
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3. Differential DNA methylation of potassium channel KCa3.1 and immune 
signalling pathways is associated with infant immune responses following 
BCG vaccination. 
 
In this chapter, I explore the relationship between the immune response in BCG 
vaccinated South African infants and their DNA methylation profile. I aim to answer 
whether there is differential methylation of genes that could predict characteristics of 
immune profiles to the BCG vaccine. I also conducted this study to establish protocols 
for the DNA methylation analysis of whole blood using the RRBS assay. I used this 
study as a platform to develop a data analysis pipeline for the DNA methylation data 
analysis.  
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Summary 
 
Bacillus Calmette–Guérin (BCG) is the only licensed vaccine for tuberculosis (TB) 
and induces highly variable protection against pulmonary disease in different 
countries. We hypothesised that DNA methylation is one of the molecular 
mechanisms driving variability in BCG-induced immune responses. DNA methylation 
in peripheral blood mononuclear cells (PBMC) from BCG vaccinated infants was 
measured and comparisons made between low and high BCG-specific cytokines 
responders. We found 318 genes and 67 pathways with distinct patterns of DNA 
methylation, including immune pathways, e.g. for T cell activation, which are known 
to affect immune responses directly. We also highlight signalling pathways that could 
indirectly affect the BCG-induced immune response: potassium and calcium channel, 
muscarinic acetylcholine receptor, G Protein-coupled receptor (GPCR), glutamate 
signalling and WNT pathway. This study suggests that in addition to immune 
pathways, cellular processes could influence vaccine-induced immune responses. 
Our results highlight mechanisms that require consideration when designing new TB 
vaccines.  
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Introduction 
 
Mycobacterium bovis Bacillus Calmette–Guérin (BCG) is the only licensed vaccine 
against tuberculosis (TB). BCG protects against severe childhood cases of miliary TB 
and tuberculous meningitis 1. However, the protection afforded by the vaccine against 
pulmonary TB varies across geographical regions with studies reporting vaccine 
efficacy ranging from 0% in India 2 to 80% in the United Kingdom (UK)3. Reasons for 
these variations remain unknown. Possible explanations include comorbidities 4, pre-
exposure to environmental mycobacteria 5, and genetics 6. Previous studies in Malawi 
7, The Gambia 8, Indonesia 9 and the UK 8,10 have shown disparate immune responses 
across these populations, with a dominant production of IFNγ in the UK and higher 
production of T helper (Th) 2 cytokines in Malawi and The Gambia 10. Multiple efforts 
are being undertaken to identify correlates of protection following BCG vaccination 
11,12. The importance of IFNγ has been highlighted in numerous studies 8,13–16, 
however, the Th1 boosting candidate TB vaccine MVA85A (Modified Vaccinia virus 
Ankara expressing Ag85A from M. tuberculosis) failed to improve on protection 
afforded by BCG in vaccinated infants 17; a large South African study did not find that 
BCG specific Th1 response correlated with risk of TB disease 18; however further 
analysis of the MVA85A clinical trial showed that the frequencies of cells producing 
BCG-specific IFNγ were associated with a reduced risk of developing disease 16.  
 
Another unknown factor in the immune response to the BCG vaccine is the molecular 
mechanism that drives these immune responses. Recent studies highlight the role of 
transcriptomics 19–21 as a means of identifying the fundamental mechanisms and the 
importance of measuring RNA profiles in vaccine trials. Epigenetics, a mechanism 
known to play a role in the regulation of gene expression, is another mechanism of 
growing importance. Specifically, DNA methylation of CpG dinucleotides in mammals 
is known to regulate gene expression and subsequent protein production 22,23. In-vitro 
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methylation of herpes thymidine kinase (Tk) genes resulted in in-vivo downregulation 
of gene expression 24 and methylation of the O6-methylguanine-DNA-
methyltransferase (MGMT) gene was negatively correlated with its protein 
concentration in humans 25.  In the context of immune responses, two recent studies 
have examined the role of epigenetic regulation, gene expression and protein 
production in responses to Hepatitis B 26 and Influenza 27 vaccines. Several 
differentially methylated genes were found between low and high immune responders 
to Hep B vaccine, and DNA methylation was correlated with gene expression and 
protein levels for multiple genes following influenza vaccination. Lastly, recent 
evidence shows that DNA methylation of macrophages is associated with anti-
mycobacterial activity in BCG vaccinated participants 28. 
 
We have examined whether the DNA methylation profile of peripheral blood 
mononuclear cells (PBMC) in BCG vaccinated infants is associated with the 
magnitude of BCG specific immune responses. We found novel pathways and genes 
that were differentially methylated between high and low BCG responders amongst 
South African infants who received BCG vaccination at birth. This knowledge will 
allow us to understand molecular mechanisms that drive vaccine-induced immune 
responses, paving the way to design better and more effective TB vaccines.  
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Results 
 
Sample collection and processing 
 
We used 60 archived frozen PBMC samples from a previous study 18. 36.7% were 
female, 83.3% Cape Mixed Ancestry, 13.3% Black African and 3.3% Asian. All 
participants received the Japanese BCG vaccine at birth, and their blood was 
collected at ten weeks post vaccination. 
 
An increase in cytokine production after BCG stimulation is not correlated with cell 
phenotype.  
 
To investigate the magnitude of immune responses to the BCG vaccine, we 
measured the cytokine production after stimulation with BCG (SSI strain, 1.2 × 
106 organisms/ml) or Staphylococcus Enterotoxin B (SEB) using an intracellular 
cytokine staining (ICS) assay. We looked at cytokine responses in the PBMC 
population (see gating strategy in figure 1A). There was a consistent increase in the 
production of all cytokines after BCG stimulation and IFNγ, TNFα, IL2 but not IL8 and 
IL4/5/13 after SEB stimulation (figure 1B). We examined whether the observed 
magnitude of immune responses was due to changes in T cell frequency and 
conducted a Spearman correlation analysis of frequencies of IFNγ-expressing cells 
following BCG stimulation with other immune parameters. The frequencies of BCG-
specific IFNγ cells (hereafter called IFNγ BCG) were correlated with IL4/5/13, IL2 and 
IL8 secreted following stimulation with BCG but not with any T cell population 
measured (table S1). This indicates that in this assay, the BCG induced IFNγ 
production is not correlated with T cell and lymphocyte composition. All samples were 
stratified based on their IFNγ BCG production and 15 highest (IFNγ Low) and 15 
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lowest (IFNγ High) IFNγ BCG producers were selected for the analysis of DNA 
methylation (Figure 1C) 
 
Differential methylation of 318 genes between low and high BCG cytokine 
respondents 
 
A total of 30 samples were selected for the DNA methylation analysis (figure 1C). 
These were stratified based on their BCG specific immune responses forming low vs 
high groups for five cytokines: IFNγ; IL4/5/13; IL2; TNFα; and IL8. For each cytokine, 
DNA methylation of low responders was compared to high responders using logistic 
regression with a minimum difference in methylation of 5%. The analysis showed 
several probes to be differentially methylated between low and high groups of: IFNγ 
(70), IL4/5/13 (108), IL2 (50), TNFα (146), and IL8 (122) (figure 2). A gene feature 
report highlighted 318 genes (table 1) that span the differentially methylated probes. 
Several novel genes of which levels of methylation can indirectly affect the magnitude 
of BCG immune responses were identified. Notably, the ZFP57 gene was found to 
be differentially methylated in all cytokine low and high groups comparisons. ZFP57 
is a transcriptional regulator of gene imprinting, and it acts by controlling DNA 
methylation during the earliest stages of multicellular development 29,30. Another gene 
candidate KCa3.1 is a protein that forms the voltage-independent potassium channel 
and was found to be differentially methylated across four cytokine low and high 
groups (IFNγ, IL2, IL4/5/13 and IL8). Kca3.1 regulates calcium influx and can 
influence TH1 and TH2 development 31. We also found ERICH-1 to be differentially 
methylated across cytokine low and high groups. ERICH-1 encodes the glutamate-
rich 1 protein and glutamate is known to regulate Ca2+ and K+ efflux thereby affecting 
T cell activation 32. 
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Hierarchical cluster analysis reveals clusters of differentially methylated genes.  
 
We conducted a t-distributed stochastic neighbour embedding (tSNE) analysis of 
gene methylation for the 30 examined samples, however, this did not show a clear 
separation of IFNγ low and IFNγ high nor the other cytokine low and high groups 
(data not shown). This indicates subtle differences in DNA methylation between 
cytokine low and high groups, suggesting that there might also be other mechanisms 
that drive immune responses to the BCG vaccine. We then proceeded with the 
hierarchical cluster analysis of the differentially methylated probes when stratified by 
cytokine respondents. We saw visible differences in cluster formation for all the 
cytokine groups measured (Figure 3). 
 
Differentially methylated genes are part of immune and cellular processes pathways.  
 
We examined biological functions of the differentially methylated genes for all the 
cytokines using the Panther Pathway Analysis (PPA). Differentially methylated genes 
are included in 67 pathways that are involved in multiple biological processes 
including immune functions (2.8%), metabolic (20.8%) and cellular (25.3%) 
processes and other processes (table 2). Several pathways of the immune system 
could explain the polarisation of cytokine responses. Notably, T cell activation, 
interferon gamma signalling, interleukin and JAK/STAT signalling pathways were all 
involved in the regulation of cytokine responses. B cell activation, TGF-beta and 
chemokine and cytokine-mediated inflammation were also highlighted as pathways 
containing genes that were differentially methylated. A large proportion of highlighted 
pathways regulate cellular and metabolic processes. We found differentially 
methylated genes that are part of the G-protein signalling pathways, which are known 
to regulate T cell migration and activation 33.  We also found six differentially 
methylated genes in the Wnt pathway, which is known to regulate IL12 signalling in 
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antigen presenting cells (APCs) 34. Lastly, we highlight the muscarinic acetylcholine 
receptor signalling pathway (mAChRs), which can mediate cytokine production 35. By 
regulating the immune signalling and cellular processes, these pathways can directly 
and indirectly affect the magnitude of the BCG induced immune response that is 
observed in our samples. 
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Discussion 
 
BCG vaccination induces variable immunity across populations 36,37 translating to 
inconsistent protection against pulmonary tuberculosis 1. This study aimed to answer 
whether epigenetic modifications, specifically DNA methylation, could be one of the 
molecular mechanisms that drive the observed disparate immune responses.   
 
We first measured the magnitude of immune responses induced after the BCG 
vaccination. We chose to include all cells in the PBMC population as the DNA used 
for the methylation analysis was extracted from matching vials of PBMC. Similar to 
the previous study 18, we saw an increase in all the measured cytokines following 
BCG stimulation in vitro. The magnitude of immune responses for IFNγ ranged from 
0% to 2.61% measured as the frequency of cytokine-producing PBMCs. As expected, 
BCG and SEB stimulation decreased the expression of the CD3 protein and had no 
effect on the expression of CD4 and CD8 proteins (data not shown) and SEB, an 
inflammatory superantigen 38, failed to increase the production of TH2 cytokines and 
IL8. CD4+ and CD8+ T cells are known to be the primary producers of IFNγ 39, 
however, we saw that none of the T cell phenotypes measured correlated with levels 
of BCG induced IFNγ (table S1). This indicates that the magnitude of immune 
responses is independent of cellular T cell composition and is likely driven by 
molecular mechanisms within individual cells. Importantly, the magnitude of cytokine 
responses for BCG and SEB stimulations did not correlate (not shown), confirming 
that observed immune responses are antigen specific. The frequencies of BCG-
induced IFNγ had a strong positive correlation with IL2 and IL4/5/13 and a weak 
negative correlation with IL8. IL2 is known to activate T cells, which are one of the 
main IFNγ producers 40, and the BCG vaccine was shown to induce both TH1 and 
TH2 cytokines 7,9 previously. We cannot exclude that changes in cell numbers of 
Natural Killer (NK) cells and monocytes between groups could explain observed 
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differences in cytokine levels. This could be addressed by analysing DNA methylation 
patterns in purified cell populations, which due to a limited sample size was beyond 
the scope of the project. 
 
Having measured the immune responses and selected samples for further analysis, 
we measured DNA methylation and stratified samples by high and low cytokine 
responses. We found probes that were differentially methylated between high and 
low cytokine responders and identified the 318 corresponding genes. Interestingly, 
genes that were differentially methylated in many of the cytokine groups were 
involved in potassium, calcium and neurotransmitter signalling.  
 
KCNN4 or Kca3.1, Potassium Calcium-Activated Channel Subfamily N Member 4, 
was found to be differentially methylated in IFNγ, IL2, IL4/5/13, and IL8 high and low 
groups. The Kca3.1 channel is a voltage-independent potassium channel, which is 
activated by an increase in intracellular calcium, resulting in membrane 
hyperpolarisation and continuous calcium influx 31. Calcium regulates multiple cellular 
processes. A prolonged contact between a CD4+ T cell and an APCs increases 
intracellular Ca2+ levels. The primary sources of Ca2+ in T cells are store-operated 
calcium channels (SOCE) and calcium-release-activated calcium (CRAC) 41–44. A 
SOCE and CRAC dependent release of calcium inside CD4+ T cells changes gene 
expression, and thus cytokine production, drives the differentiation of naïve T cells to 
TH1 or TH2 cells, and the development of immature T cells 41. A strong Ca2+ signal 
favours TH1 differentiation 45 whereas weak Ca2+ release skews cells to a TH2 
phenotype 46–48. Kca3.1 can thus affect T cell activation by maintaining a negative 
membrane potential and continuing Ca2+ release via CRAC channels 31.  
 
ERICH1, which encodes the glutamate-rich 1 protein, was found to be differentially 
methylated in 4 out of 5 low and high cytokine groups. Glutamate is an excitatory 
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neurotransmitter of the nervous system, which is critical for brain development and 
function and plays a signalling role in peripheral organs, including T lymphocytes 32,49. 
It can be produced by several cells of the immune system including T cells, dendritic 
cells and others. Glutamate mediates intracellular Ca2+ fluxes and outward K+ flows 
thereby affecting adhesion, migration, proliferation, survival, activation and 
metabolism of T cells 32,49,50. Differential methylation of ERICH1 could, therefore, lead 
to varied intracellular glutamate levels affecting the immune response to the BCG 
vaccine.   
 
To look more broadly at differentially methylated genes, we investigated the array of 
pathways which contained differentially methylated genes. As expected, we found 
several immune pathways: T cell activation, JAK/STAT signalling, Interleukin 
signalling, Interferon-gamma signalling, inflammation mediated by chemokine and 
cytokine signalling, integrin signalling, TGF-beta signalling, B cell activation. All these 
pathways could contribute to the underlying differences observed in the cytokine 
response to the BCG vaccine. Interestingly, we also found a large proportion of 
pathways that were involved in metabolic and cellular processes. Several 
neurotransmitter mediating pathways were highlighted.  
 
Muscarinic acetylcholine receptor signalling pathway signals via muscarinic 
acetylcholine receptors (mAChRs), which is made up of five types (M1-M5) of class A 
G protein-coupled receptors (GPCRs) 51. Activation of T cells with PHA and PMA 
upregulates the expression of mAChRs 52,53; a stimulation via CD11a upregulates M5 
gene expression 52 suggesting an increase in cholinergic transmission following T cell 
activation; a stimulation of mAChRs in PBMC upregulated the IL2 production 35; and 
M1-M5 knockout mice produced lower levels of OVA-Specific IgG1, TNFα and IL-6 54.  
Seven genes in the GPCRs signalling pathway were differentially methylated across 
low and high cytokine groups. G proteins act as molecular switches to control 
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downstream effector molecules including chemokines and chemokine receptors 33. In 
immune cells, G proteins impact signal transduction and affect survival, proliferation, 
differentiation and cell migration, and recent evidence suggests non-canonical GPCR 
signalling in immune cells 33,55.  
 
The WNT pathway, of which six genes were differentially methylated, is known to 
influence the immune system indirectly. There are 19 WNT genes in the human 
genome, and they all encode lipid-modified secreted glycoproteins. There is 
numerous evidence that show how the WNT proteins affect the immune system: 
WNT1 and WNT4 deficient mice have impaired T and B cell development 56,57; WNT 
proteins are crucial for the initial proliferation of thymocytes before β-selection 58; the 
overexpression of WNT signalling increases the survival of CD4+CD25+ regulatory T 
cells (Tregs) 59; and WNT signalling in APCs results in  increased IL12 production and 
subsequent TH1 differentiation 34. Variation in methylation of WNT genes could, 
therefore, lead to changes in WNT proteins, ultimately leading to mediating the 
immune response to the BCG vaccine. 
 
A report by Verma et al. 28 has recently investigated the effect of BCG vaccination on 
the DNA methylation of PBMCs in vivo. They found an enrichment of the DNA 
methylation in genes of immune pathways, including T cell activation, after the BCG 
vaccine vs before vaccination. Their study shows that several non-immune pathways 
such as regulation of biological processes are enriched however these processes 
were not discussed in the report. It is essential to highlight notable differences 
between the current study and that of Verma et al. We investigated the preceding 
methylation patterns induced by BCG vaccination and how they regulate the immune 
response to BCG stimulation in infants whereas the  Verma et al. study examined 
how BCG vaccination modulates the DNA methylation of PBMCs in adults.  
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Hierarchical cluster analysis of DNA methylation revealed visible differences in cluster 
formation between high and low IFNγ groups as well as other cytokines but tSNE 
analysis failed to separate infants based on their DNA methylation patterns. 
Importantly, tSNE analysis incorporates all methylated probes whereas hierarchical 
clustering methodology focuses on probes that are differentially methylated, allowing 
for clear separation and formation of clusters. These findings suggest that DNA 
methylation is probably not the primary mechanism to regulate the immune response 
to the BCG vaccine and other epigenetic mechanisms might play a role. Histone 
modifications and microRNA are other types of epigenetic modifications that could 
explain differences in observed immune responses. Histone modifications are known 
to control the transcriptional profile of memory lymphocytes thereby shaping their 
function60. They also regulate mechanisms of adaptive features of trained immunity61. 
microRNAs have shown to play a role in the modulation of inflammatory responses62. 
  
We acknowledge that the observed differences in DNA methylation patterns may not 
be specific to the BCG vaccine responses and may, in fact, represent regulation of 
general vaccine-induced immune responses. However, it is important to highlight that 
in a context of this study, cytokine levels were measured after BCG stimulation, hence 
they are BCG specific. Thus, the differences in cytokine levels and the subsequent 
stratification to low and high cytokine responding groups is BCG specific. The DNA 
methylation differences observed between these groups are associated with BCG 
specific differences in cytokine responses, however, we cannot exclude that they may 
also be associated with immune responses to other vaccines.  
 
Taken together, the data reported here identified genes and pathways that were 
differentially methylated in PBMC from infants with high or low cytokine responses to 
BCG vaccination. As expected we observed differential methylation of multiple 
immune pathways that could directly influence the disparate immune responses to 
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the BCG vaccine. Unexpectedly, we identified several genes and pathways that could 
indirectly affect the BCG specific cytokine production. These findings suggest that in 
addition to immune pathways, vaccine-induced immune responses could be 
modulated by molecular mechanisms and mediators that regulate cellular processes 
such as the glutamate, the flux of potassium and calcium through membrane 
channels, the GPCRs and mACHRs signalling and the WNT pathway. Studies should 
focus on investigating the role of methylation as well as other epigenetic marks in the 
regulation of the genes and pathways in question as well as measuring differences in 
gene expression when stratified by high and low cytokine responses.  This knowledge 
will allow us to understand the molecular mechanisms that drive vaccine-induced 
immune responses, paving a way to design better and more effective TB vaccines. 
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Methods 
 
The datasets generated during and/or analysed during the current study are 
available from the corresponding author on reasonable request. 
 
Study participants 
 
We retrieved blood samples collected from a subset of 10 week old infants who were 
enrolled into a large study of BCG vaccination at the South African Vaccine Initiative 
(SATVI) field site in the Worcester area, near Cape Town, South Africa (Hawkridge 
et al., BMJ 2008; 18. All participants were vaccinated with BCG at birth and samples 
were collected ten weeks after birth. Participants were excluded from the study if any 
of the exclusion criteria were met: infant not immunised with BCG within 24 hours; 
mother infected with human immunodeficiency virus (HIV); chronic and acute disease 
in the infant at the time of enrolment; clinical anaemia in the infant; significant perinatal 
complications in the infant; and contact with any person with TB disease or anyone 
who was coughing. Participants were followed for two years to observe the 
development of TB disease. Only healthy infants who did not develop TB disease 
were selected for this study. Parents gave consent for their infants to participate in 
the study. The study was conducted according to the U.S. Department of Health and 
Human Services and Good Clinical Practice guidelines, and included protocol 
approval by the University of Cape Town Research Ethics Committee and written 
informed consent from the parent or legal guardian. The study also received ethical 
approval from the Ethics Committee of the London School of Hygiene and Tropical 
Medicine (LSHTM, #8720).   
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Cell separation, processing and stimulation 
 
The methods below have been previously published in other studies 18,63. Heparinized 
blood samples were collected from infants. Peripheral blood mononuclear cells were 
isolated using the density gradient centrifugation. The remaining 1 ml of blood was 
incubated with BCG (SSI, 1.2 × 106 organisms/ml), medium alone, and 
staphylococcal enterotoxin B (10 μg/ml; Sigma-Aldrich) (SEB). The co-stimulatory 
antibodies, anti-CD28 and anti-CD49d antibodies (1 μg/ml each; BD Biosciences, 
San Jose, CA) were added to all conditions. Samples were incubated for 7 hours at 
37°C. Later, Brefeldin-A was added and samples were incubated for another 5 hours. 
The role of Brefeldin-A is to capture cytokines inside the cell. The time point of 
Brefeldin-A incubation was decided in the previous study to best reflect dynamics of 
cytokine production. Red blood cells were lysed and white cells fixed using FACS 
Lysing Solution (BD Biosciences). Cells were collected, fixed and cryopreserved as 
described elsewhere 63. Thus, for each participant, non-stimulated PBMC sample and 
three stimulated and fixed whole blood samples were available. 
 
Intracellular cytokine staining  
 
Previously stimulated samples were thawed and washed in FACS buffer (PBS, 5% 
FBS v/v, 0.05% sodium azide w/v) and stained for 30 minutes at 4oC in the dark, with 
a cocktail of surface marker antibodies: CD3-BV650 (clone SK7), CD4-BV605 (clone 
S3.5), CCR7-PECF594 (clone 150503), CD45RO-APC-H7 (clone UCHL1), (all BD 
Bioscience) and CD8-BV570 (clone RPA-T8; BioLegend). Samples were then 
permeabilised using the Cytoperm/Cytofix (BD Pharmingen) solution for 20 mins. 
After permeabilisation, cells were stained for 30 minutes at room temperature in the 
dark with a cocktail of intracellular cytokine antibodies: TNFα-PE-Cy7 (clone Mab11), 
IFNγ-V450 (clone B27), IL-2-FITC (clone MQ1-17H12), (BD Bioscience), IL-4-PE 
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(clone 3010.211; FastImmune), IL-5-PE (clone TRFK5), IL-13-PE (JES10-5A2) and 
IL-8-APC (clone E8A1), (BioLegend). IL4, 5 and 13 were collected in one PE channel. 
After staining, samples were washed and stored at 4oC in the dark to be acquired 
within 24 hours using BD LSRII Flow Cytometer and obtaining a minimum of 200,00 
events.  
 
Sample selection and DNA isolation 
 
Samples were stratified based on the results of the ICS assay and the BCG specific 
IFNγ response. Corresponding PBMC samples of the 15 lowest (hereafter called IFNγ 
Low) and 15 highest IFNγ (hereafter called IFNγ High) respondents were selected for 
the DNA methylation analysis. The selected 30 samples were later stratified based 
on their IL2, IL8, IL4/5/13 and TNFα responses effectively forming five low and high 
cytokine groups. DNA was extracted using the Dneasy Blood & Tissue Kit (Qiagen). 
The quality of the DNA was checked with NanoDrop (Thermo Fisher Scientific) and 
the concentration measured with Qubit dsDNA HS Assay Kit (Thermo Fisher 
Scientific).  
 
Measurement of the DNA methylation 
 
The DNA methylation was examined using a reduced representation bisulphite 
sequencing (RRBS) method and with the Premium Reduced Representation 
Bisulphite Sequencing Kit (Diagenode) according to manufacturer’s instructions.  
 
DNA quality control and MiSeq sequencing 
 
DNA concentration was measured using the Qubit dsDNA HS Assay Kit and size 
examined with the High Sensitivity DNA Analysis Kit (Genomics Agilent) using 
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Bioanalyzer 2100 (Genomics Agilent). DNA was denatured with 0.2M NaOH, and its 
concentration was adjusted to 16 pM. Samples were sequenced with the MiSeq 
Reagent Kit v3 (Illumina) at 51 cycles per run and single-end reads. A 12.5 pM PhiX 
v3 library (Illumina) was added for positive control.   
 
Data processing 
 
FASTA files were generated as the DNA sequencing output. Sequences were 
trimmed using the TrimGalore (v0.4.3) and Cutadapt software discarding all reads 
below 30 Phred quality score. The quality of samples was measured using the 
FastQC software (v0.11.5). A bisulphite treated human genome reference sequence 
was prepared using the GrCh38p7 assembly and Bismark Genome Preparation 
(v0.16.3) and Bowtie2 (v2.2.9) software. Samples were mapped to the reference 
genome using Bismark (v0.16.3) and Bowtie2. The DNA methylation was extracted 
using Bismark Methylation Extractor (v0.16.3).  
 
Data analysis: DNA methylation 
 
The methylation of DNA sequences was analysed using SeqMonk (v1.38.2) and 
Rstudio (1.0.44) software. Contig methylation probes were generated with a 10-fold 
depth cut off, ignoring duplicate reads and merging probes closer than 500bp. Probes 
were quantified using read count quantitation and filtered to include probes measured 
at least ten times. Chromosomes X, Y and any mitochondrial DNA were removed, 
and probes were quantitated using bisulphite methylation pipeline embedded in the 
SeqMonk software. Based on the previous ICS responses of whole blood samples, 
DNA samples were then separated into two groups: IFNγ low & IFNγ high and logistic 
regression with a P-value cut-off of 0.05 and multiple testing correction was run. The 
logistic regression test was then performed on other cytokine groups: IL4/5/13 low & 
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IL4/5/13 high; IL2 low & IL2 high; TNFα low & TNFα high; and IL8 low and IL8 high. 
Genes that were differentially methylated were visualised using SeqMonk, Panther 
Pathway Analysis and Cytospace (v3.5.1).  
 
Data analysis: correlation of immune responses 
 
We used StataSE (v15.0) software to measure whether the magnitude of the BCG 
induced immune response is cell population dependent. Frequencies of BCG specific 
cytokines (TNFα, IFNγ, IL2, IL8 and IL4/5/13) and cell phenotypes 
(CD3+CD4+CCR7+, CD3+CD4+CD45RO+, CD3+, CD3+CD4+, CD3+CD8+, % of 
Lymphocytes) were correlated with the BCG specific IFNγ response using the 
Spearman correlation. 
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Figure 1. The immune response to the BCG vaccine was used to select samples for analysis. 
A) The FACS gating strategy used to measure all immune responses. Singlet cells and CD3+ 
populations were chosen to measure intracellular cytokine responses as well as phenotypic 
markers such as CD3+, CD3+CD4+, CD3+CD8+, CD3+CD4+CCR7+, CD3+CD4+CD45RO+. 
B) The magnitude of immune responses of PBMCs after 12 hours stimulation with BCG and 
SEB (% of PBMCs). Each column represents one donor sample. Stimulated samples were 
compared to non-stimulated with the Wilcoxon paired t-test. N=60; ns=not significant; *= p< 
0.05; ****= p<0.0001 C) A magnitude of IFNγ BCG responses when stratified by origin (CD3+ 
population). Fifteen lowest (non-responders) and fifteen highest (responders) IFNγ BCG 
producers (red) were selected for the DNA methylation analysis. Samples coloured in grey 
were not selected. N=60 
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Figure 2. A scatter plot of all probes of 
which methylation was compared between 
a high and low cytokine responder group. 
Each dot represents a probe of which % 
methylation is measured in a high cytokine 
group (X-axis) and low cytokine group (Y-
axis). Red dots represent probes which are 
significantly differentially methylated. BCG 
specific low and high cytokine groups that 
were compared included: IFNγ (A), IL2 (B), 
IL8 (C), IL4/5/13 (D), and TNFα (E). 
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Figure 3. A hierarchical per probe normalised clustering analysis of the DNA methylation 
profile between high and low IFNγ (A), IL2 (B), IL8 (C), IL4/5/13 (D) and TNFα (E) responder 
groups. First fifteen columns represent methylation of probes in cytokine high responder group 
and last fifteen columns represent methylation of probes in the low responder group. Each 
horizontal line represents a differentially methylated probe. The scale represents the 
percentage of methylation of each probe. The white colour represents low DNA methylation 
whereas the red colour represents high DNA methylation. n=30. 
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Tables  
 
Table 1: A summary of all genes that were differentially methylated across all low and high cytokine groups. Each row shows single or multiple genes that were 
differentially methylated across one or multiple cytokine groups. n=30 
 
Name of Cytokine Pairs 
Total 
Number of 
Differentially 
Methylated 
Genes 
Names of Genes 
IFNγ IL2 IL4/5/13 IL8 TNFα 1 ZFP57 
IFNγ   IL2 IL4/5/13 IL8 2 PTPRN2 KCNN4 
IFNγ   IL2 IL4/5/13 TNFα 4 ERICH1 GPR124 RP5-1029F21.3 COLEC11 
IL2 IL4/5/13 IL8 TNFα 2 CTC-281F24.1 MIR4520-1 
IFNγ   IL2 IL4/5/13 5 RP11-609L3.1 ZMIZ1 AURKC NEURL1B SEPT7P3 
IFNγ   IL2 TNFα 1 DNAH1 
IFNγ   IL4/5/13 IL8 1 AZU1 
IFNγ IL4/5/13 TNFα 3 LMTK3 LY6K ANO8 
IL2 IL8 TNFα 1 CRYGEP 
IL2 IL4/5/13 TNFα 1 DTX1 
IL4/5/13 IL8 TNFα 2 EHBP1L1 SIPA1 
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IFNγ   IL2 2 PRSS36 MVB12B 
IFNγ   IL8 1 GCSAML 
IFNγ   IL4/5/13 
 
17 TTN DEAF1 CARS2 RP11-108K14.12 HELZ2 RGS3 COL1A1 MTHFR GRK1 DUSP15 CYP2E1 FIP1L1 LPIN1 
TTN-AS1 C1orf167 FBXO41 CMTM7 
IFNγ   TNFα 1 LINC00539 
IL2 IL8 1 HCN2 
IL2 IL4/5/13 3 PDIA3P2 CATSPER2 KCNAB1 
IL2 TNFα 2 PROSER3 MAN1C1 
IL8 TNFα 3 CUX1 PLEC SLC43A2 
IL4/5/13 TNFα 9 PKNOX2 HNRNPH1 AC010907.2 RP11-687M24.8 MAST4 LHX6 ADARB2 AC096649.3 NLGN2 
IFNγ 
 
13 MED15P5 NTM CTD-3080P12.3 PIAS4 SPG7 TIMP2 CAMSAP3 SOGA3 CD9 MALRD1 PXDN NTNG2 RP11-
599J14.2 
IL2 15 RP4-724E13.2 TGFBR3 RP11-452L6.8 COX6A2 CARD11 NINJ2 SNRPN MAP1LC3BP1 RP11-218M22.1 
C20orf96 ANK1 FANCC MEGF6 RP4-559A3.7 LEFTY1 
IL8 
 
 
 
 
 
 
 
 
 
 
 
 
88 RN7SL646P FAM222B ZFP41 PBX4 LINC01169 KCNQ1OT1 TRPV2 EDARADD UMODL1-AS1 DTNB bP-
21264C1.2 RP11-216L13.18 KIAA1161 CDH23 ZNF473 LINC01266 COL23A1 AC011850.2 FLJ26850 RP11-
394I13.3 LINC00467 SOX10 MSL3P1 AC018688.1 HIST1H3E FAM217B 5_8S_rRNA RNMTL1 RAI1 RELT 
LRRC24 NFATC1 UNC93B1 ZNF790-AS1 EMC9 ITPR1 POU5F1 EGOT UMODL1 MIR4508 AC005481.5 
VOPP1 AC005538.3 ATP8B3 POLR2F MIR6820 SDK1 MIR138-2 FRRS1 MIR6813 WDR60 COL5A1 CTD-
2126E3.3 THSD4 OPCML TMPRSS12 RABL6 RP11-133L14.5 PROSER2-AS1 PIK3R2 PRSS21 RYR1 
CLEC9A CTD-2269E23.4 MAN2B1 ARHGEF10 GLI4 RP11-497G19.1 ATG16L2 LZTS3 WDR20 SH3GL1 
EXD3 AMOTL2 LRRC14 MROH1 CTD-2192J16.22 TARID CFD TNFRSF11A MMP17 RGS19 KCNQ1 
C8orf82 RNF165 LOXL1 LINC01312 SYCP2 
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IL4/5/13 41 TPM4P1 GNAL AC131097.4 RP11-244F12.1 RP11-867G23.12 NBPF13P RNVU1-8 RIMBP2 LINC01237 
ZNF718 RP11-680G24.4 TAF1C TBCE PHACTR3 RP11-662M24.2 RP11-452D2.2 RP11-545A16.3 HLA-
DRB9 PRDM15 KCNN3 PRDM16 DRAXIN ARID3A SNRNP27 COL18A1 RP11-1260E13.1 RPH3AL RP3-
522J7.6 AP001347.6 LRRC37A6P PRDM7 MYBPC2 PNPLA6 AC147651.1 PDXDC1 SRC NYAP2 
ADAMTS12 ANKRD20A18P C5orf17 RIN1 
TNFα 
 
98 GABRB3 MKRN3 PRKAR1B PAX8-AS1 FAM189A1 RNA5-8S5 ACOT2 WT1 ACVR1B LINC00839 AOX3P 
PRDM8 LDLRAD2 CHCHD3 FBXO16 PEBP4 MARK4 CTU1 HLA-DPA1 ATP5J2 RPL13A MEST RASAL2 
PRAM1 PRKCQ GNAI2 RP11-127L20.3 RP11-726G23.10 BRSK1 BCAN CROCC GABRA5 LINC00887 
PTCD1 SDF4 FNDC3B RPL13P12 CYGB NCOR2 CLIP2 GALNT9 BCR AOX2P OPRL1 RP11-377G16.2 
FLT3LG CTD-3148I10.9 CPT1A RP11-54O7.17 RPS6KA4 RP11-284F21.7 PIGQ RP11-492E3.2 PRCD 
AC093609.1 HLA-DPB1 SEMA6B CH507-513H4.1 UHRF1 CTD-3148I10.15 SEMA3B ZNF331 GEMIN7 
MPPED1 ERICH1-AS1 RP5-906A24.1 PPAPDC3 MGRN1 ZNF395 FLT4 ITPRIP RP11-426C22.5 KAZN 
MST1L PSPN ITFG2 ARL5C RP11-137H2.4 FBXW4P1 PAX8 ALKBH7 C17orf98 RBM19 NOS3 CCNYL2 
RP11-273G15.2 HTRA4 RP11-231D20.2 RP11-65I12.1 SCARF1 ITGAX RP11-230C9.1 PPP1R37 RP11-
56P9.10 OSBPL5 ATP5J2-PTCD1 CBFA2T3 PLEKHA2 
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Table 2: An overview of biological processes and selected pathways of the differentially 
methylated genes when stratified by low and high cytokine groups. Each row shows a 
biological process or a pathway and a number of differentially methylated genes associated 
with it.  
 
Biological Processes Of Differentially Methylated Genes 
Name of the Biological 
Process 
Number of Genes Involved % of Total Genes 
Cellular Process 80 25.3 
Metabolic Process 66 20.8 
Response To Stimulus 34 10.8 
Biological Regulation 30 9.4 
Developmental Process 30 9.4 
Multicellular Organismal 
Process 
25 7.8 
Localization 18 5.6 
Cellular Component 
Organization Or Biogenesis 
13 4.2 
Immune System Process 9 2.8 
Biological Adhesion 6 1.9 
Locomotion 4 1.1 
Reproduction 3 0.8 
 
Highlighted Pathways of Differentially Methylated Genes 
Pathway Name Number of Genes Involved % of Total Genes 
Heterotrimeric G-Protein 
Signaling Pathway-Gi Alpha 
And Gs Alpha Mediated 
Pathway 
7 4.2 
Integrin Signaling Pathway 6 3.6 
Heterotrimeric G-Protein 
Signaling Pathway-Gq Alpha 
And Go Alpha Mediated 
Pathway 
6 3.6 
Wnt Signalling Pathway 6 3.6 
T Cell Activation 5 3.0 
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Inflammation Mediated By 
Chemokine And Cytokine 
Signaling Pathway 
3 1.8 
Muscarinic Acetylcholine 
Receptor 1 And 3 Signaling 
Pathway 
3 1.8 
 
Table S1: The Spearman correlation analysis of IFNγ BCG levels with immune parameters. 
There is a strong correlation between IFNγ BCG and IL/4/5/13 BCG, IL2 BCG and a weak 
correlation with IL8 BCG. No other parameters were correlated with IFNγ BCG. n=60. 
 
Immune Parameter Correlation "R" P value 
IFNγ  BCG 1.00 0.0000 
IL4/5/13 BCG 0.53 0.0000 
IL2 BCG 0.53 0.0000 
IL8 BCG -0.28 0.0313 
CD3+CD4+CCR7+ -0.24 0.0614 
CD3+CD4+CD45RO+ 0.22 0.0959 
TNFα BCG 0.21 0.1042 
CD3+ 0.11 0.3999 
% of Lymphocytes 0.10 0.4340 
CD3+CD4+ 0.09 0.4867 
CD3+CD8+ 0.05 0.7093 
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Table S2: An overview of all pathways of the differentially methylated genes when stratified 
by low and high cytokine response. Each row shows a biological process or a pathway and a 
number of differentially methylated genes associated with it. 
 
Pathway Genes Involved % of Total 
Axon guidance mediated by netrin (P00009) 2 1.20% 
Beta3 adrenergic receptor signalling pathway (P04379) 1 0.60% 
Axon guidance mediated by Slit/Robo (P00008) 1 0.60% 
Metabotropic glutamate receptor group III pathway (P00039) 2 1.20% 
Beta2 adrenergic receptor signalling pathway (P04378) 2 1.20% 
JAK/STAT signalling pathway (P00038) 1 0.60% 
Beta1 adrenergic receptor signalling pathway (P04377) 2 1.20% 
Apoptosis signalling pathway (P00006) 3 1.80% 
5HT4 type receptor-mediated signalling pathway (P04376) 1 0.60% 
Angiogenesis (P00005) 7 4.20% 
Interleukin signalling pathway (P00036) 1 0.60% 
Alzheimer disease-presenting pathway (P00004) 1 0.60% 
Interferon-gamma signalling pathway (P00035) 1 0.60% 
5HT2 type receptor-mediated signalling pathway (P04374) 2 1.20% 
Alzheimer disease-amyloid secretase pathway (P00003) 2 1.20% 
Integrin signalling pathway (P00034) 6 3.60% 
5HT1 type receptor-mediated signalling pathway (P04373) 1 0.60% 
Alpha-adrenergic receptor signalling pathway (P00002) 2 1.20% 
Insulin/IGF pathway-protein kinase B signalling cascade 
(P00033) 
1 0.60% 
Insulin/IGF pathway-mitogen activated protein kinase/MAP 
kinase cascade (P00032) 
1 0.60% 
Inflammation mediated by chemokine and cytokine signalling 
pathway (P00031) 
3 1.80% 
Hypoxia response via HIF activation (P00030) 1 0.60% 
GABA-B receptor II signalling (P05731) 1 0.60% 
Huntington disease (P00029) 2 1.20% 
Heterotrimeric G-protein signalling pathway-rod outer 
segment phototransduction (P00028) 
1 0.60% 
p53 pathway (P00059) 1 0.60% 
p53 pathway feedback loops 2 (P04398) 1 0.60% 
Heterotrimeric G-protein signalling pathway-Gq alpha and 
Go alpha-mediated pathway (P00027)  
6 3.60% 
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Heterotrimeric G-protein signalling pathway-Gi alpha and Gs 
alpha-mediated pathway (P00026)  
7 4.20% 
Wnt signalling pathway (P00057) 6 3.60% 
Hedgehog signalling pathway (P00025) 1 0.60% 
VEGF signalling pathway (P00056) 5 3.00% 
Allantoin degradation (P02725) 1 0.60% 
Transcription regulation by bZIP transcription factor 
(P00055) 
3 1.80% 
Thyrotropin-releasing hormone receptor signalling pathway 
(P04394) 
2 1.20% 
General transcription regulation (P00023) 2 1.20% 
Ras Pathway (P04393) 1 0.60% 
General transcription by RNA polymerase I (P00022) 1 0.60% 
T cell activation (P00053) 5 3.00% 
FGF signalling pathway (P00021) 3 1.80% 
TGF-beta signalling pathway (P00052) 3 1.80% 
Oxytocin receptor mediated signalling pathway (P04391) 2 1.20% 
Endothelin signalling pathway (P00019) 7 4.20% 
EGF receptor signalling pathway (P00018) 4 2.40% 
p38 MAPK pathway (P05918) 1 0.60% 
Parkinson disease (P00049) 1 0.60% 
PI3 kinase pathway (P00048) 3 1.80% 
Opioid proopiomelanocortin pathway (P05917) 1 0.60% 
PDGF signalling pathway (P00047) 4 2.40% 
Opioid prodynorphin pathway (P05916) 1 0.60% 
Histamine H2 receptor mediated signalling pathway 
(P04386) 
1 0.60% 
Oxidative stress response (P00046) 2 1.20% 
Opioid proenkephalin pathway (P05915) 1 0.60% 
Histamine H1 receptor mediated signalling pathway 
(P04385) 
3 1.80% 
Notch signalling pathway (P00045) 1 0.60% 
Cadherin signalling pathway (P00012) 2 1.20% 
Enkephalin release (P05913) 2 1.20% 
Muscarinic acetylcholine receptor 2 and 4 signalling pathway 
(P00043) 
2 1.20% 
Dopamine receptor mediated signalling pathway (P05912) 1 0.60% 
Muscarinic acetylcholine receptor 1 and 3 signalling pathway 
(P00042) 
3 1.80% 
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B cell activation (P00010) 3 1.80% 
Angiotensin II-stimulated signalling through G proteins and 
beta-arrestin (P05911) 
1 0.60% 
Metabotropic glutamate receptor group I pathway (P00041) 2 1.20% 
Cortocotropin releasing factor receptor signalling pathway 
(P04380) 
1 0.60% 
Metabotropic glutamate receptor group II pathway (P00040) 2 1.20% 
CCKR signalling map (P06959) 6 3.60% 
Gonadotropin-releasing hormone receptor pathway 
(P06664) 
12 7.30% 
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4. Terminally differentiated T cells and inflammatory cytokines define the 
immunogenicity profile of Ugandan compared to UK infants following BCG 
vaccination.  
 
In this chapter I compare the immune response to the BCG vaccine in UK and 
Ugandan infants. I aim to answer whether Ugandan infants have a different BCG-
induced immune profiles to their UK peers. I also investigate T cell phenotypes and 
explain how they could influence the observed differences in BCG immunogenicity.  
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Abstract 
 
Introduction: Bacillus Calmette–Guérin (BCG) is the only licensed vaccine for 
tuberculosis (TB), and its efficacy against pulmonary TB is lower in countries closer 
to the equator. Previous studies have investigated the immune signature of BCG 
vaccinated infants in  UK, Malawian and  Gambian infants. They found a predominant 
T helper 1-like  (TH1) immune response in the UK and TH2 responses in Malawi and 
The Gambia. However, the cellular phenotypes in these populations have not been 
studied.  
 
Methods: We investigated cytokines responses in  BCG vaccinated, UK and Ugandan 
infants using a six-day whole blood stimulation assay. We also investigated 
phenotypes of T cells and their cytokine production across these populations. Lastly, 
we employed novel flow cytometry data analysis techniques to find rare cell 
populations and describe their dynamics in the UK and Uganda.  
 
Results: We report that Ugandan infants produce higher levels of IL1b and TNFa 
cytokines compared to UK infants. This might be mediated by a higher proportion of 
terminally differentiated T cells, and a lower proportion of naïve T cells at 52 weeks 
in Uganda. We report no differences in TH1 cytokines when measured using the 
whole blood assay, and moderately higher frequencies of IFNg or IL2 producing CD4 
or CD8 T cells at 52 weeks in the UK.   
 
Implications: These results reveal that  Ugandan infants have a different 
immunogenicity profile following BCG vaccination when compared with previous 
findings in Malawian and Gambian infants. We highlight the role of these immune 
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differences in the mediation of BCG immunogenicity and their potential impact on 
efficacy.  
 
Introduction  
 
Despite continuous research efforts, the burden of tuberculosis (TB) remains high 
with  10.4 million people falling ill with TB in 2016 alone1. The disease 
disproportionately affects low-income countries, especially in Africa, where 82% of 
TB related deaths occurred1. Mycobacterium bovis Bacillus Calmette–Guérin (BCG) 
is the only licensed vaccine for TB. Efficacy studies show that BCG protects well 
against severe childhood cases of TB meningitis and tuberculous miliary2. However, 
the protection against pulmonary TB varies across the globe and studies reported 
efficacy ranging from 0% in India3 to 80% in the United Kingdom4 (UK). Numerous 
reasons have been proposed to explain these variations. They include co-infections 
with malaria or helminthic parasites5; pre-exposure to environmental mycobacteria, 
including non-tuberculous mycobacteria6; and genetics7. Interferon γ (IFNγ) and T 
helper 1 (TH1) immune responses have been highlighted as paramount in an 
effective immune response against TB8, however, a South African study found no 
evidence for an association between TH1 responses following BCG vaccination and 
reduced risk of pulmonary TB9. A recent vaccine candidate  MVA85A (Modified 
Vaccinia virus Ankara expressing Ag85A from M. tuberculosis) that boosts TH1 
responses failed to demonstrate efficacy in BCG vaccinated infants10; however, in 
contrast to the study mentioned above8, the frequencies of BCG-specific IFNγ-
producing cells correlated with a reduced risk of developing TB11. The levels of IFNγ, 
TH1, TH2, TH17 and other cytokines were investigated in studies in Malawi12, The 
Gambia13, Indonesia14 and the UK12,13. A comparative analysis of immune responses 
following BCG vaccination of infants in Malawi and the UK revealed differences in 27 
out of 42 cytokines, chemokines and growth factors measured in PPD-stimulated, 
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diluted whole blood. UK infants had more prominent type 1 responses with a high  
IFNγ production, whereas Malawian infants had a type-2 and regulatory immune 
profile with higher IL13 and IL10 production12. The differences in immune responses 
could help to explain observed variations in BCG efficacy between these countries.  
 
To fully understand the mechanisms underpinning BCG efficacy, we need to 
characterise further the underlying BCG-specific immune responses in countries 
where efficacy varies. In Malawi and The Gambia, we measured whole blood cytokine 
concentrations but were unable to investigate cell populations that produce them. In 
this study, we investigated BCG-induced immune responses in the UK and Uganda, 
a country where BCG efficacy is predicted to be low due to its equatorial latitude.  We 
conducted a comparative analysis of diluted whole blood cytokine concentrations 
following antigen stimulation, T cell phenotypes and frequencies of cytokine-
producing T-cells between BCG vaccinated infants residing in these two countries. 
We hypothesise that, as in Malawi, Ugandan infants would have a disparate profile 
of immune responses with a dominating type-2 and regulatory phenotype compared 
to stronger type-1 immune responses in  UK infants.  
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Methods 
 
Ethical approval and informed consent 
 
Only infants whose mothers gave written, informed consent for participation were 
included in the study. This project was approved by the NRES Committee London – 
Camden & Islington (#15/LO/0048), the Research Ethics Committee of the London 
School of Hygiene and Tropical Medicine (LSHTM) (#8720), the Uganda National 
Council for Science and Technology (UNCST) (#HS1526), and the Uganda Virus 
Research Institute (UVRI) Research and Ethics Committee (#GC/127/14/02/432).  
 
Study design and sample collection in Uganda 
 
This was a nested study within a large cohort study aimed at examining the effect of 
maternal LTBI on infants’ BCG immune responses. Mothers and their infants were 
included in this study if they delivered in Entebbe General Hospital; resided in 
Entebbe Municipality and Katabi sub-county, Wakiso district, Uganda; were HIV 
negative; and had a singleton pregnancy with a healthy delivery of a neonate above 
2500g. Infant cord blood was taken at delivery and screened for LTBI one week after 
birth. T-SPOT.TB assay (Oxford Immunotec) and a tuberculin skin test (TST; 2 
tuberculin units, Statens Serum Institut) were used to detect LTBI. Mothers were 
considered LTBI positive when both tests were positive, and LTBI negative when both 
tests were negative. Mothers with discordant assay results were excluded from the 
study. If TB disease was suspected, mothers were referred for treatment. All infants 
were BCG vaccinated at birth with BCG SSI strain. Up to 5ml of heparinised 
peripheral venous blood and up to 10ml of cord blood was obtained from each infant. 
In the larger study, infants gave blood at 0, 1, 4, 6, 10, 14, 24 and 52 weeks but due 
to multiple blood draws, infants were randomised to give blood at either 1 and 6 
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weeks, or 4 and 10 weeks, and all gave blood at 0 and 52 weeks. For this study, and 
to allow comparison with UK responses, only samples at 10 and 52 weeks were used. 
Overall, 313 Ugandan samples were used in this analysis (108 samples at 10 weeks 
and 205 samples at 52 weeks, out of which 82 samples were paired). Due to limited 
blood volume at sample collection, not all infant samples were available for all 
analyses.  
 
Study design and sample collection in the United Kingdom 
 
Infants were included in the study if their mothers had a singleton pregnancy in North 
Middlesex Hospital, London, United Kingdom; had an uncomplicated delivery of a 
neonate above 2500g; and were LTBI negative as determined by T-SPOT.TB assay 
(Oxford Immunotec). All infants were BCG vaccinated at birth or within the first week 
of life with BCG SSI strain. Up to 5ml of heparinised peripheral venous blood was 
collected from each infant at 10 and 52 weeks of age. We collected samples from 28 
infants at 10 weeks of age and collected follow-up samples from 12 of these infants 
at 52 weeks of age. Due to limited blood volume at sample collection, not all infant 
samples were available for all analyses. 
 
EBV and CMV viral DNA detection from whole blood using droplet digital PCR 
(ddPCR) assay 
 
DNA was extracted from 200µl whole blood using the QIAamp DNA Blood Mini Kit 
(Qiagen, Hilden, Germany) in 100µl elution buffer and according to manufacturer’s 
guidelines. The ddPCR reaction mix included probe mixture (final concentration 250 
nM) for EBV and CMV (table S1), 10 µl ddPCR™ Supermix for Probes (Bio-Rad 
Laboratories, Hercules, USA), 10 µl of template DNA, and 1.1 µl of 20 x primers (final 
concentration 900nM). 20 µl of the mixture was partitioned in oil-in-water with 70 µl of 
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droplet generator oil using a QX-100 droplet generator (Bio-Rad). The generated 
droplets (around 40 µl) were then heated for 5 sec at 170 °C using a PX1™ PCR 
Plate Sealer (Bio-rad). PCR amplification was performed with the following thermal 
cycling: 95 °C for 10 min, 40 cycles consisting of 94 °C for 30 sec (denaturation) and 
60 °C for 1 min (extension), followed by 98°C for 10 min and holding at 12 °C. Droplets 
were analyzed using a QX100 droplet reader (Bio-rad) and the target DNA 
concentration was calculated using QuantaSoft software (Bio-Rad). All samples were 
tested in duplicate. 
 
Immune cell phenotyping and flow cytometry 
 
Standard operating procedures (SOPs) were shared between the UK and Uganda, 
and an assay harmonisation exercise involving members of both teams took place in 
Uganda. Reagents from the same manufacturers were used.  Heparinised whole 
blood was diluted 1:3 with  RPMI 1640 (Life Technology, #21875-091) supplemented 
with a mixture of penicillin and streptomycin (Sigma, P4458) (final concentration of 
penicillin 5 units/ml, final concentration of streptomycin 50µg/ml) and L-glutamine 
(Sigma, #59202C) (final concentration 2mM). Diluted blood was aliquoted, and 
samples were stimulated with PPD (Tuberculin PPD-SSI batch RT 50) (final 
concentration 10µg/ml) and PHA (Sigma, #L8902) (final concentration 10µg/ml). An 
unstimulated sample was also included. GolgiPlug with brefeldin A (BD, #512301KZ), 
anti-CD28 (BD, #555726) and anti-CD49d (BD, #340976) were added to all samples 
at 1µl each. Samples were incubated with loose lids at 37°C in 5% CO2 for 24 hours. 
After incubation, red blood cells were lysed with  1x BDPharmLyse (BD, #555899) for 
10 minutes in the dark. Samples were centrifuged at 400g for 5 minutes and washed 
in 2ml of PBS. After another centrifugation (400g, 5 minutes), samples were stained 
with a viability dye (LIVE/DEAD™ Fixable Aqua Dead Cell Stain Kit, L34957) for 20 
minutes in the dark at 4°C; washed with FACS buffer (1XPBS, 5% FBS, 0.05% 
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Sodium Azide) and stained with FcR blocking antibody (14-9161-73, eBiosciences) 
for 10 minutes in the dark at 4°C. Samples were washed with FACS buffer and stained 
with a mixture of surface stain antibodies: CD3 BV650 (BD, #563999, clone SK7), 
CD4 BV605 (Life Technology, #562658, clone S3.5), CD8 BV570 (Biolegend, 
#301038, clone RPA-T8), CCR7 PECF594 (BD Horizon, #562382, clone 120503), 
CD45RO APC-H7 (BD Pharmingen, #561137, clone UCHL1) for 30 mins at 4°C in 
the dark. After incubation, samples were washed with FACS buffer and permeabilised 
using 200µl of Cytoperm/Cytofix (BD Pharmingen, #554722) for 20 minutes at room 
temperature in the dark. After permeabilisation, samples were washed with  1x 
BDPerm wash buffer (BD, #554723). Samples were stained with a cocktail of 
intracellular antibodies: IFNγ V450 (BD, #560371, clone B27), TNFα Pe-Cy7 
(eBioscience, #557647, clone Mab11), IL2 FITC (BD Pharmingen, #554565, clone 
MQ1-17H12), IL4 PE (BD FastImmune, #340451, clone 3010.211), IL5 PE 
(Biolegend, #504304, clone TRFK5), IL13 PE (Biolegend, #501903, clone JES10-
5A2), and IL8 APC (Biolegend, #511410, clone E8N1) for 30 minutes at room 
temperature in the dark. After staining, samples were washed with perm wash buffer 
and stored at 4oC in the dark in PBS with 1% paraformaldehyde (PFA) to be acquired 
within 24 hours using a BD LSRII Flow Cytometer and acquiring a minimum of 
100,000 events. 
 
Whole blood stimulation and Luminex assay 
 
Heparinised whole blood was diluted 1:4 in RPMI 1640 (Life Technology, #21875-
091) supplemented with a mixture of penicillin and streptomycin (Sigma, P4458) 
(1:100, v:v) and L-glutamine (Sigma, #59202C) (1:100, v:v). 200 µl of diluted whole 
blood was stimulated in duplicate with PPD (Tuberculin PPD-SSI batch RT 50) (final 
concentration 10µg/ml) and  PHA (Sigma, #L8902) (final concentration 10µg/ml). An 
unstimulated sample was also included. Samples were incubated at 37ᵒC in 5% CO2 
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for six days. After incubation, supernatants were collected, and a viral incubation 
buffer (1:188 TNBP, Sigma Aldrich T4908; 1:100 Tween 80, Sigma Aldrich P-1754; 
RPMI 1640, Life Technology #21875-091 supplemented with a mixture of penicillin 
and streptomycin, Sigma, P4458, final concentration of penicillin 5 units/ml, final 
concentration of streptomycin 50µg/ml, and L-glutamine, Sigma, #59202C, final 
concentration 2mM) was added to each sample for 30 minutes. Samples were stored 
at -80°C until analysis. Reference samples were included at both sites to ensure data 
compatibility. Cytokine concentrations were measured using Bio-Plex ProTM Human 
Cytokine 17-plex (GM-CSF, IFNg, IL12p40, IL13, IL17A, IL1a, IL1b, IL1RA, IL2, IL5, 
IL8, IP10, MCP1, MIP1a, MIP1b, TNFa) Assay (Bio-Rad, #m5000031yv) according 
to manufacturer’s instructions. Samples were acquired using Bio-Rad Luminex 
reader.  
 
Data analysis Luminex and Flow cytometry assays 
 
For the Luminex assay, extrapolated and out of range values were assigned  1.6 
pg/ml at the low end of the scale (half the bottom standard concentration) and 11000 
pg/ml at the upper end of the scale. Background values measured in unstimulated 
samples were subtracted from concentrations of stimulated samples. If concentration 
values were less than 1.6 pg/ml, 1.6 pg/ml was assigned.  
 
In the flow cytometry assay, cells were gated for T cell phenotype. Live, singlet, CD3+ 
lymphocytes were included. Within that population T cell phenotypic markers (CD4, 
CD8, CCR7, CD45RO) and intracellular cytokines (IFNγ, IL2, TNFα, IL4/5/13, and 
IL8) were measured. We investigated phenotypes of CD4+, CD4 Naïve 
(CD4+CCR7+CD45RO-), CD4 central memory (CM, CD4+CCR7+CD45RO+), CD4 
effector memory (EM, CD4+CCR7-CD45RO), CD4 terminally differentiated (TD, 
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CD4+CCR7-CD45RO-), total CD8+, CD8 Naïve (CD8+CCR7+CD45RO-), CD8 CM 
(CD8+CCR7+CD45RO+), CD8 EM (CD8+CCR7-CD45R) and CD8 TD (CD8+CCR7-
CD45RO-). The full gating strategy is described in figure S1. For cytokine responses, 
values measured in unstimulated samples were subtracted from those measured in 
stimulated ones, and negative values were assigned 0. Only unstimulated samples 
were selected to measure changes in phenotypes. In Uganda, 94/111 samples were 
stained for IL8 as IL8 staining was introduced later into the assay.  
 
Data analysis viSNE and SPADE algorithms 
 
The “downsample” plugin available in FlowJo was used to select 1000 most 
representative cells per sample of the lymphocyte gate. Downsampled events were 
concatenated and the t Stochastic Neighbour Embedding (tSNE) algorithm was used 
to reduce data dimensionality with the following parameters: perplexity 40; iterations 
1000, Eta learning rate 200 and Theta 0.5. Samples were loaded to Cytobank 
(www.cytobank.org), where Spanning-tree Progression Analysis of Density-
normalized Events (SPADE) was used to identify distinct cell clusters from previously 
calculated tSNE parameters.  The viSNE algorithm was used to analyse phenotypes 
of T cells.   
 
The viSNE algorithm distributed cells based on the expression of markers (CD4, CD8, 
CD45RO, CCR7, IFNγ, IL2, TNFα, IL4/5/13, and IL8) and the SPADE algorithm 
identified 50 distinct T cell clusters. Clusters are defined as groups of cells with similar 
phenotypes. Cluster size is defined as the number of cells within a cluster. Cluster 
size can change in response to a stimulant, sample characteristics, time etc. These 
clusters were overlayed onto a viSNE plot, and cell ontology was assigned based on 
marker expression within each cluster. Samples were chosen randomly for viSNE 
analysis. The number of samples for viSNE plots must be equal across conditions. 
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As the maximum available number of samples was 12 at 52 weeks in the UK, we had 
to select 12 samples at each time point in each country. Due to technical limitations 
(UK and Ugandan samples were acquired at different sites) viSNE and SPADE 
analyses were calculated independently for each country, and thus viSNE plots and 
ontology differ.    
 
Statistical analysis 
 
To test whether sample characteristics differed across countries the Mann-Whitney 
test was used for continuous variables (mother’s median age and birth weight) and 
the Chi-square test for categorical variables (the proportion of tuberculosis infected 
mothers, the proportion of CMV infected infants, the proportion of EBV infected 
infants). Cytokine concentrations and T cell phenotypes measured by Luminex or flow 
cytometry were compared between countries using linear regression adjusting for 
mother’s age; and between time points using the Mann-Whitney test. Some samples 
were paired and to avoid type 1 error they were checked for correlation of cytokine 
concentrations. There was no evidence of the Spearman correlation between paired 
samples (not shown). To compare cytokine concentrations across countries, median 
responses were compared. If median concentrations were equal, mean responses 
were compared.  
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Results  
 
Higher levels of proinflammatory cytokine secretion in Ugandan infant blood after 
PPD stimulation. 
 
Overall 313 Ugandan and 40 UK samples were included in this analysis. Mothers of 
Ugandan infants had a lower  median age (34 years in the UK vs 25 years in Uganda, 
p<0.001); a larger proportion of mothers were tuberculosis-infected  (146/313 in 
Uganda vs 0/40 in the UK, p<0.001); a larger proportion of infants were CMV infected 
(44/168 in Uganda vs 0/40 in the UK, p<0.001); and a larger proportion of infants 
were EBV infected (47/168 in Uganda vs 1/40 in the UK, p=0.001) (table 1). Using 
the Luminex assay, we measured concentrations of 17 cytokines in 10 and 52 weeks 
diluted whole blood UK and Ugandan infant samples stimulated with PPD. 
 
After background subtraction, we found that Ugandan infants produced up to seven-
fold higher PPD specific concentrations of IL1b at 10 weeks (8.6 pg/ml in the UK, 
60.06 pg/ml in Uganda, p<0.001), and up to five-fold higher concentrations at 52 
weeks (5.1 pg/ml in the UK, 24.1 pg/ml in Uganda, p=0.012). The concentrations of 
IL1b remained elevated in Uganda at both time points when CMV or EBV infected, or 
infants born to LTBI mothers were excluded from the analysis (figure 1, table 2). In 
Uganda, we also observed two-fold higher concentrations of tumour necrosis factor 
a (TNFa) at 10 (59.5 pg/ml in the UK, 127.6 pg/ml in Uganda, p=0.036) and 52 (37.6 
pg/ml in the UK, 69.6 pg/ml in Uganda, p=0.010) weeks and these concentrations 
remained elevated when CMV and EBV infected infants were taken out of the analysis 
(figure 1, table 2). When infants born to LTBI mothers were taken out of the analysis, 
TNFa remained higher in Ugandan infants at 52 (37.6 pg/ml in the UK, 66.9 pg/ml in 
Uganda, p=0.042) but not 10 (59.5 pg/ml in the UK, 111.1 pg/ml in Uganda, p=0.139) 
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weeks. Interestingly, both TNFa and IL1b levels were elevated in Uganda in 
unstimulated and phytohaemagglutinin (PHA) stimulated samples at 10 and 52 weeks 
(table S2, table S3). Conversely, we report that at 10 weeks UK infants produced 
higher concentrations of IL10 (8.4 pg/ml in the UK, 1.6 pg/ml in Uganda, p=0.007) 
and IL2 (32.2 pg/ml in the UK, 7.0 pg/ml in Uganda, p=0.017). When CMV or EBV 
infected infants were taken out of the analysis, the levels of IL10 were similar in the 
UK and Uganda (8.4 pg/ml in the UK, 10.0 pg/ml in Uganda without CMV infants) 
suggesting that CMV and EBV infections decrease PPD specific IL10 levels. 
Similarly, the analysis without CMV or EBV infected infants indicated higher interferon 
g (IFNg) levels in Uganda at 10 (349.8 pg/ml in the UK, 855.4 pg/ml in Uganda, 
p=0.030 without CMV infants; 349.8 pg/ml in the UK, 1002.6 pg/ml in Uganda, 
p=0.025 without EBV infants) but not at 52 (266.7 pg/ml in the UK, 261.4 pg/ml in 
Uganda, p=0.554 without CMV infants; 266.7 pg/ml in the UK, 252.5 pg/ml in Uganda, 
p=0.594 without EBV infants) weeks of age. We report no differences in TH1 cytokine 
concentrations IL12p40 (6.7 pg/ml in the UK, 3.8 pg/ml in Uganda, p=0.977 at 10 
weeks; 5.2 pg/ml in the UK, 2.9 pg/ml in Uganda, p=0.567 at 52 weeks); for TH17 
cytokine IL17A (21.2 pg/ml in the UK, 18.5 pg/ml in Uganda, p=0.907 at 10 weeks; 
15.0 pg/ml in the UK, 16.2 pg/ml in Uganda, p=0.843 at 52 weeks); TH2 cytokines 
IL13 (330.0 pg/ml in the UK, 165.4 pg/ml in Uganda, p=0.508 at 10 weeks; 140.1 
pg/ml in the UK, 120.8 pg/ml in Uganda, p=0.811 at 52 weeks) and IL5 (38.0 pg/ml in 
the UK, 38.4 pg/ml in Uganda, p=0.292 at 10 weeks; 40.0 pg/ml in the UK, 29.5 pg/ml 
in Uganda, p=0.711 at 52 weeks) and other cytokines granulocyte-macrophage 
colony-stimulating factor (GMCSF), IL1a, IL1RA, IL8, interferon gamma-induced 
protein 10 (IP10), monocyte chemoattractant protein 1 (MCP1), macrophage 
Inflammatory protein 1a (MIP-1a), and MIP-1b (figure 1, table 2). 
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Ugandan infants have lower frequencies of total CD8, Effector Memory (EM) CD8 
and Naïve CD8 T cells at 52 weeks 
 
Having measured cytokine responses after  PPD stimulation, we decided to further 
investigate the immune response following BCG vaccination and measured T cell 
phenotypes in the UK and Ugandan infants. For this analysis samples from 111 
Ugandan and 35 UK infants were available. The Ugandan infants had younger 
mothers (median age 34 in Uganda and 25 in the UK p<0.001), had a larger 
proportion of LTBI mothers (56/111 in Uganda vs 0/35, p<0.001), a larger proportion 
of infants were CMV infected (17/88 in Uganda vs 0/35 in the UK, p=0.005), and a 
larger proportion of infants were EBV infected (26/88 in Uganda vs 1/35 in the UK, 
p=0.001) (table 3). In Uganda, there was a decrease in the frequency of CD4 
(p=0.035), naïve CD4 (p<0.001), CM CD4 (p<0.001), and an increase in CD4 TD 
(p<0.001) T cells over time (figure 2A). We also observed a decrease in  naïve CD8 
(p<0.001), CM CD8 (p<0.001), and an increase in  EM CD8 (p=0.028) and  TD CD8 
(p<0.001) T cells over time (figure 2B). In the UK, we report a decrease in  CD4 
(p=0.031), and an increase in  EM CD4 (p=0.022), CD8 (p<0.001), and  EM CD8 
(0.010) T cells over time (figure 2A). When T cell phenotypes where compared 
between countries, we found that UK infants had higher frequencies of  naïve CD4 
(p<0.001), CM CD4 (p<0.001), CD8 (p<0.001), naïve CD8 (p<0.001), CM CD8 
(p<0.001), and  EM CD4 (p<0.001) T cells at 52 weeks of life. We also found that 
Ugandan infants had higher frequencies of EM CD4 (p=0.017) at 10 weeks of life, 
higher TD CD4 (p<0.001), and TD CD8 (p<0.001) T cells at 52 weeks of life (figure 
2A, B).  
 
 
We also investigated CD4:CD8 T cell ratios and found that there was no difference in 
the CD4:CD8 ratio between UK and Uganda at 10 weeks (p=0.477), but at 52 weeks, 
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Ugandan infants had a higher CD4/CD8 ratio (p=0.001) (figure 3A). We have also 
found that the CD4:CD8 ratio has decreased in the UK over time (p<0.001), but 
remained unchanged in Uganda (p=0.460) (figure 3A). The observed differences in 
CD4:CD8 ratios are mainly driven by the increased frequency of  CD8 T cells over 
time. Notably, the median frequency of  CD8 T cells is 26.8% of all CD3+ T cells in 
the UK and 15.4% in Uganda at 52 weeks (figure 3B). In summary, we observed an 
increase in  CD8 populations in the UK but not in Uganda. We also report that 
Ugandan infants have a higher proportion of terminally differentiated T cells.  
 
Frequencies of IL2, IL4/5/13 and IL8 CD8 producing T cells are higher in the UK than 
Uganda 
 
Having measured T cell phenotypes, we also investigated cytokines that they 
produce.  We report that frequencies of PPD specific IFNg or IL2 producing CD4 
(0.017% in the UK, 0.006 in Uganda, p<0.001 for IFNg; 0.141% in the UK, 0.006 in 
Uganda,  p<0.001 for IL2) or CD8 (mean frequency 0.023% in the UK, 0.006 in 
Uganda, p=0.010 for IFNg; 0.003% in the UK, 0.000% in Uganda, p=0.005 for IL2) T 
cells are higher in the UK than Uganda at 52 weeks of age (figure 4A, 4B, table 4). 
We also observed that frequencies IL8 CD8  producing T cells are higher in the UK 
at 52 weeks (0.500% in the UK, 0.011 in Uganda, p=0.001). In contrast, in Uganda,  
frequencies of TNFα producing CD4 T cells were higher at 10 weeks (0.016% in the 
UK, 0.050 in Uganda, p=0.033), and frequencies of IL4/5/13 producing CD8 T cells 
were increased at 52 weeks (0.001% in the UK, 0.013 in Uganda, p=0.024) when 
compared to the UK. Interestingly, the frequencies of unstimulated TNFα producing 
CD4 or CD8 T cells were elevated in Uganda at 10 and 52 weeks (table S4), and 
frequencies of PHA stimulated TNFα producing CD4 or CD8 T cells were increased 
in Uganda at 10 weeks of life (table S5). When infants that were CMV or EBV infected, 
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or born to LTBI mothers were taken out of the analysis we found that frequencies of 
IFNg, IL2 and IL8 producing T cells remained higher in the UK, however, we did not 
observe higher frequencies of TNFα producing T cells in Uganda. This suggests that 
CMV or EBV infection, or being born to an LTBI mother, increases the frequency of 
PPD specific TNFα producing T cells at 10 weeks of age in Ugandan infants, however, 
this finding is not supported by the Luminex data discussed earlier. Taken together, 
we report increased frequencies in IFNg or IL2 producing CD4 or CD8 T cells at 52 
weeks in the UK when compared to Uganda.  
 
viSNE analysis reveals that CD8 clusters increase in size with age 
 
To study rare populations of T cells and how they change over time and in response 
to PPD stimulation, we adopted viSNE and SPADE techniques to reduce the 
dimension and cluster T cells in the UK and Uganda. The acquisition of samples in 
different laboratories introduced technical limitations due to which, we were unable to 
calculate one viSNE plot for both countries. Thus, direct comparisons between 
countries cannot be made, however, observed trends over time and PPD stimulation 
remain informative.  For this analysis, we used 24 samples from the UK (12 at 10 
weeks, 12 at 52 weeks) and 24 samples from Uganda (12 at 10 weeks, 12 at 52 
weeks). Ugandan infants had younger mothers (median mother age in Uganda 24 
years, median mother age in the UK 35.5 years, p<0.001) and a higher proportion of 
tuberculosis infected mothers (8/24 in Uganda and 0/24 in the UK, p=0.002) (table 5).  
 
In both countries, PPD had a limited effect on T cell cluster size (figure 5A, 5B, 5C-D 
left two columns) and age had a much higher impact on the dynamics of T cell 
populations. In the UK, non-cytokine producing CD4 (clusters 24, 26, 29, 36, 37, 4, 
44 and 48) and the naïve CD4 (clusters 28, 45 and 47) T cell populations decrease 
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in size at 52 weeks of age. The diminished non-cytokine producing CD4 T cells are 
replenished by cytokine producing CD4 populations (clusters 13, 5, 34, 14), and 
cytokine-producing CD8 T cells (clusters 33 and 42) (figure 5A, 5B right three 
columns). In Uganda, changes with age are less pronounced. Similarly as in the UK, 
the non-cytokine producing CD4 clusters decrease with age (clusters 25-27), giving 
way to a number of unidentified clusters (30, 33, 34, 36, 37, 40-44, 49), cytokine 
(clusters 8, 18) and non-cytokine (cluster 29) producing CD8 populations, as well as  
EM CD4 (cluster 10) and EM CD8 (cluster 13) T cells (figure 5A, 5C right three 
columns). In contrast to the UK, we also observed a decrease in cytokine-producing 
CD8 populations (clusters 3 and 19). Taken together, we report that in both countries, 
non-cytokine producing CD4 T cells decrease with age and these cells are 
replenished by cytokine-producing CD8 T cells. 
Having analysed sizes of T cell clusters, we examined the MFI expression of T cell 
markers and assigned ontology to 45/50 (90%) T cell populations in the UK and 27/50 
(54%) in Uganda (figure 6A and 6B respectively). We found limited evidence of 
changes in marker expression after PPD stimulation in both countries (figure 6C, 6D) 
We also examined the effect of time on MFI and found that in the UK, there is an 
overall decrease in the IFNg producing clusters in unstimulated and PPD stimulated 
cells with time (figure 7A). In Uganda, we observed an increase in IL8 producing 
clusters in unstimulated and PPD stimulated cells (figure 7B). Overall, we found that 
age had an aberrant effect on T cell clusters, and no clear pattern of marker 
expression emerged.  
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Discussion 
 
BCG efficacy varies across geographical regions and between low and high-income 
countries2.  This study aimed to investigate the immunogenicity of BCG in  UK and 
Ugandan infants.  
 
We first examined the PPD-stimulated, diluted whole blood cytokine responses 
measured by the Luminex assay. Both at 10 and 52 weeks, we observed an increase 
in TNFa and IL1b concentrations in Uganda, and this increase was independent of 
CMV, EBV or maternal LTBI. We have also examined unstimulated and PHA 
responses and confirmed that Ugandan unstimulated and PHA responses of TNFa 
and IL1b were higher at both time points. One study, conducted in Malawian and UK 
adolescents, confirms increased levels of TNFa and IL1b before and after BCG 
vaccination in Malawi15. However, our findings contrast with previous observations 
between  UK, Malawian and Gambian infants, who had similar levels of IL1b and 
TNFa13,16. Importantly, in our study, all infants were vaccinated within the first week 
of life with BCG SSI, and samples were collected 10 and 52 weeks after BCG 
immunisation. However, in the study comparing  UK and Malawian responses, UK 
infants were vaccinated around the fifth week of life and  Malawian infants around the 
seventh week of life, and their samples were collected three months after BCG 
immunisation. The Gambian infants were vaccinated in the first week of life but 
received a different vaccine strain, BCG Russia, which is known to elicit distinct 
immune responses17. Previous studies have reported higher inflammatory signals in 
individuals of African descent. A study in African American women highlights that they 
are more likely to carry allelic variants that up-regulate proinflammatory cytokines, 
including IL118. Another study has investigated the inflammatory profile of 
macrophages and found that individuals of African ancestry have a markedly higher 
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expression of pro-inflammatory genes and better control of bacterial growth19. One of 
the explanations proposed by Nédélec et. al19, could be that as European ancestors 
have moved out of Africa, they were exposed to fewer of bacterial pathogens20, 
whereas African ancestors and their exposure to bacterial pathogens remained high 
due to a hotter climate. As a consequence, our immune systems have adapted 
accordingly, and individuals of European ancestry produce lower amounts of 
proinflammatory cytokines than their African colleagues21. On a molecular level, these 
differences in levels of proinflammatory cytokines could be driven by changes in 
frequencies of non-T cell populations (monocytes, macrophages, natural killer (NK) 
cells, neutrophils, mast cells, or eosinophils), epigenetic modifications, higher 
expression of Toll-like receptors (TLRs), induced gene expression and protein 
transcription and translation, or other mechanisms.  
 
Surprisingly, we found no differences in TH1 or TH2 cytokines between UK and 
Uganda. This is in contrast to the Malawian study, where higher IFNg and IL12p40 
were observed in the UK, and higher IL13 in Malawi. This could be explained by the 
study differences outlined before (time of vaccination, time of sample collection), but 
could also be a reflection of the characteristics of study cohorts. In the Malawian and 
Gambian studies, both cohorts were rural, whereas in our study, the Ugandan cohort 
resides in Entebbe, a prosperous city with an urban population. This has significant 
implications as urban populations have a reported reduced exposure to 
environmental mycobacteria22, one of the mechanisms proposed to influence the 
immunogenicity and efficacy of the BCG vaccine, also known as BCG masking23.  
 
To dissect the source of cytokines, we investigated T cell function and phenotype in 
both countries. We found that in both countries, the frequency of CD4 T cells 
decreased over time, and in the UK the frequency of CD8 T cells increased. This is 
in agreement with a previously published study in US infants, where the frequency of 
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CD4 T cells decreased, and CD8 T cells increased during the first year of life24. 
Changes in T cell frequencies are not well understood. Viral infections such as CMV 
and EBV, as well as vaccines, the majority of which are delivered in the first year of 
life, can change the frequency of CD4 and CD8 T cells. Due to the increase in CD8 
T cell frequency in the UK at 52 weeks, we have observed an increased CD4:CD8 
ratio in Uganda. A healthy CD4:CD8 ratio is around 2 and above, and an inverted 
ratio (less than 1) has been associated with increased morbidity and mortality across 
age groups25. Interestingly, we report that the CD4 and CD8 naïve populations, as 
well as the TD CD4 and the TD CD8 populations, are higher in frequency in Uganda 
than the UK at 52 weeks of life. At birth and before antigen exposure, a majority of T 
cells are naïve. The exposure to antigens, usually within the first year of life 
differentiates them from central memory T cells, which traffic to lymphoid tissues; and 
effector memory T cells, which migrate to peripheral tissues. Repetitive antigen 
exposure and proliferation further differentiate memory T cells into their terminally 
differentiated state26. We hypothesise that differences in naïve and TD T cells 
observed in the UK and Uganda could be explained by higher and repetitive antigen 
exposure in Uganda, differentiating naïve T cells to memory and eventually to a 
terminal state, all within the first year of life. In the UK, where pathogen exposure is 
lower, this T cell differentiation could happen later in life.  
 
To complement our understanding of the BCG induced immune responses, we 
examined frequencies of cytokine-producing cells in the UK and Uganda. We 
reported moderately higher frequencies of IFNg or IL2-producing CD4 and CD8 T  
cells in the UK at 52 weeks. IFNg is an important cytokine that stimulates 
macrophage-mediated killing of Mycobacterium tuberculosis (Mtb)27. An increase in 
IFNg producing polyfunctional T cells was observed after BCG vaccination28; IFNg has 
been studied extensively as a potential correlate of protection29; and higher levels of 
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IFNg were measured in whole blood stimulation assays in the UK as compared to 
Malawi or The Gambia13. We have also observed higher frequencies of IL4/5/13 
producing CD8 T cells at 52 weeks in Uganda. TH2 cytokine-producing CD8 T cells 
have been observed before in vitro, however, their role is unclear30. Higher production 
of TH2 cytokines could impair TH1 immune responses, and induce alternative 
activation of macrophages, both factors that could impair effective Mtb killing resulting 
ultimately in a lower BCG efficacy. However, the observed differences and median 
frequencies are small, and the effect could diminish when, like in the Luminex assay, 
other non-T cell populations and their cytokines are measured. This could explain 
why frequencies of cytokines producing T cells do not agree with Luminex results and 
vice versa, i.e. ICS measurement is restricted to T cells, whereas the Luminex assay 
is not.  
 
Lastly, we employed tSNE and SPADE algorithms to visualise rare populations of T 
cells and examine their dynamics. We found that over time there was a decrease in 
non-cytokine producing T cell populations and an increase in cytokine-producing T 
cell populations in both countries. We suggest that this could be explained by a 
development of the immune system over time. Exposure to pathogenic antigens and 
vaccines drives T cell differentiation from their naïve state (with limited cytokine 
production) to a memory and TD state (with increased cytokine production and 
proliferation)26. 
 
We have identified some limitations to our study. We measured immune parameters 
in peripheral blood. Cells that are present in peripheral blood are not representative 
of the whole cell population and peripheral blood T cells represent only ~2.5% of total 
T cells in the body26. Secondly, more Ugandan infants were infected with CMV, EBV, 
or born to LTBI mothers. We adjusted for these coinfections in the Luminex analysis, 
but not in the flow cytometry analysis, mainly due to a smaller number of samples. 
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However, the limited effect of CMV, EBV and maternal LTBI on cytokine levels 
measured by Luminex gives us confidence in the flow cytometry analysis. 
 
This paper describes a comprehensive comparison of the immune response following 
BCG vaccination of UK and Ugandan infants. We report that the immune response 
of Ugandan infants has an inflammatory profile, which could be mediated by lower 
levels of naïve T cell populations, and higher levels of terminally differentiated T cells 
in Uganda at 52 weeks. We emphasise that IFNg, IL2 and TH2 cytokines appear to 
be important, as we observed different frequencies in cytokine-producing T cells. We 
highlight the role of these immune differences in the mediation of BCG 
immunogenicity and their implied impact on efficacy. Vaccinologists should continue 
to design vaccines that focus on the expansion of TH1, TH17 or other immune 
compartments, while having in mind and continuing to explore the observed 
differences in inflammatory profiles as well as frequencies of terminally differentiated 
T cells.   Future studies that dissect BCG immunogenicity should be conducted, and 
include multiple countries in both urban and rural settings, as well as investigate other 
cell types such as NK cells.   
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Figure 1. PPD specific cytokine levels corrected for background and acquired using a 17-plex Luminex assay after 6-day whole blood stimulation. Cytokines 
were examined in Uganda at 10 (n=108) and 52 weeks (n=205); in the UK at 10 (n=28) and 52 weeks (n=12). The linear regression was used to test for 
significance adjusting for mother’s age between the UK and Uganda over a single time point. P value ≤ 0.05 was considered significant, is highlighted in bold 
and printed above each compared pair of countries. The asterisk indicates that the p-value remains significant after the Bonferroni multiple testing adjustment. 
The horizontal line depicts the median value with 95% confidence intervals (CI). 
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Figure 2. CD4 (A) and CD8 (B) T cell phenotypes of unstimulated samples examined with flow 
cytometry. Phenotypes were examined in Uganda at 10 (n=19) and 52 weeks (n=92); in the 
UK at 10 (n=23) and 52 weeks (n=12). The Linear regression was used to test for significance 
adjusting for mother’s age between the UK and Uganda over a single time point. The Mann-
Whitney test was used to test for significance between 10 and 52 weeks over a single country. 
P value ≤0.05 was considered significant, highlighted in bold and printed above each 
comparison. The asterisk indicates that the p value remains significant after the Bonferroni 
multiple testing adjustment. The horizontal line depicts the median value with 95% confidence 
intervals (CI).    
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Figure 3. The median frequencies of CD3+CD4+, CD3+CD8+ and CD3+CD4-CD8- T cell 
phenotypes of unstimulated samples were examined in Uganda at 10 (n=19) and 52 weeks 
(n=92); in the UK at 10 (n=23) and 52 weeks (n=12), and measured with flow cytometry. A 
comparison of CD4/CD8 ratios over time and country (A). A breakdown of median frequencies 
of each T cell population over time and country (B). The Mann-Whitney test was used to test 
for significance of CD4/CD8 ratio between 10 and 52 weeks over a single country and the 
linear regression adjusting for mother’s age was used to test between the UK and Uganda 
over a single time point. P value ≤0.05 was considered significant, is highlighted in bold and 
printed in between each compared pair of countries or time points. The horizontal line depicts 
the median value with 95% confidence intervals (CI).  
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Figure 4. PPD specific cytokine responses corrected for background and measured by flow 
cytometry in CD4 (A) and CD8 (B) cells. Cytokines were examined in Uganda at 10 (n=19) 
and 52 weeks (n=92); in the UK at 10 (n=23) and 52 weeks (n=12). The linear regression was 
used to test for significance adjusting for mother’s age between the UK and Uganda over a 
single time point. P value ≤ 0.05 was considered significant, is highlighted in bold and printed 
above each compared pair of countries. The asterisk indicates that the p-value remains 
significant after the Bonferroni multiple testing adjustment. The horizontal line depicts the 
median value with 95% confidence intervals (CI).  
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Figure 5. viSNE analysis that represents changes in cluster sizes of T cell populations over 
time and PPD stimulation in the UK (n=24) (A) and Uganda (n=24) (C). Different clusters are 
represented by the associated colour palette. Fold change of cluster size over time points and 
PPD stimulation in the UK (B) and Uganda (D). The green colour indicates that cluster size 
was larger in the first condition whereas the red colour indicates that cluster size was larger 
in the second condition. Numbers in brackets indicate cluster numbers. Abbreviations used: 
wks (weeks), Th2 (IL4/5/13).  
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Figure 6. viSNE analysis that represents median fluorescence intensity (MFI) across clusters 
in the UK (A) and Uganda (B). Fold change of the MFI across clusters after PPD stimulation 
at all time points in the UK (C) and Uganda (D). The pink colour indicates higher MFI whereas 
the black and the blue lower MFI(A,B). The pink colour indicates higher MFI after PPD 
stimulation for a given cluster whereas the blue colour indicates lower MFI after PPD 
stimulation for a given cluster (C,D). Numbers in brackets indicate cluster numbers. 
Abbreviations used: Th2 (IL4/5/13), EM (effector memory), CM (central memory).  
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Figure 7. viSNE analysis fold change of the MFI across clusters between 10th and 52nd week 
in the UK (A) and Uganda (B) in unstimulated samples. The pink colour indicates higher MFI 
at  52nd week of life for a given cluster whereas the blue colour indicates lower MFI at 52nd 
week of life for a given cluster. Numbers in brackets indicate cluster numbers. Abbreviations 
used: Th2 (IL4/5/13), EM (effector memory), CM (central memory). 
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Figure S1. The FACS gating strategy used to measure all immune responses. 
Live, single, CD3+ lymphocytes were chosen to measure intracellular 
cytokine responses as well as phenotypic markers. 
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Tables  
 
Characteristics Uganda UK P value 
Mother's Age (Median Years) 25.0 34.0 <0.001 
Birth Weight (kg) 3.2 3.3 0.310 
Proportion of Boys 170/313 20/40 0.606 
Proportion of Tuberculosis Infected Mothers 
146/313 
(46.6%) 
0/40  
(0.0%) 
<0.001 
Proportion of CMV Infected Infants 
44/168 
(26.2%) 
0/40  
(0.0%) 
<0.001 
Proportion of EBV Infected Infants 
47/168 
(28.0%) 
1/40 
(2.5%) 
0.001 
 
Table 1: Characteristics of all samples included in the Luminex analysis in Uganda (n=313) 
and the UK (n=40). P value ≤0.05 was considered significant and highlighted in bold. The 
Mann-Whitney test was used for continuous variables (mother’s median age and birth weight) 
and the Chi-square test for categorical variables (the proportion of tuberculosis-infected 
mothers, the proportion of CMV infected infants, the proportion of EBV infected infants). Due 
to a limited sample volume, not all infants were tested for CMV and EBV in Uganda. 
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Table 2. A summary of median background-corrected concentrations (pg/ml) and p values of 
cytokines between all infants, CMV uninfected, EBV uninfected, or infants born to non-LTBI 
mothers in the UK and Uganda at 10 and 52 weeks of life. Cytokines were examined in 
Uganda at 10 (n=108) and 52 weeks (n=205); in the UK at 10 (n=28) and 52 weeks (n=12). 
None of the UK infants had CMV, or were born to LTBI mothers, and one infant had EBV (not 
shown). Cytokine levels were acquired using a 17-plex Luminex assay after a 6-day whole 
blood stimulation assay. The linear regression was used to test for significance adjusting for 
mother’s age between the UK and Uganda over a single time point. P value ≤0.05 was 
considered significant and highlighted in bold. The asterisk indicates that the p-value remains 
significant after the Bonferroni multiple testing adjustment. The blue colour means that the 
median cytokine concentration was higher in the UK whereas the red colour indicates that the 
median cytokine concentration was higher in Uganda. If medians were equal, then the mean 
concentration was compared. Abbreviations used: United Kingdom (UK), Uganda (UG), LTBI 
(latent TB infection), CMV (cytomegalovirus), EBV (Epstein-Barr virus).  
 
a Median concentrations of cytokines in Uganda in infants born to LTBI negative mothers only 
b Median concentrations of cytokines in Uganda in infants uninfected with CMV 
c Median concentrations of cytokines in Uganda in infants uninfected with EBV 
d Fold difference between all UK and all Ugandan infants  
e P values for a comparison between all UK and all Ugandan infants  
f P values for a comparison between UK and Ugandan infants born to LTBI negative mothers 
only  
g P values for a comparison between UK and Ugandan infants uninfected with CMV 
h P values for a comparison between UK and Ugandan infants uninfected with EBV 
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Characteristics Uganda UK P value 
Mother's Age (Median Years) 25.0 34.0 <0.001 
Birth Weight (kg) 3.2 3.3 0.327 
Proportion of Boys 57/111 19/35 0.762 
Proportion of Tuberculosis Infected 
Mothers 
56/111 0/35 <0.001 
Proportion of CMV Infected Infants 17/88 0/35 0.005 
Proportion of EBV Infected Infants 26/88 1/35 0.001 
 
Table 3: Characteristics of all samples included in the flow cytometry analysis in Uganda 
(n=111) and the UK (n=35). P value ≤0.05 was considered significant and highlighted in bold. 
The Mann-Whitney test was used for continuous variables (mother’s median age and birth 
weight) and the Chi-square test for categorical variables (the proportion of tuberculosis 
infected mothers, the proportion of CMV infected infants, the proportion of EBV infected 
infants). Due to a limited sample volume, not all infants were tested for CMV and EBV in 
Uganda.  
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Table 4. A summary of PPD specific background-corrected median frequencies (%) and p 
values of cytokines between all infants, CMV uninfected, EBV uninfected, or infants born to 
non-LTBI mothers. Cytokines were examined in Uganda at 10 (n=19) and 52 weeks (n=92); 
in the UK at 10 (n=23) and 52 weeks (n=12). None of the UK infants had CMV, or were born 
to LTBI mothers, and one infant had EBV (not shown). Cytokine levels were acquired using 
flow cytometry after a 24 hours whole blood stimulation assay. The linear regression was used 
to test for significance adjusting for mother’s age between the UK and Uganda over a single 
time point. P value ≤0.05 was considered significant and highlighted in bold. The asterisk 
indicates that the p-value remains significant after the Bonferroni multiple testing adjustment. 
The blue colour means that the median cytokine concentration was higher in the UK whereas 
the red colour indicates that the median cytokine concentration was higher in Uganda. If 
medians were equal, then the mean concentration was compared. Abbreviations used: United 
Kingdom (UK), Uganda (UG), LTBI (latent TB infection), CMV (cytomegalovirus), EBV 
(Epstein-Barr virus), Not Applicable (NA).  
 
a Median frequency of cytokines in Uganda in infants born to LTBI negative mothers only 
b Median frequency of cytokines in Uganda in infants uninfected with CMV 
c Median frequency of cytokines in Uganda in infants uninfected with EBV 
d Fold difference between all UK and all Ugandan infants  
e P values for a comparison between all UK and all Ugandan infants  
f P values for a comparison between UK and Ugandan infants born to LTBI negative mothers 
only  
g P values for a comparison between UK and Ugandan infants uninfected with CMV 
h P values for a comparison between UK and Ugandan infants uninfected with EBV 
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Characteristics UK Uganda P value 
Mother's Age (Median Years) 35.50 24.00 <0.001 
Birth Weight (kg) 3.26 3.15 0.951 
Proportion of Boys 12/24 8/24 0.242 
Proportion of Tuberculosis Infected 
Mothers 
0/24 8/24 0.002 
Proportion of CMV Infected Infants 0/24 2/21 0.122 
Proportion of EBV Infected Infants 1/24 5/24 0.053 
 
Table 5: Characteristics of all samples included in the tSNE analysis in Uganda (n=24) and in 
the UK (n=24). P value ≤0.05 was considered significant and highlighted in bold. The Mann-
Whitney test was used for continuous variables (mother’s median age and birth weight) and 
the Chi-square test for categorical variables (the proportion of tuberculosis infected mothers, 
the proportion of CMV infected infants, the proportion of EBV infected infants). Due to a limited 
sample volume not all infants were tested for CMV and EBV in Uganda.  
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Table S1. Primer/Probe sequences used for EBV and CMV detection 
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Table S2. A summary of median background concentrations (pg/ml) and p values of cytokines 
between infants. Cytokines were examined in Uganda at 10 (n=108) and 52 weeks (n=205); 
in the UK at 10 (n=28) and 52 weeks (n=12). Cytokine levels were acquired using the 17-plex 
Luminex assay after the 6-day whole blood stimulation assay. The linear regression was used 
to test for significance adjusting for mother’s age between the UK and Uganda over a single 
time point. P value ≤0.05 was considered significant and highlighted in bold. The asterisk 
indicates that the p-value remains significant after the Bonferroni multiple testing adjustment. 
The blue colour means that the median cytokine concentration was higher in the UK whereas 
the red colour indicates that the median cytokine concentration was higher in Uganda. If 
medians were equal, then the mean concentration was compared. Abbreviations used: United 
Kingdom (UK), Uganda (UG). 
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Table S3. A summary of PHA-induced background-corrected concentrations (pg/ml) and p 
values of cytokines between infants. Cytokines were examined in Uganda at 10 (n=108) and 
52 weeks (n=205); in the UK at 10 (n=28) and 52 weeks (n=12). Cytokine levels were acquired 
using a 17-plex Luminex assay after a 6-day whole blood stimulation assay. The linear 
regression was used to test for significance adjusting for mother’s age between the UK and 
Uganda over a single time point. P value ≤0.05 was considered significant and highlighted in 
bold. The asterisk indicates that the p-value remains significant after the Bonferroni multiple 
testing adjustment. The blue colour means that the median cytokine concentration was higher 
in the UK whereas the red colour indicates that the median cytokine concentration was higher 
in Uganda. If medians were equal, then the mean concentration was compared. Abbreviations 
used: United Kingdom (UK), Uganda (UG). 
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Table S4. A summary of background median frequencies (%) and p values of cytokines 
between all infants. Cytokines were examined in Uganda at 10 (n=19) and 52 weeks (n=92); 
in the UK at 10 (n=23) and 52 weeks (n=12). Cytokine levels were acquired using flow 
cytometry after a 24 hours whole blood stimulation assay. The linear regression was used to 
test for significance adjusting for mother’s age between the UK and Uganda over a single time 
point. P value ≤0.05 was considered significant and highlighted in bold. The asterisk indicates 
that the p-value remains significant after the Bonferroni multiple testing adjustment. The blue 
colour means that the median cytokine concentration was higher in the UK whereas the red 
colour indicates that the median cytokine concentration was higher in Uganda. If medians 
were equal, then the mean concentration was compared. Abbreviations used: United Kingdom 
(UK), Uganda (UG), Not Applicable (NA).  
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Table S5. A summary of median frequencies (%) and p values of PHA-induced and 
background corrected cytokines between all infants. Cytokines were examined in Uganda at 
10 (n=19) and 52 weeks (n=92); in the UK at 10 (n=23) and 52 weeks (n=12). Cytokine levels 
were acquired using flow cytometry after a 24 hours whole blood stimulation assay. The linear 
regression was used to test for significance adjusting for mother’s age between the UK and 
Uganda over a single time point. P value ≤0.05 was considered significant and highlighted in 
bold. The asterisk indicates that the p-value remains significant after the Bonferroni multiple 
testing adjustment. The blue colour means that the median cytokine concentration was higher 
in the UK whereas the red colour indicates that the median cytokine concentration was higher 
in Uganda. If medians were equal, then the mean concentration was compared. Abbreviations 
used: United Kingdom (UK), Uganda (UG), Not Applicable (NA).  
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5. Profound phenotypic changes following birth and the effect of common 
early-life infections on Ugandan infant dendritic cells during the first year 
of life. 
 
In the previous chapter, I have examined the immune profiles of BCG vaccinated 
infants in the UK and Uganda and their T cell phenotypes. In this chapter, I aim to 
dissect the mechanisms that drive BCG immunogenicity in Uganda and look at the 
role of dendritic cells over time. I also examine how common infections affect 
phenotypes of dendritic cells, and discuss how these changes could influence the 
immune response to the BCG vaccine.   
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Summary 
 
We report that known dendritic cell (DC) subsets are absent at birth but appear within 
the first month of life. Cytomegalovirus, Epstein-Barr virus and maternal latent 
tuberculosis infection are associated with profound changes in DC phenotype. This 
work provides new insights into DC biology in infancy and the potential role of DCs 
as mediators of the effects of infection exposure on adaptive immune responses.  
 
Abstract 
 
Dendritic cells (DCs) are key antigen presenting cells that bridge between innate and 
adaptive immune responses. They include plasmacytoid dendritic cells (pDCs), and 
classical (c) DC1 and DC2. Few studies have investigated changes in phenotype of 
DCs over the course of life as well as in response to common pathogens.  We have 
conducted a longitudinal study of Ugandan infants from birth to one year of life and 
investigated phenotypes of dendritic cells, how they change over time, and how 
common infections in infancy (cytomegalovirus, Epstein-Barr virus) and exposure to 
maternal latent tuberculosis infection (LTBI) affect DC phenotype. Using t-Stochastic 
Neighbour Embedding (tSNE) and Spanning-tree Progression Analysis of Density-
normalized Events (SPADE) algorithms we show that pDCs, cDC1 and cDC2 subsets 
are absent in cord blood but appear within the first month of life; and highlight the 
profound effects of pathogens on DC phenotypes.  These findings are important for 
understanding the biology of DCs and the potential impact of common infections on 
adaptive immunity.  
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Introduction 
 
Dendritic cells (DC) are highly heterogeneous antigen presenting cells (APCs) that 
mediate immune functions by presenting antigens to T cells1 and B cells2. As they 
bridge between innate and adaptive immunity, they are vital mediators of vaccine-
induced immune responses3. Numerous studies have classified and examined DC 
populations in murine models4 but a comprehensive description of human DC 
ontology, phenotype and function is lacking.   The nomenclature of human DCs is 
complicated; DCs can be classified based on their origin, their location or their 
function. DC progenitors are released to blood from the bone marrow and differentiate 
into lymphoid tissue (LT) and non-lymphoid tissue (NLT) DCs in situ. LT DCs present 
lymph and bloodstream antigens to local T cells in lymphoid tissue. NLT DCs migrate 
from peripheral blood into tissues and then to lymph nodes where they present tissue-
derived antigens to T cells5. There are three main subsets of NLT DCs in humans. 
Plasmacytoid DCs (pDC) can be characterised by the expression of CD123 and 
production of type I Interferons (IFN)6. The remaining two subsets are cDC1 and 
cDC2, which are collectively and interchangeably known as myeloid, conventional or 
classical DCs (cDC). cDC1 can be differentiated by their expression of BDCA-1, 
BDCA-3 and CD1c, whereas cDC2 express high levels of CD1417. cDC1 are known 
to prime CD4 T cells 8 and induce differentiation of Th17 and Th29 immune responses 
to extracellular pathogens. In contrast, cDC2 promote Th1 immune responses and 
cross-present tumour and pathogenic antigens to prime CD8 T cells10. Lastly, 
monocytes have shown the ability to differentiate into a dendritic cell-like phenotype 
after encountering tissue antigens. These cells, known as monocyte-derived dendritic 
cells (MDDCs) originate from monocyte precursors and are characterised by the 
expression of CD14 and CD16 markers11. DC phenotypes have been shown to 
change with age and in response to antigens. DCs from aged subjects had a reduced 
capacity to prime T cells, aberrant cytokine secretion and decreased response to 
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foreign antigens12.  Pathogen encounter stimulates antigen processing and activates 
DCs by modulating expression of markers including HLA-DR, CD83 and CD8613.  
 
In this study, we used visual Stochastic Neighbour Embedding (viSNE) to 
characterise 50 human DC clusters, each resembling a distinct DC phenotype. We 
examined the expression of common DC markers for the identified clusters over the 
first year of life of Ugandan infants. We also investigated how maternal latent 
tuberculosis infection (LTBI), and common pathogens such as cytomegalovirus 
(CMV) and Epstein-Barr virus (EBV), affect cluster size and phenotype of these DC 
subsets. To our knowledge, this is the first study to describe dendritic cells subsets 
and how they change during the first year of life in an African infant, and how common 
exposures modify DCs subsets in this setting.
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Methods  
 
Ethical approval and informed consent 
 
Infants were included in the study only when mothers gave consent for participation. 
This project was approved by the Uganda Virus Research Institute (UVRI) Research 
and Ethics Committee, the Uganda National Council for Science and Technology 
(UNCST), and the Research Ethics Committee of the London School of Hygiene and 
Tropical Medicine (LSHTM).  
 
Study design and setting 
 
This was a nested study within a larger cohort designed to examine the impact of 
maternal latent TB infection (LTBI) on the infant immune response to the Bacillus 
Calmette–Guérin (BCG) vaccine. Women who resided within Entebbe Municipality 
and Katabi sub-county, Wakiso district, Uganda, and who delivered in Entebbe 
General Hospital, were considered for study inclusion. They were approached for 
consent at hospital admission and included if they had a singleton pregnancy, were 
HIV negative (confirmed by Determine, Inverness Medical), the delivery was 
uncomplicated, and the neonate was healthy with birth weight above 2500g. Cord 
blood was obtained at delivery and mothers were invited to attend a neonatal clinic 
one week post-delivery, where maternal BCG scar was measured and a 
questionnaire completed. Mothers were tested for LTBI using both the T-SPOT.TB 
assay (Oxford Immunotec) and a tuberculin skin test (TST; 2 tuberculin units, Statens 
Serum Institut). They were considered LTBI positive when both tests were positive, 
and LTBI negative when both tests were negative. Mothers with discordant assay 
results were excluded from the study. Mothers with signs or symptoms of TB disease 
were excluded from the study and referred for treatment. For the larger study, 284 
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mother/infant pairs were included. There were 132 mothers with LTBI, and 152 
mothers without LTBI. 
 
Samples 
 
Up to 10ml of cord blood was collected at birth, and up to 5ml of peripheral venous 
blood was obtained from each infant at selected time points. Samples were collected 
at 0, 1, 4, 6, 10, 14, 24 and 52 weeks of infant’s age.  To reduce the burden of blood 
draws from any one child, infants were randomised to give blood at either 1 and 6 
weeks, or 4 and 10 weeks.  Blood was collected from all infants at birth (cord blood) 
and 52 weeks. A subset of infants gave blood at 14 and 24 weeks, as these time 
points were included later into the study. Due to limited blood volume, not all infants 
had their DC profile examined. For infants where sufficient volume of blood was 
collected, DNA was extracted, and blood samples were examined for CMV and EBV. 
Numbers of samples available at 1 and 4 weeks was low and therefore these time 
points were combined. For all time points, we recruited 284 infants and examined DC 
profiles of 265 of them. Some infants donated samples at more than one time point, 
hence we examined a total of 296 DC profiles over eight time points. We examined 
115 infants for CMV and EBV infections across time points resulting in a total of 134 
samples. All infants were BCG vaccinated at birth with BCG SSI strain.   
 
 EBV and CMV viral DNA detection from whole blood using droplet digital PCR 
(ddPCR) assay 
 
DNA was extracted from 200 µl whole blood using the QIAamp DNA Blood Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer's instruction, in 100 µl of 
the elution buffer. The ddPCR reaction mix contained 10 µl ddPCR™ Supermix for 
Probes (Bio-Rad Laboratories, Hercules, USA), 10 µl of template DNA, 1.1 µl of 20 x 
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primers (final concentration 900nM) and probe (final concentration 250 nM) mixture 
for EBV and CMV (Table S1). 20 µl of the mixture was partitioned in oil-in-water with 
70 µl of droplet generator oil using a QX-100 droplet generator (Bio-Rad). The 
generated droplets (around 40 µl) were then transferred to a ddPCR™ 96-Well Plates 
(Bio-Rad) and heat-sealed with PCR plate heat seal for 5 sec at 170 °C using a PX1™ 
PCR Plate Sealer (Bio-rad). PCR amplification was performed with the following 
thermal cycling: 95 °C for 10 min, 40 cycles consisting of 94 °C for 30 sec 
(denaturation) and 60 °C for 1 min (extension), followed by 98°C for 10 min and 
holding at 12 °C. Droplets (positive and negative) were then analyzed using a QX100 
droplet reader (Bio-rad) and the target DNA concentration was calculated and 
presented as copies/µl in the reaction mixture using QuantaSoft software (Bio-Rad). 
DNA samples were tested in duplicates. 
 
Immune cell phenotyping and flow cytometry 
 
Two hundred µl of heparinised whole blood was spun at 1000g for 5 minutes, and 
plasma was removed and stored. FACS Lysing Solution (BD Biosciences, 349202) 
reconstituted in distilled water was added to cells for 15 minutes at room temperature 
to lyse red blood cells. Cells were spun at 400g for 5 minutes and washed twice with 
phosphate-buffered saline (PBS). They were stained with a viability dye 
(LIVE/DEAD™ Fixable Aqua Dead Cell Stain Kit, L34957) for 20 minutes, in the dark 
at 4°C; washed with FACS buffer (1XPBS, 5% FBS, 0.05% Sodium Azide) and 
stained with FcR blocking antibody (14-9161-73, eBiosciences) for 10 minutes in the 
dark at 4°C. Cells were washed twice with FACS buffer and stained for 30 mins, in 
the dark at 4°C with a cocktail of antibodies containing: HLA-DR BV570 (#307637, 
Biolegend, clone L243), CD3 FITC (#344804, BioLegend, clone SK7), CD19 FITC 
(BD Pharmingen, #555412, clone HIB19), CD56-FITC (340410, BD Bioscience, clone 
NCAM16), CD14 APC-H7 (560180, BD Pharmingen™, clone MφP9), CD16 Alexa 
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Fluor® 700 (557920, BD Pharmingen™, clone 3G8), CD11c BV605 (563929, BD 
Horizon™, clone B-ly6), CD141 PE (559781, BD Pharmingen™, clone 1A4), CD123 
BV650 (563405, BD Horizon™, clone 7G3), CD40 BV421 (563396, BD Horizon™, 
clone 5C3), CD70 PE-CF594 (562484, BD Horizon, clone Ki-24), CD83 PE-Cy™7 
(561132, BD Pharmingen™, clone HB15e), CD86 PE-Cy™5 (555659, BD 
Pharmingen™, clone 2331 (FUN-1)), CD1c APC (130-090-903, MACS Biotec 
Miltenyi, clone AD5-8E7). After staining, samples were washed with FACS buffer and 
stored at 4oC in the dark in PBS with 1% paraformaldehyde (PFA)  to be acquired 
within 24 hours using a BD LSRII Flow Cytometer and obtaining a minimum of 200,00 
events. 
 
Flow cytometry data analysis  
 
Cells were gated for DC phenotype. Dead cells, doublets, monocytes (CD14+), T 
Cells (CD3+), B Cells (CD19+) and Natural Killer Cells (NK Cells, CD56+) were 
excluded, and cells that were highly positive for HLA-DR were included. Within that 
population, various markers that define dendritic cell phenotypes were measured. 
The full gating strategy is described in Figure 1. The “Downsample” plugin available 
in FlowJo was used to select 1000 most representative cells per sample within the 
final gate. The downsampled samples were concatenated, and t Stochastic 
Neighbour Embedding (tSNE) algorithm was used to reduce data dimensionality 
using the following parameters: perplexity 40-100; iterations 1000, Eta learning rate 
200 and Theta 0.5. Samples were exported to Cytobank (www.cytobank.org), where 
Spanning-tree Progression Analysis of Density-normalized Events (SPADE) was 
used to identify distinct cell clusters from previously calculated tSNE parameters.  The 
viSNE algorithm was used to analyse phenotypes of dendritic cells.  
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The viSNE algorithm separated cells based on their marker expression and SPADE 
algorithm identified 50 distinct DC clusters with a minimum of 50 cells per cluster. A 
cluster is a group of cells with a similar phenotype. It contains a number of cells 
(cluster size), which can change depending on condition and/or sample 
characteristics. These clusters were overlayed onto a viSNE plot. The expression of 
markers (CD1c, CD14, CD141, CD83, CD16, CD86, CD70, CD40, CD11c and 
CD123) for all cells was used to assign cell ontology following established 
guidelines14. Despite excluding CD14+ cells during the gating process, we included 
this marker when naming DC subsets, as CD14- cells continue to express varying 
levels of CD14.  Samples from different infants were available for each sub-analysis 
(DCs phenotypes over time, the effect of EBV infection, the effect of CMV infection 
and the effect of maternal LTBI). viSNE and SPADE calculations were performed 
independently for each sub-analysis and thus plots and ontology differ.  
 
Statistical Analysis 
 
The linear regression was used to examine whether continuous characteristics 
(mother's age, number of pregnancies, a total number of born children, birth weight) 
vary between samples available at different time points. The logistic regression was 
used to measure if categorical characteristics (the proportion of boys, the proportion 
of tuberculosis latently infected mothers, the proportion of mothers with BCG scar, 
the proportion of CMV infected infants, the proportion of EBV infected infants) of 
samples vary between time points. For a comparison of sample characteristics 
between CMV infected and uninfected, EBV infected and uninfected and infants born 
to mothers with and without LTBI, the Mann-Whitney test was used for continuous 
and the Chi-squared (X2) for categorical sample characteristics. Stata/SE 15.1 was 
used.  
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Results 
 
Sample characteristics 
 
Infants had a median birth weight of 3.2kg, 50% (148/296) were male, 39% (94/242) 
were born to mothers with latent TB infection, 32% (41/134) had CMV, and 14% 
(19/134) had EBV (Table 1).   
 
Known dendritic cell subsets are absent at birth but appear during the neonatal 
period 
 
Samples from 70 infants were analysed,  stratified over seven time points (0, 1 and 
4, 6, 10, 14, 24, 52weeks; 10 samples per time point). Infants’ and mothers’ 
characteristics did not differ across time points (Supplementary Table S2). 
 
We first analysed the sizes of DC clusters and how these change over time. Of the 
50 DC clusters identified 1-20 and 22-27 are present in blood at birth (Figure 2A). In 
contrast, known DC phenotypes such as pDCs (clusters 21, 40 and 43), cDC1 
(clusters 42, 44), cDC2 (clusters 29, 35, 36, 39, 46-49) and MDDC (clusters 31 and 
41) are absent in blood at birth but appear within the neonatal period, with full 
reconstitution of mature DC subsets by 10 weeks of life (Figure 2B). Most pDCs 
appear at 6-10 weeks of life (clusters 21, 40, 45) and most cDC2 (clusters 35, 48-49) 
appear at 6 weeks of life followed by cDC1 cluster 44 and others (Figure 2B, green 
squares). 
 
Having looked at changes in cluster size over time, we then proceeded to analyse the 
median fluorescence intensity (MFI) of markers in DC clusters over time. We assigned 
ontology to 16/50 (32.00%) clusters of DCs based on their median marker expression 
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(Figure 3A) and looked at a fold change of MFI over time in all clusters. We found an 
overall increase between 0 to 1 and 4 weeks of life in marker expression for the 
majority of clusters (Figure 3B). There was a consistent increase in CD1c and CD141 
expression, and some downregulation of CD16 at 1 and 4 weeks of life. The 
expression pattern for other markers does not appear to follow a consistent pattern 
over time. Interestingly, the expression of markers in clusters 1-20 and 22-27 
increases at 6 and 10 weeks and then decreases at 14 and 24 weeks, slightly 
increasing again at 52 weeks of life. In contrast, the marker expression of clusters 21 
and 28-49 that contain known DC subsets remains unchanged throughout the first 
year of life.  This data suggests that the DC subsets that are present at birth are likely 
immature, but rapidly mature into known DC subsets in the first few weeks of life.   
 
Maternal LTBI expands key DC populations in the early weeks of life  
 
We investigated how maternal LTBI alters DC cluster size and phenotype. We 
analysed 48 samples from 24 infants who were born to mothers with, and 24 who 
were born to mothers without a LTBI, at 6, 14 and 52 weeks. Infants’ and mothers’ 
characteristics did not differ with maternal LTBI status (Supplementary Table S3). We 
stratified viSNE plots by time and maternal LTBI status (Figure 4A). We then 
determined the size of each cluster and calculated the fold change of cluster size for 
all clusters (Figure 4B). We report a notably increased cluster size for MDDC (cluster 
32), cDC2 (clusters 41 and 48) and cDC1 (cluster 49) in infants that were born to 
mothers with LTBI, at all time points (Figure 4B, 1st column). In contrast, the size of 
clusters 1-30 is similar or moderately lower in infants born to mothers with LTBI at 6 
and 14 weeks of life (Figure 4B). Based on the MFI of markers, we assigned ontology 
to 12/50 (24.00%) clusters (Figure 5A) and calculated fold change of MFI between 
infants born to mothers with and without a LTBI. We report increased expression of 
CD14 and CD16 markers in clusters 6, 15, 17, 19, and higher overall expression of 
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markers in MDDC cluster 32 in infants born to mothers with a LTBI. However, for 
clusters of other known DC subsets (29,30, 34-50), we report no change in marker 
expression associated with the exposure to LTBI (Figure 5B). Taken together, this 
data suggests that infants born to mothers with LTBI are likely exposed to M.tb 
antigens in utero, and that this exposure markedly increases MDDC populations in 
the early weeks of life.   
 
CMV infection delays development of key DC populations 
 
We examined the impact of CMV infection DC cluster size and phenotype, analysing 
49 samples, 25 from CMV uninfected and 24 from CMV infected infants, at 6, 10, 14, 
24 and 52 weeks of age. Infants’ and mothers’ characteristics did not differ by CMV 
infection status (Supplementary Table S4). We stratified viSNE plots over time and 
CMV infection status (Figure 6A) and determined cluster sizes. We then calculated 
fold change of cluster sizes between CMV uninfected and CMV infected infants for a 
given time point (Figure 6B). We report moderately lower cluster size of MDDC 
(cluster 34), CD11c/CD86 DCs (clusters 35 and 36), cDC2 (clusters 42 and 43) and 
other clusters (30, 46 and 48) in CMV infected infants at all time points (Figure 6B, 1st 
column).  The highest fold change in cluster size is mostly at 6 weeks of life and 
remains up to the 24th week of life. In contrast, clusters 2-29, are larger in CMV 
infected infants at 6 and 10 weeks of life, but are reduced in these infants at 14 and 
24 weeks of life (Figure 6B, columns 2-5). We then analysed MFI of markers, 
assigning ontology to 14/50 (28.00%) of clusters (Figure 7A) and calculated the fold 
change of MFI between CMV uninfected and CMV infected infants in all clusters at 
all time points (Figure 7B). Except for cluster 37, where we see a lower marker 
expression in CMV infected infants, we report no overall difference of marker 
expression with CMV infection. In summary, this data indicates that CMV infection 
delays the development of known dendritic cell populations, but which eventually 
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recover to a similar distribution of clusters in infants with and without CMV infection 
at 52 weeks. 
 
EBV infection reduces DC subsets known to be important in initiating anti-viral 
immune responses. 
 
We investigated how EBV infection affects DC subsets and their phenotype. The 
majority of infants (18/19, 94.7%) across all time points were EBV infected by the 52nd 
week of life. As only one infant was EBV infected and younger than 52 weeks (table 
1), and viSNE analysis requires an equal number of samples across time points,  we 
limited the analysis to a single time point of 52 weeks. We analysed 32 samples, 16 
from infants that were infected with EBV and 16 from uninfected infants. Infants’ and 
mothers’ characteristics did not differ with EBV infection status (Supplementary Table 
S5). We stratified viSNE plots based on the EBV infection status (Figure 8A) and 
determined the size of each cluster. We then looked at a fold change of cluster size 
between EBV non-infected and EBV infected infants (Figure 8B). We found reduced 
cluster sizes in EBV infected infants for pDCs (clusters 8, 24, 33, 39, 40 and 50), 
cDC1 (clusters 36, 37, 39 and 45), cDC2 (clusters 18, 32, 33, 36, 37 and 39) and 
MDDC (clusters 12 and 38). These changes are reflected in viSNE plots where we 
see a decrease in the colour intensity of clusters 33 (cadet blue), 45 (electric blue) 
and the presence of cluster 41 (cinnamon brown) in EBV infected infants (Figure 8A).  
We then analysed the MFI of markers for all clusters, assigned ontology to 21/50 
(42.00%) clusters (Figure 8C) and calculated the fold change of MFI in all clusters 
between EBV uninfected and EBV infected infants. We found an overall decrease in 
marker expression in EBV infected infants. The downregulation of markers was most 
noticeable for CD14 and CD16, markers associated with an MDDC phenotype. Taken 
together, these results indicate that EBV infection reduces cluster size and 
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downregulates marker expression of DC subsets known to be important in initiating 
anti-viral immune responses. 
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Discussion 
 
Following birth, a nascent and underdeveloped immune system begins to mature, 
with immune cells appearing, differentiating and developing over time and after 
antigen exposure. In this study, we examined infant DC phenotypes over time directly 
ex vivo, and analysed the impact of maternal LTBI, and infant CMV and EBV infection 
on these developing subsets.  
 
We used flow cytometry combined with viSNE and SPADE techniques to analyse DC 
populations. The advantages of viSNE and SPADE over a standard biaxial analysis 
include reduced dimensionality of data while retaining single cell resolution, without 
an assumption of a linear relationship15. These approaches allow us to look at more 
markers simultaneously and aid identification of new cell populations.  
 
Based on the number of examined phenotypic markers and their expression, the 
viSNE analysis identified 50 distinct DC clusters. We report clusters whose marker 
expression corresponds to previously identified subsets, based on the current 
literature (pDCs, cDC1, cDC2 and MDDC). We also report novel DC clusters that do 
not express the full array of phenotypic markers (1-20, 22-27), however, they have 
an intermediate expression of CD40, CD11c and low expression of CD123. We have 
shown here that all DC cluster sizes change over time and that fully developed pDC, 
cDc1 and cDc2 phenotypes are absent in cord blood, but appear within the first month 
of life. Previous studies have investigated frequencies of DCs in infancy, but none 
have focussed on the first weeks of life, or indeed at multiple time points throughout 
the first year of life. Studies have reported that frequencies of both pDC and cDC 
subsets increase with age from 6 months to 5 years of life16; that CD11b+ cells are 
absent in neonatal lungs but not in adults17; and that infants have significantly fewer 
pDC and cDC as a proportion of peripheral blood mononuclear cells when compared 
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to adults18. In adulthood, levels of pDC but not cDC decrease with age19. Two studies 
find that in the UK and Spanish infants, pDCs and cDCs are present in cord blood but 
in a much reduced frequency20, and with a lower marker expression21. They could be 
merely highlighting populations that were identified in our study as clusters 1-20 and 
22-27, with a low CD123 expression; identifying cells with medium HLA-DR 
expression (which were excluded from this analysis due to established ontology 
guidelines14); or reflecting differences between European and African infants. These 
observations (both published and reported in this article) could be explained by the 
development of DCs over time from DC precursors. Studies suggest high frequencies 
of hematopoietic CD34+ stem cells in cord blood, a vital source of DCs in infancy22,23.   
DC development occurs over time and is also induced by antigen exposure, both 
environmental and vaccine-derived. We also report that the expression of markers for 
identified clusters is markedly increased in the neonatal period. This suggests that 
DC subsets in cord blood have an immature profile, in agreement with the literature 
that reports cord blood DC subsets to express lower levels of MHC-II, ICAM-1, CD80 
and CD8624. After the 4th week of life, we observe an increase in marker expression 
of unidentified clusters (1-20, 22-27) up to week 10 and a decrease from week 10 
onwards. Despite overall low marker expression, clusters 1-20 and 22-27 are 
phenotypically dynamic and distinct from identified DC clusters. These DCs may be 
DC precursors that differentiate into known DC populations throughout the first 10 
weeks of life.  Alternatively, they may be novel DC populations that are active in the 
neonatal period and disappear as the immune system develops with age. Further 
functional studies will be needed to determine whether they are indeed an immature 
subset, or in fact a new DC subset.  Importantly, developed DCs only migrate in blood 
when transporting antigens from tissues to lymph nodes. Hence, blood-circulating 
DCs are not considered to be fully representative of tissue resident DCs, which may 
have a different profile and development dynamics. We acknowledge that this is a 
limitation of this study. In summary, we have identified 50 distinct DC clusters and 
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show that they are dynamic over the first year of life. We emphasise the absence of 
pDC, cDC1 and cDC2 in cord blood.  
 
Having identified DC clusters and examined their qualitative and quantitative changes 
over time, we examined the effect of maternal LTBI, and of two common pathogens 
CMV and EBV, on the infant DC profile.  
 
LTBI affects a quarter of the world’s population25. Mycobacterium tuberculosis, the 
intracellular pathogen responsible for tuberculosis (TB) infection, mainly resides in 
macrophages but has also been shown to infect DCs26. Mycobacterial antigens can 
cross the placenta in murine models27 potentially leading to mycobacterial exposure 
in utero and an altered, sensitised immune profile of the fetus28.  We hypothesised 
that infants born to mothers with a LTBI would have an altered DC profile that may 
affect their response to BCG vaccination, which is given at birth in this setting. We 
report an increase in cluster sizes of cDC1, cDC2 and MDDC, but not pDC, in infants 
born to mothers with a LTBI. We also highlight an increased expression of CD14 and 
CD16 markers in unidentified DC clusters in infants born to mothers with a LTBI. 
Previous studies have examined the effect of maternal LTBI on the infants' immune 
responses. We have previously found that frequencies of PPD specific IFNg, tumour 
necrosis factor a (TNFa) and total cytokine (IFNg, IL2, TNFa) expressing CD4+ T 
cells were lower at 1 week post-BCG vaccination in infants born to mothers with a 
LTBI29. Conversely,  others have reported no differences in BCG specific immune 
responses in infants exposed to maternal M. tb30, however, the study design differed 
between the two groups, and may explain the differences that were reported. Our 
current study gives evidence for modulation of an infant’s DC phenotype after (likely) 
mycobacterial exposure in utero. Importantly, changes in DC numbers could be one 
of the mechanisms that may explain observed differences in immune responses 
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measured in the same infants29. The term BCG masking has been used before to 
describe this effect31. In utero sensitisation may confer some level of protection and 
reduced early response to the BCG vaccine, as observed in our previous study29. 
This finding has significant implications for BCG vaccine immunity and effectiveness 
and may help to explain the variable efficacy of BCG observed across the globe.  
 
Human cytomegalovirus, also known as human herpesvirus-5 (HHV-5), is a member 
of the β-herpes virus family. Almost 100% of adults in Sub-Saharan Africa are CMV 
positive32  and in Uganda, ~75% of infants under one year of age have CMV-specific 
IgG antibodies33.  DCs act as a source of primary lytic infection as well as reactivation 
from CMV latency34. We examined how CMV infection affects DC subsets and found 
that CMV infected infants have delayed development and reduced sizes of DC 
clusters that correspond to known DC phenotypes, compared to their uninfected 
counterparts. We observed larger DC clusters in CMV uninfected infants in 13/50 
clusters, including cDC1, MDDC, cDC2 and CD11c DCs with high CD86 expression. 
This agrees with previous studies that show reduced cellular differentiation of CMV-
infected DCs. Indeed, CMV gene UL111A encodes viral homologs of interleukin 10 
(cmvIL-10) that inhibit the differentiation of CD34+ DC progenitors (and known CMV 
reservoirs) to mature DC subsets35. We show no differences in the cluster size of 
pDCs, in agreement with the literature confirming that blood pDCs are resistant to 
CMV infection in vitro36. We looked at phenotypic changes of identified DC 
phenotypes but observed no differences in marker expression for all clusters 
regardless of the CMV status. Whereas previous studies describe how CMV infection 
impairs DC function by lowering their expression of CD80, HLA-DR, CD86 and CD83 
after viral reactivation or infection in vitro37, we did not observe this immune 
downregulation in latently infected infants ex vivo. Our study is the first longitudinal 
analysis of CMV infection ex vivo, and further studies should be conducted to explore 
the mechanisms of latent and active CMV infection and its timing on DC phenotype.  
 214 
 
Epstein-Barr Virus is one of the most ubiquitous viruses in humans, reaching an 
estimated worldwide seroprevalence of 90%38. It promotes malignant differentiation 
of B cells in immunosuppressed hosts39, drives innate immune dysregulation40, 
regulates CD8+ NKT cell development41 and is associated with reduced vaccine 
antibody responses in infants42. We quantified DC cluster sizes and measured their 
phenotypes in EBV infected and non-infected infants. We report that EBV infection 
markedly decreases all three main clusters of DCS: pDCs, cDC1 and cDC2. We also 
highlight that EBV infection decreases the expression of surface markers, especially 
CD14 and CD16, in the majority of identified clusters. In humans, the recognition of 
EBV antigens is modulated by Toll-like receptor 2 (TLR2), and 3 and the central role 
of DCs43 is thought to be in T cell priming of EBV-specific protective T cell 
responses44. The central role of DCs in EBV protective immunity is highlighted by 
studies in humanised, non-obese diabetic severe combined immune deficiency 
(NOD-SCID) mice, a model for human EBV infection. They show increased mortality 
in pDC depleted mice from disseminated EBV infection and improved survival in pDC 
enriched mice, indicating a critical role of pDC in anti-EBV immune responses45. We 
did not observe an increase in mortality of EBV infected infants, suggesting that pDC 
levels are sufficient to mediate a healthy state; or that the role of pDC and protection 
against EBV does not correlate well between humans and NOD-SCID mice; or that 
we were merely not powered to detect mortality in this study. In humans, a study 
reports a loss of all DC subsets during Epstein-Barr virus-associated acute infectious 
mononucleosis in vivo46. Lastly, studies say that EBV infection impairs the 
differentiation of monocytes to MDDC phenotype, as defined by decreased CD14 and 
CD16 expression47,48.  Taken together, these studies highlight the role of DCs in EBV 
infection and are consistent with our findings. Our study is the first to examine the 
effect of the EBV infection on an infants’ DC phenotype directly ex vivo. In addition to 
the available literature, we find that EBV infection markedly decreases cluster size 
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and downregulates marker expression of DC populations that are known to mediate 
anti-viral immune responses.   
 
This study is the first comprehensive, longitudinal and cross-sectional analysis of 
infant blood DC phenotypes. We used state-of-the-art techniques to analyse and 
identify unique populations of DCs. We show that infant DC populations change over 
time and in response to CMV, EBV and maternal LTBI. These findings highlight how 
dynamic DCs are and challenges our perception of typical DC populations and their 
profiles. This study highlights that this dynamic milieu of DCs should be considered 
when designing new vaccines. This is an early discovery research study and further 
studies need to be conducted to examine the impact of DC development on vaccine 
efficacy in early infancy and its implications for vaccinologists. Additionally, we must 
consider the prevalence of common pathogens such as CMV and EBV or stress the 
importance of vaccine design for these pathogens.  Future studies should include a 
comprehensive analysis of changes in DC phenotypes and the effect of common 
pathogens beyond one year of life.  
 
  
 216 
Figures 
 
 
 
Figure 1. Flow cytometry gating strategy used for the identification of dendritic cells. Live and 
single cells were included. CD3, CD19, CD56 and CD14 cells were excluded from the 
analysis. Only cells with a high expression of HLA-DR were included in the analysis.  
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Figure 2. Changes in sizes of clusters of dendritic cell phenotypes over time. Different clusters 
are represented by the associated colour palette (A). The first row indicates cell clusters that 
appeared at a given time point. The second row indicates a cumulative number of cells for 
each cluster over time (A). Quantified numbers of cells in each cluster that appear at a given 
time point as a  % of all cells (B). Black colour indicates that near 0% of cells appeared in 
blood at a particular time point; bright red indicates that around 14% of cells appeared in a 
given time point; green indicates that 28% or more of DCs appeared in a given time point (B). 
A quantified cumulative number of cells for each cluster over time (C). The black colour 
indicates that near 0% of cells were present up to particular time point; bright red indicates 
that 50% of cells were present in blood up to a given time point; green indicates that 100% of 
cells were present up to a given time point (C). All infants were 0, 1 and 4, 6, 10, 14, 24 and 
52 weeks old, n=70 (10 samples per time point). Abbreviation used: wks (weeks), pDC 
(plasmacytoid dendritic cell), cDC1 (classical dendritic cell 1), cDC2 (classical dendritic cell 
2), MDDC (monocyte-derived dendritic cell). 
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Figure 3. An overview of median expression (MFI) of markers in clusters in cells at all time points 0 to 52 weeks (A). A fold change difference of median 
expression of markers in clusters between measured time points (B). All infants were 0, 1 and 4, 6, 10, 14, 24 and 52 weeks old, n=70 (10 samples per time 
point). Abbreviation used: wks (weeks), pDC (plasmacytoid dendritic cell), cDC1 (classical dendritic cell 1), cDC2 (classical dendritic cell 2), MDDC (monocyte-
derived dendritic cell), MFI (median fluorescence intensity). 
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Figure 4. Changes in sizes of clusters of dendritic cells over time and LTBI maternal status. 
Different clusters are represented by the associated colour palette (A). Fold change of cluster 
size between maternal LTBI non-exposed and maternal LTBI exposed cells across time points 
(B). Red colour indicates that there were more cells in infants exposed to maternal LTBI, the 
green colour indicates that there were more cells in infants not exposed to maternal LTBI. 
Infants were 6, 10, and 52 weeks old, n=48 (24 LTBI+ and 24 LTBI-). Abbreviation used: pDC 
(plasmacytoid dendritic cell), cDC1 (classical dendritic cell 1), cDC2 (classical dendritic cell 
2), MDDC (monocyte-derived dendritic cell), LTBI (latent tuberculosis infection). 
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Figure 5. An overview of median expression (MFI) of markers in clusters in all cells and over 
maternal LTB infection status (A). A fold change difference of median expression of markers 
in clusters between maternal LTBI exposed and non-exposed infants (B). The yellow colour 
indicates higher marker expression in LTBI exposed infants, the blue colour indicates higher 
marker expression in LTBI non-exposed infants. Infants were 6, 10, and 52 weeks old, n=48 
(24 LTBI+ and 24 LTBI-). Abbreviation used: pDC (plasmacytoid dendritic cell), cDC1 
(classical dendritic cell 1), cDC2 (classical dendritic cell 2), MDDC (monocyte-derived 
dendritic cell), LTBI (latent tuberculosis infection). 
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Figure 6. Changes in clusters size of dendritic cell over time and CMV infection status. 
Different clusters are represented by the associated colour palette (A). Fold change of cluster 
sizes between CMV non-infected and CMV infected infants across time points (B). The red 
colour indicates that there were more cells in the CMV infected infants, the green colour 
indicates that there were more cells in the CMV non-infected infants. Infants were 6, 10, 14, 
24 and 52 weeks old, n=49 (24 CMV+ and 25 CMV-). Abbreviation used: wks (weeks), pDC 
(plasmacytoid dendritic cell), cDC1 (classical dendritic cell 1), cDC2 (classical dendritic cell 
2), MDDC (monocyte-derived dendritic cell), CMV (cytomegalovirus).  
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Figure 7. An overview of median expression (MFI) of markers in clusters in all cells and over 
the CMV infection status (A). A fold change of median expression of markers in clusters 
between the CMV non-infected and the CMV infected infants (B). The yellow colour indicates 
higher marker expression in the CMV non-infected infants, the blue colour indicates higher 
marker expression in the CMV infected infants. Infants were 6, 10, 14, 24 and 52 weeks old, 
n=49 (24 CMV+ and 25 CMV-).  Abbreviation used: pDC (plasmacytoid dendritic cell), cDC1 
(classical dendritic cell 1), cDC2 (classical dendritic cell 2), MDDC (monocyte-derived 
dendritic cell), MFI (median fluorescence intensity), CMV (cytomegalovirus).  
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Figure 8. Changes in cluster size of dendritic cell phenotypes over the EBV infection status (A). Different clusters are represented by the associated colour 
palette (A). Fold change cluster size between the EBV non-infected and the EBV infected infants (B,  next page). The red colour indicates that there were more 
cells in a cluster in the EBV infected infants, the green colour indicates that there were more cells in a cluster in the EBV non-infected infants. Median expression 
of markers in clusters in all cells and over the EBV infection status (C, next page). Fold change of median expression of markers in clusters between the EBV 
non-infected and the EBV infected cells (D, next page). The yellow colour indicates higher marker expression in the EBV infected cells, the blue colour indicates 
higher marker expression in the EBV non-infected cells. All infants were 52 weeks old, n=32 (16 per EBV status). Abbreviation used: pDC (plasmacytoid 
dendritic cell), cDC1 (classical dendritic cell 1), cDC2 (classical dendritic cell 2), MDDC (monocyte-derived dendritic cell), EBV (Epstein-Barr Virus).  
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Tables 
 
Table 1: Characteristics of infants and their mothers from whom samples were collected over 
time. Note that some data was missing and/ or infection testing was not performed. Values in 
brackets indicate the standard deviation (SD). 
 
Characteristic Total 
0 
weeks 
1  
week 
4 
weeks 
6 
weeks 
10 
weeks 
14 
weeks 
24 
weeks 
52 
weeks 
Number of 
Samples 
296 127 5 8 20 15 18 15 88 
Mother’s Age 
(Median Years) 
24 
(4.57) 
24 
(4.87) 
26 
(4.55) 
24 
(1.39) 
22 
(3.91) 
22 
(2.61) 
25.5 
(3.65) 
24 
(5.87) 
25 
(4.61) 
Total Number 
of Pregnancies 
(Median) 
2 
(1.48) 
2 
(1.46) 
4 
(1.87) 
2 
(0.74) 
2 
(1.14) 
2 
(0.99) 
2.5 
(1.17) 
2 
(1.72) 
2 
(1.68) 
Total Number 
of Born 
Children 
(Median) 
2 
(1.39) 
2 
(1.41) 
1 
(1.64) 
2 
(0.89) 
2 
(1.01) 
2 
(1.03) 
2 
(1.25) 
2 
(1.50) 
2 
(1.52) 
Birth Weight 
(kg) 
3.2 
(0.41) 
3.29 
(0.38) 
3.5 
(0.54) 
3.45 
(0.47) 
3.15 
(0.33) 
3.2 
(0.52) 
3.35 
(0.43) 
3.1 
(0.34) 
3.2 
(0.43) 
The Proportion 
of Boys 
148/296 66/127 1/5 4/8 9/20 7/15 8/18 11/15 42/88 
The proportion 
of 
Tuberculosis 
Latently 
Infected 
Mothers 
94/242 25/73 2/5 1/8 8/20 5/15 8/18 10/15 35/88 
The proportion 
of Mothers 
with BCG scar 
208/293 97/127 2/5 6/7 15/20 11/14 10/18 10/15 57/87 
The proportion 
of CMV 
infected 
infants 
41/134 0/5 1/2 1/7 5/16 4/12 10/16 6/11 14/65 
The proportion 
of EBV 
infected 
infants 
19/134 0/5 0/2 0/7 0/16 0/12 1/16 0/11 18/65 
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Table S1. Primer/Probe sequences used for the detection of EBV and CMV. 
 
Target gene Forward Primer Reverse Primer Probe 
EBV(BALF5) CGGAAGCCCTCTGGACTTC CCCTGTTTATCCGATGGAATG 6FAM-TGTACACGCACGAGAAATGCGCC-BHQ1 
CMV (UL55) TGGGCGAGGACAACGAA TGAGGCTGGGAAGCTGACAT HEX-TGGGCAACCACCGCACTGAGG-BHQ1 
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Table S2: Characteristics of infants and their mothers from whom samples were collected over 
time and included in the analysis of dendritic cell phenotypes over time, n=70, ten samples 
per time point. The linear regression was used to measure if continuous variables (mother's 
median age, the total number of pregnancies and birth weight) change over time. The logistic 
regression was used to see if categorical variables (the proportion of boys, the proportion of 
tuberculosis latently infected mothers, the proportion of malaria positive mothers during 
pregnancy, the proportion of mothers with BCG scar, the proportion of CMV infected infants, 
the proportion of EBV infected infants) change over time. Note that some data was missing 
and/ or infection testing was not performed.  
 
Characteristic 
0 
weeks 
1 & 4 
weeks 
6 
weeks 
10 
weeks 
14 
weeks 
24 
weeks 
52 
weeks 
P Value 
Mother’s Age 
(Median Years) 
24 24 22 22.5 25.5 24 25.5 0.190 
Total Number of 
Pregnancies 
(Median) 
 
2.5 
2 2.5 2 2.5 2 1.5 0.376 
Total Number of 
Born Children 
(Median) 
2 2 2 2 2 2 1.5 0.823 
Birth Weight (kg) 3.175 3.45 3 3 3.6 3.15 3.1 0.112 
The proportion of 
Boys 
5/10 2/10 3/10 5/10 5/10 7/10 5/10 0.265 
The proportion of 
Tuberculosis 
Latently Infected 
Mothers 
1/6 3/10 3/10 3/10 5/10 8/10 5/10 0.087 
The proportion of 
Mothers with 
BCG scar 
9/10 6/10 7/10 7/10 7/10 6/10 5/10 0.105 
The proportion of 
CMV infected 
infants 
0/1 1/6 2/9 3/8 5/9 5/8 2/6 0.416 
The proportion of 
EBV infected 
infants 
0/1 0/6 0/9 0/8 1/9 0/8 1/6 0.165 
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Table S3: Characteristics of infants and their mothers from whom samples were collected over 
time and included in the analysis of dendritic cell phenotypes over the maternal LTBI status, 
n=48, 24 samples from infants born to LTBI mothers and 24 from infants born to non-LTBI 
mothers. The Mann-Whitney test was used to measure if continuous variables (mother's 
median age, the total number of pregnancies and birth weight) varied by maternal the LTBI 
status. The Chi2 test was used to see if categorical variables (the proportion of boys, the 
proportion of malaria positive mothers during pregnancy, the proportion of mothers with BCG 
scar, the proportion of EBV infected infants, the proportion of CMV infected infants) differed 
by the maternal LTBI status. Note that some data was missing and/ or infection testing was 
not performed.  
 
Characteristic LTBI+ LTBI- P Value  
Mother’s Age 
(Median Years) 
24 23.5 0.2462 
Total Number of 
Pregnancies 
(Median) 
3 2 0.1870 
Total Number of 
Born Children 
(Median) 
3.5 2 0.0537 
Birth Weight (kg) 3.35 3.1 0.1355 
The proportion of 
Boys 
9/24 12/24 0.383 
The proportion of 
Mothers with BCG 
scar 
13/24 19/24 0.066 
The proportion of 
CMV infected 
infants 
6/19 10/20 0.242 
The proportion of 
EBV infected 
infants 
2/19 2/20 0.957 
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Table S4: Characteristics of infants and their mothers from whom samples were collected over 
time and included in the analysis of dendritic cell phenotypes over CMV infection status, n=49, 
24 samples from infected and 25 from non-infected CMV infants. The Mann-Whitney test was 
used to measure if continuous variables (mother's median age, the total number of 
pregnancies and birth weight) change over the CMV infection status. The Chi2 test was used 
to see if categorical variables (the proportion of boys, the proportion of tuberculosis latently 
infected mothers, the proportion of malaria positive mothers during pregnancy, the proportion 
of mothers with BCG scar, the proportion of EBV infected infants) change over the CMV 
infection status. Note that some data was missing and/ or infection testing was not performed.   
 
Characteristic CMV+ CMV- P Value 
Mother’s Age 
(Median Years) 
24 22 0.2318 
Total Number of 
Pregnancies 
(Median) 
2 2 0.0845 
Total Number of 
Born Children 
(Median) 
2 2 0.2272 
Birth Weight (kg) 3.3 3.05 0.1343 
The proportion of 
Boys 
10/25 10/24 0.062 
The proportion of 
Tuberculosis 
Latently Infected 
Mothers 
12/25 14/24 0.656 
The proportion of 
Mothers with BCG 
scar 
16/24 19/25 0.470 
The proportion of 
EBV infected 
infants 
1/24 1/25 0.976 
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Table S5: Characteristics of infants and their mothers from whom samples were collected over 
time and included in the analysis of dendritic cell phenotypes over the EBV infection status, 
n=32, 16 samples from infected and 16 from non-infected EBV infants. The Mann-Whitney 
test was used to measure if continuous variables (mother's median age, the total number of 
pregnancies and birth weight) change over the EBV infection status. The Chi2 test was used 
to see if categorical variables (the proportion of boys, the proportion of tuberculosis latently 
infected mothers, the proportion of malaria positive mothers during pregnancy, the proportion 
of mothers with BCG scar, the proportion of CMV infected infants) change over EBV infection 
status. Note that some data was missing and/ or infection testing was not performed.   
 
Characteristic EBV+ EBV- P Value 
Mother’s Age 
(Median Years) 
26 25 0.5252 
Total Number of 
Pregnancies 
(Median) 
3 2 0.2239 
Total Number of 
Born Children 
(Median) 
3 2 0.2136 
Birth Weight (kg) 3.135 3.4 0.1397 
The proportion of 
Boys 
9/16 7/16 0.480 
The proportion of 
Tuberculosis 
Latently Infected 
Mothers 
4/16 7/16 0.264 
The proportion of 
Mothers with BCG 
scar 
11/15 10/16 0.519 
The proportion of 
CMV infected 
infants 
3/16 7/16 0.127 
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6. Whole blood DNA methylation landscape of UK and Ugandan infants. 
 
In chapter four, I established protocols for the analysis of the DNA methylation, and 
in chapter five, I examined the immunogenicity of the BCG vaccine in the UK and 
Uganda. Here, I utilise the developed data analysis pipeline and examine DNA 
methylation patterns of UK and Ugandan infants. I also discuss how DNA methylation 
profiles could explain the variations in BCG immunogenicity.  
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Summary 
 
Introduction: Epigenetic modifications have shown to regulate innate and adaptive 
immune responses and mediate vaccine-induced immunity. Bacillus Calmette–
Guérin (BCG) has variable protection against pulmonary tuberculosis (TB) and 
induces different immune responses across countries. The vaccine works well in the 
UK and produces a strong T helper like 1 (TH1) response, but in African countries, it 
stimulates a TH2 response and has a variable efficacy.  
 
Hypothesis & Methods: We hypothesised that DNA methylation could drive 
sustained differences in BCG immunogenicity and compared DNA methylation 
patterns between UK and Ugandan infants in the first year of life. We measured DNA 
methylation using reduced representation bisulphite sequencing (RRBS) and 
compared DNA methylation patterns between BCG vaccinated UK and Ugandan 
infants at 10 and 52 weeks of life, focusing on immune pathways.   
 
Results and Conclusions: We found that genes of the B cell activation pathway, as 
well as vital immune regulators NFATC1 and SOCS5 have higher methylation in 
Uganda at 10 weeks of life. We report that at 10 weeks, the integrin pathways, TGF-
beta signalling and key interferon and T cell activation signalling genes JAK1 and 
JAK2 are hypermethylated in the UK. We report genes and pathways that should be 
considered in mechanisms of vaccine-induced immunity.  
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Introduction 
 
Vaccines are the best life-saving health intervention to date, but they differ in efficacy 
across countries and populations, and the efficacy tends to be lower in regions near 
the equator or in low-income countries1–3. This is particularly the case for rotavirus1 
and  pneumococcal3 vaccines as well as the Bacillus Calmette–Guérin2 (BCG) 
vaccine against tuberculosis (TB).  We have previously reported striking differences 
in BCG immunogenicity between the United Kingdom (UK) and African populations4,5. 
UK infants produced twelve-fold higher levels of interferon g (IFNg) and six-fold higher 
levels of interleukin 2 (IL2), whereas Malawian infants produced thirty-fold higher 
levels of IL13 and eleven-fold higher levels of IL55. We proposed thatthese 
immunogenicity differences could explain lower vaccine effectiveness in low-income 
countries. Transfer of placental antibodies, nutritional status, exposure to 
environmental mycobacteria, co-infections with other pathogens such as helminths 
or malaria parasites, have all been proposed as potential mechanisms to cause 
variations in vaccine efficacy, effectiveness and immunogenicity6. Whereas the 
causes of variations in vaccine efficacy and immunogenicity are widely discussed, 
the molecular mechanisms that drive these differences are less often considered. 
Numerous host molecular mechanisms could contribute to explaining observed 
differences in vaccine responses: genetics, epigenetics, gene transcription and 
translation, and post-translational protein formation and modification. Genetic studies 
report a high degree of gene heritability involvement in  the response to vaccines7; 
that 76% of immune traits show a predominantly heritable influence8; and a growing 
body of research highlights the contribution of transcriptomes in the regulation of 
vaccine immune responses7.  
 
Epigenetic modifications are heritable regulators of  gene expression that do not alter 
the DNA sequence9. They work by modifying the binding of transcription factors by 
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either limiting chromatin access and reducing gene expression, or conversely, 
increasing chromatin access and allowing gene expression and subsequent protein 
translation10. Epigenetic modifications can also affect post transcription proteins and 
affect mRNA stability10. The three most discussed epigenetic mechanisms include 
DNA methylation, histone methylation and acetylation and micro RNAs (miRNAs). In 
the context of vaccines, studies have highlighted that DNA methylation was correlated 
with gene expression of multiple genes after influenza vaccination11; and several 
differentially methylated genes were identified in low and high responders to Hepatitis 
B vaccine12. Epigenetic modifications mediate multiple immune processes. Increased 
production of tumour necrosis factor a (TNFa) and interleukin 6 (IL6), as well as 
expression of toll-like receptor 4 (TLR4) was associated with increased trimethylation 
of lysine 4 at histone 3 (H3K4me3) after BCG vaccination of Dutch adults13. High DNA 
methylation of the IL4 gene was observed in T Helper 1 (TH1) T cells whereas high 
methylation of the IFNg gene was reported in TH2 T cells. Lastly, miRNA-21 targets 
IL12 mRNA and inhibits its translation and subsequently impairs TH1 development14; 
miRNA-29 inhibits the translation of IFNg mRNA and impairs the immune response 
to Mtb15; and other miRNAs were implicated to play a role in the immunity against 
Mtb16,17.  
 
Having observed disparate immune responses to  BCG vaccination in UK and African 
populations, we decided to investigate potentially underlying molecular mechanisms 
that drive sustained differences in BCG immunogenicity and subsequent BCG 
efficacy. This study investigates differences in DNA methylation between UK and 
Ugandan infants, specifically focusing on immune genes and pathways. We 
hypothesise that DNA methylation patterns mirror previously observed differences in 
BCG immunogenicity. Specifically, we hypothesise that regulatory and TH2 genes 
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have lower methylation in Uganda whereas TH1 genes have lower methylation in the 
UK.  
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Methods 
 
Ethical approval and informed consent 
 
Infants were only included in the study if their mothers gave written, informed consent 
for participation. This project was approved by the Research Ethics Committee of the 
London School of Hygiene and Tropical Medicine (LSHTM) (#8720), the Uganda 
National Council for Science and Technology (UNCST), (#Hs 1526), and the Uganda 
Virus Research Institute (UVRI) Research and Ethics Committee 
(#GC/127/14/02/432).  
 
Study Participants 
 
This study was nested into a larger trial that examined the effect of maternal latent 
tuberculosis infection (LTBI) on the infant’s immune response to the BCG vaccination. 
Mothers and their infants were enrolled in the study if they were HIV negative; had a 
singleton pregnancy with a healthy neonate above 2500g; delivered in Entebbe 
General Hospital, Entebbe, Uganda; or North Middlesex Hospital, London, United 
Kingdom. In Uganda, mother’s tuberculosis infection was examined using T-
SPOT.TB assay (Oxford Immunotec) and a tuberculin skin test (TST; 2 tuberculin 
units, Statens Serum Institut); and mothers were included only if both tests showed 
concordant results. In the UK, the TB infection status was measured using T-
SPOT.TB assay (Oxford Immunotec). All infants were BCG vaccinated at birth with 
BCG SSI strain. In Uganda, up to 5ml of peripheral venous blood and up to 10ml of 
cord blood was taken at birth, 1, 4, 6, 10, 14, 24 and 52 weeks. In the UK, up to 5ml 
of blood was taken at 10 and 52 weeks. To allow comparison between samples, for 
this analysis only samples from 10 and 52 weeks infants were included.  
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EBV and CMV viral DNA detection from whole blood using droplet digital PCR 
(ddPCR) assay 
 
DNA was extracted from 200µl whole blood using the QIAamp DNA Blood Mini Kit 
(Qiagen, Hilden, Germany) in 100µl elution buffer and according to manufacturer’s 
guidelines. The ddPCR reaction mixe included the probe mixture (final concentration 
250 nM) for Epstein-Barr virus (EBV) and cytomegalovirus (CMV) (table S1), 10 µl 
ddPCR™ Supermix for Probes (Bio-Rad Laboratories, Hercules, USA), 10 µl of 
template DNA, and 1.1 µl of 20 x primers (final concentration 900nM). 20 µl of the 
mixture was partitioned in oil-in-water with 70 µl of droplet generator oil using a QX-
100 droplet generator (Bio-Rad). The generated droplets (around 40 µl) were then 
heated for 5 sec at 170 °C using a PX1™ PCR Plate Sealer (Bio-rad). PCR 
amplification was performed with the following thermal cycling: 95 °C for 10 min, 40 
cycles consisting of 94 °C for 30 sec (denaturation) and 60 °C for 1 min (extension), 
followed by 98°C for 10 min and holding at 12 °C. Droplets were analyzed using a 
QX100 droplet reader (Bio-rad) and the target DNA concentration was calculated 
using QuantaSoft software (Bio-Rad). All samples were tested in duplicates. 
 
DNA extraction, methylation, and sequencing 
 
DNA was extracted from 200µl of whole blood using DNeasy Blood & Tissue Kit 
(Qiagen), the quality was checked with NanoDrop (Thermo Fisher Scientific) and the 
concentration with Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific). The DNA 
library was prepared using the reduced representation bisulphite sequencing (RRBS) 
method with the Premium Reduced Representation Bisulphite Sequencing Kit 
(Diagenode) following the manufacturer’s instructions. The concentration of the DNA 
library was measured again with Quibit dsDNA Assay Kit and size examined with the 
High Sensitivity DNA Analysis Kit (Genomics Agilent) using Bioanalyzer 2100 
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(Genomics Agilent). For sequencing, the DNA library was denatured with 0.2 M NaOH 
and concentration adjusted to 16 pM. A positive control PhiX v3 library (Illumina) was 
added at 12.5pM. Samples were sequenced using the Miseq Reagent Kit v3 
(Illumina), running at 51 cycles per run with single end reads.  
 
Data processing and analysis 
 
FASTA files with a DNA sequence were generated as the final DNA sequencing 
output. They were trimmed with TrimGalore (v0.4.3) and Cutadapt software with a 
quality cut-off of 30 Phred score. The quality of the samples was confirmed with the 
FastQC software (v0.11.5). A homo sapiens genome reference post-bisulphite 
treatment was prepared using the GrCh38p7 assembly and Bismark Genome 
Preparation (v0.16.3) and Bowtie2 (v2.2.9) software. Trimmed FASTA sequences 
were mapped to the reference genome using Bismark (v0.16.3) and Bowtie2. The 
methylation of DNA sequences was analysed using SeqMonk (v1.41.0) and Rstudio 
(3.4.2) software. Contig methylation probes were generated with a 10-fold depth cut-
off, duplicate reads were ignored, and probes closer than 500bp merged. Probes 
were quantified using read count quantitation and only probes sequenced at least ten 
times were included.  The methylation of probes was quantified using bisulphite 
methylation pipeline embedded in the SeqMonk software. To eliminate gender bias 
chromosomes X and Y were excluded from the analysis. To identify differentially 
methylated regions (DMRs) logistic regression with multiple testing adjustment was 
conducted for the following groups of probes: UK all time points vs Uganda all time 
points; UK at 10 weeks vs Uganda at 10 weeks; UK at 52 weeks vs Uganda at 52 
weeks; Uganda at 10 weeks vs Uganda at 52 weeks; UK at 10 weeks vs UK at 52 
weeks. A probe was considered to be a DMR when the adjusted p value was ≤0.05 
and the minimum average difference in methylation between comparison groups was 
5%. To identify differentially methylated genes (DMGs), a gene feature report of 
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DMRs was conducted, i.e. a list of genes, which contain DMRs was produced. We 
refer to genes or DMRs that had higher methylation as “hypermethylated”, and genes 
or DMRs that had lower methylation as “hypomethylated”.  
 
The datasets generated  and/or analysed as part of the current study are available 
from the corresponding author on reasonable request. 
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Results 
 
Sample characteristics 
 
We included 62 Ugandan infants (16 at 10 weeks, 46 at 52 weeks) and 43 UK infants 
(31 at 10 weeks, 12 at 52 weeks). None of the samples were paired in Uganda and 
11/12 samples were paired in the UK. Infants recruited for this study had a similar 
median birth weight across countries (3.31kg in the UK, 3.14kg in Uganda (p=0.095)) 
and a similar proportion of infants were male (51% in the UK, 48% in Uganda). There 
were more CMV (p=0.001) and EBV (p=0.002) infected infants in Uganda than in the 
UK. In Uganda, more mothers had LTBI during pregnancy (p=0.023), and their 
median age at delivery was lower than in the UK (34 years in the UK, 24 years in 
Uganda, p<0.001) (table 1).  
 
Identification of longitudinal and inter-population differences in the methylation of 
DNA regions and genes  
 
We aimed to compare DNA methylation of genomic regions in infants at 10 and 52 
weeks of age in the UK and Uganda. Firstly, we compared DNA methylation between 
all UK and Ugandan infant samples, irrespective of time point. We found that only 37 
probes were identified as DMRs with a minimum difference of 5% DNA methylation 
between groups (figure 1A). We then conducted a further four comparisons: UK and 
Ugandan infants at 10 weeks of age (figure 1B); Ugandan infants between 10 and 52 
weeks of age (figure 1C); UK and Ugandan infants at 52 weeks of age (figure 1D); 
UK infants between 10 and 52 weeks of age (figure 1E). Altogether we have found 
2073 DMRs that were located within 2783 DMGs (figure 2, table  S2) of which 2251 
were unique DMGs which were differentially methylated in only one comparison. We 
report several DMGs which were differentially methylated across multiple 
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comparisons (table S2). Notably, paired box protein (PAX6), a regulator of 
transcription and cell development after birth18 was found to be differentially 
methylated across five comparisons.  The MSLN gene was found to be differentially 
methylated across four comparison groups. MSLN encodes megakaryocyte 
potentiating factor, a cytokine that can induce colony formation of bone marrow 
megakaryocytes. MSLN also encodes mesothelin that is suspected to function as a 
cell adhesion protein19. SMAD3, another gene of interest was found to be differentially 
methylated across four comparisons. SMAD3 is a ubiquitous intracellular signal 
transducer and transcriptional modulator activated by transforming growth factor b 
(TGF-b)20.  
 
Hierarchical clustering reveals different methylation patterns of identified DMRs 
 
We conducted a t-distributed stochastic neighbour embedding (tSNE) DNA 
methylation analysis of all samples. We did not observe a clear separation of samples 
based on  origin or time point (figure S1). We then conducted a hierarchical clustering 
analysis of all samples and found moderate differences in DNA methylation across 
DMRs and between comparisons (figure 3).  
 
Differentially methylated genes are part of 111 biological pathways.  
 
 We then proceeded with the analysis of DMGs. We conducted a Panther Pathway 
Analysis (PPA) for 2783 identified genes. We found that DMGs were involved in a 
total of 111 pathways involved in multiple biological processes including immune, 
physiological, metabolic and cellular processes as well as signalling, disease and 
other pathways (figure 4 and 5). Altogether, we conducted four comparisons (two 
longitudinal comparisons within each country and two cross-country comparisons at 
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both time points)  and highlighted DMGs that were hypermethylated in each arm of 
the comparison (table S3).  
 
Comparison of DMGs between UK and Uganda at 10 or 52 weeks of life 
 
We analysed DMGs between UK and Uganda at both time points. We found the 
following DMGs to have higher methylation in UK infant 10 week samples: two DMGs 
in the B cell activation pathway (SDK1, MAPK12); five DMGs of inflammation 
mediated by chemokine and cytokine signalling (ARPC2, ARPC1A, ARPC1B, JAK2, 
ARPC5L); eight DMGs in the integrin signalling pathway (ARPC2, ARPC1A, PIK3R1, 
ARPC1B, SH3D21, PARVB, ARPC5L, LAMB1); three DMGs in the interferon-gamma 
or JAK/STAT signalling pathways (JAK1, JAK2, MAPK12); a T cell activation pathway 
DMG, PIK3R1; and the TGF-beta signalling pathway DMGs (SMAD4, SMAD3, 
MAPK12). In contrast, we found that in Uganda the following DMGs had higher 
methylation in infant 10 week samples: five DMGs of the B cell activation pathway 
had higher methylation (ITPR3, MAPK11, PPP3CB, MAP3K3, NFATC1); five DMGs 
in inflammation mediated by chemokine or cytokine signalling (ITPR3, SOCS5, 
MYH10, CAMK2G, NFATC1); three DMGs in the integrin signalling pathway 
(MAP3K3, ELMO2, ASAP1); two DMGs in the interferon-gamma signalling pathway 
(SOCS5, MAPK11); two DMGs in the T cell activation pathway (PPP3CB, NFATC1); 
and one DMG MAPK11 in the TGF-beta signalling pathway.  
 
At 52 weeks of life, NFATC1 was hypermethylated in the B or T cell activation 
pathways in the UK; three DMGs in the inflammation mediated by chemokine or 
cytokine signalling (NFAT5, NFATC1, GRK6); and two DMGs (GDF7 and SMAD3) in 
the TGF-beta signalling pathway, all had higher methylation in the UK than Uganda 
at 52 weeks. In Uganda, two DMGs (IFNGR2, CISH) of the inflammation mediated 
by chemokine and cytokine signalling or interferon-gamma signalling pathways were 
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hypermethylated; and one DMG MEGF9 of the integrin signalling pathway, all had 
higher methylation in Uganda at 52 weeks (figure 4). 
 
Comparison of DMGs between 10 and 52 weeks of life in the UK or Uganda 
 
The longitudinal analysis of 10 and 52 week infant samples found a total number of 
1055 DMRs and 1423 DMGs in the UK, and 157 DMRs and 223 DMGs in Uganda, 
suggesting that changes in DNA methylation in Uganda over time are less 
pronounced. We report that more genes in the B cell activation pathway were 
hypermethylated at 10 (SOS2, PPP3CC, BRAF in the UK; VAV3 in Uganda) than at 
52 weeks (MAPK11, NFATC1 in the UK; none in Uganda), both in the UK and Uganda 
(figure 4). We found 15 DMGs to be differentially methylated between 10 and 52 
weeks in the UK (ARPC1A, ARPC1B, PLCD1, RRAS, BRAF, PLCB4, IFNGR2, 
GNAQ hypermethylated at 10 weeks; CCRL2, PRKCE, MAP3K4, PAK1, CCR6, 
NFATC1, GRK6 hypermethylated at 52 weeks) in the inflammation mediated by 
chemokine and cytokine signalling pathway. In contrast, in Uganda we found only one 
APRC4 DMG to be hypermethylated at 52 weeks. We found 17 DMGs to be 
differentially methylated in the integrin signalling pathway between 10 and 52 weeks 
in the UK (SOS2, APRC1A, APRC1B, SH3D21, RRAS, BRAF, MEGF9, VASP, 
COL4A1, LAMB1, ARF1, COL4A2, BCAR1 were hypermethylated at 10 weeks; 
MAP3K4, ITGB8, RHOB, MAP2K3 were hypermethylated at 52 weeks). In Uganda, 
one DMG, SH3D21, was hypermethylated at 52 weeks. In the UK, we found three 
DMGs to be differentially methylated in the interferon-gamma signalling pathway 
(INFGR2 was hypermethylated at 10 weeks; MAPK11 and SOCS2 were 
hypermethylated at 52 weeks); five in the interleukin signalling pathway (SOS2, 
BRAF, IL5RA were hypermethylated at 10 weeks; MAP3K4, STAT5A were 
hypermethylated at 52 weeks); and one (STAT5A was hypermethylated at 52 weeks) 
in the JAK/STAT signalling pathway. None of these pathways had identified DMGs in 
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Uganda. In Uganda, one T cell activation gene was hypermethylated at 10 (VAV3) 
than at 52 (none) weeks. VAV3 is a gene encoding protein that regulates nuclear 
factor of activated T cells (NFAT) and subsequent T cell activation21.   
 
In the UK, we also observed changes in the number of hypermethylated DMGs in 
physiological pathways. Notably, the thyrotropin-releasing hormone receptor 
signalling pathway and the angiogenesis pathway had increased numbers of 
hypermethylated DMGs over time (from one to six for the thyrotropin pathway, and 
from seven to twelve for the angiogenesis pathway). In the UK, we have also found 
cellular signalling and processes pathways that decreased in the number of 
hypermethylated DMGs over time. Two heterotrimeric G-protein signalling pathways 
and histamine H1 receptor-mediated signalling pathway decreased in a number of 
hypermethylated DMGs over time, suggesting an increased G-protein and H1 
mediated signalling (figure 5).  
 
Taken together, we report numerous pathways in which DMGs were identified 
between countries and within countries at different time points. In Uganda, we 
observed a higher number of DMGs in B cell activation pathways, as well as 
increased methylation of key immune genes such as SOCS5 and NFATC1. In the 
UK, we observe increased methylation of genes involved in integrin and TGF-beta 
signalling, as well as key genes involved in T cell activation such as JAK1 and JAK2.  
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Discussion 
 
Vaccines induce disparate immune responses across the globe giving rise to uneven 
efficacy against diseases. Here, we investigate whether DNA methylation patterns 
differ between the UK and Uganda. We focus on immune pathways, of which different 
methylation could help to explain observed variations in vaccine responses between 
high and low-income countries.  
 
We first compared DMGs between UK and Uganda at 10 weeks of life. We found 111 
pathways of which genes were identified as DMGs. We report that there are more 
DMGs that are hypermethylated in Uganda than in the UK in the B cell activation 
pathway. MAPK11, MAP3K3, ITPR3 and NFATC1 were all hypermethylated in 
Uganda. MAPK11 and MAP3K3 play a ubiquitous role in the modulation of immune 
responses, by phosphorylation and activation of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB)24,25, an important protein complex that controls 
inflammation, cell proliferation and maturation26. In the context of B cells, NF-κB 
regulates B cell development, maintenance and function27; ITPR3 mediates 
intracellular calcium release, which indirectly affects immune responses28; NFATC1 
mediates activation, proliferation and differentiation of T cells, lymphoid and non-
lymphoid cells, and induces cytokine expression29,30.  Higher methylation of these 
genes in Uganda could indicate lower gene expression and subsequently impaired B 
cell activation and function. Of note, MAPK11, MAP3K3, ITPR3 and NFATC1 are not 
exclusively involved in B cell pathways, and higher methylation of these genes in 
Uganda could ubiquitously affect immune responses to pathogens and vaccines. 
NFATC1 is also involved in the inflammation mediated by chemokine and cytokine 
signalling and T cell activation pathway, and ITPR3 is involved in the inflammation 
mediated by the chemokine and cytokine signalling pathway. However, the increased 
methylation of NFATC1 observed at 10 weeks in Uganda, is not apparent at 52 
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weeks, and both NFATC1 and NFAT5 were hypermethylated in the UK at 52 weeks. 
These findings could indicate that the NFAT immune mediation is more prominent in 
the UK than Uganda at 10 but not at 52 weeks, where NFAT mediation of immune 
responses is more evident in Uganda.  
 
Laminin Subunit Beta 1 (LAMB1) and four ARPC genes were hypermethylated in the 
UK at 10 weeks. ARPC genes are involved in the integrin or inflammation signalling 
pathways, and they encode for an Arp2/3 protein complex, which is critical in driving 
integrin-dependent processes such as actin assembly and cellular protrusion31. 
LAMB1 is a laminin protein-encoding gene, which plays a role in cell binding via high-
affinity receptors32. In Uganda, we observed hypermethylation of ITPR3 (intracellular 
calcium modulator), CAM2KG (calcium-dependent protein kinase)33, NFATC1 
(cytokine inducer), SOCS5 (inhibitor of STAT signalling)34 and MYH10 (conventional 
myosin formation)35. These differences were diminished by 52 weeks of life, NFATC1 
became hypermethylated in the UK, and a new gene CISH, a cytokine-induced STAT 
inhibitor36, became hypermethylated in Uganda. This suggests that at 10 weeks 
integrin-mediated pathways are more methylated in the UK than Uganda, suggesting 
that in Uganda, these pathways and integrin processes are more active. The picture 
for inflammation pathways and genes is less clear as the Arp2/3 complex was 
hypermethylated in the UK and some key cytokine-inducing genes but also some 
inflammation inhibitors were hypermethylated in Uganda.   
 
Analysis of the T cell activation, interferon-gamma or interleukin or JAK/STAT 
signalling pathways revealed that both JAK1 and JAK2 were hypermethylated in the 
UK at 10 weeks, whereas NFATC1 and SOCS5 were hypermethylated in Uganda. 
This suggests that at 10 weeks JAK1 and JAK2 play a smaller role in the mediation 
of T cell activation and IFNg as they do in Uganda (perhaps highlighting a role for 
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JAK3), and that SOCS5 plays a limited role in the regulation of these immune 
responses in Uganda.  
 
Analysis of the TGF-beta regulatory pathway revealed hypermethylation of SMAD3 
and SMAD4 at 10 weeks, and GDF7 and SMAD3 at 52 weeks in the UK. SMAD 
proteins mediate TGFb induced intracellular signalling that regulates cellular 
processes such as differentiation, proliferation and cytokine activation37;  the GDF7 
gene encodes a  TGFb ligand38. This suggests that the role of TGFb in the regulation 
of immune responses in the UK is limited when compared to Uganda. In the UK, other 
mechanisms of immune regulation might be more prominent, including IL10 or 
regulatory T cell (Treg)-mediated regulation.   
 
We also highlight non-immune pathways of which DMGs were hypermethylated in 
the UK or Uganda. At 10 weeks, the PI3 kinase, NOTCH and GABA-B receptor II 
signalling pathways had more hypermethylated DMGs in the UK. All of these 
pathways could indirectly affect immune responses. Previous studies show that PI3 
kinases regulate cell growth and survival and are involved in T cell contact with 
antigen presenting cells (APCs)39; GABA receptors mediate immunomodulatory 
functions in T cells40; and NOTCH signalling mediates T cell immune responses41. At 
52 weeks, the WNT pathway had more hypermethylated DMGs in the UK. Proteins 
of the WNT pathway are known to increase both the survival of Tregs42 and IL12 
production by APCs, thereby driving TH1 differentiation43.  
 
When we looked at pathways and DMGs between 10 and 52 weeks in the UK and 
Uganda, we found that there were more DMGs over time in the UK (1424) than 
Uganda (223). This suggests that the dynamics of DNA methylation are more 
pronounced in the UK within the first year of life and that whereas the 10 weeks to 52 
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weeks window represents a time of changing DNA methylation content in the UK, this 
is less so in Uganda where any DNA methylation changes either happen earlier than 
10 weeks or later than 52 weeks of age. Both in the UK and Uganda, we found more 
DMGs of the B cell activation pathway to be hypermethylated at 10 weeks. This 
suggests that over time, as the DNA methylation of the B cell pathway decreases, the 
B cell pathway becomes more active, possibly leading to an increase in antibody 
production and cytokine signalling. This activation of the B cell pathway could likely 
be driven by exposure to environmental pathogens as well as vaccines. We also 
found that there were more hypermethylated DMGs in the integrin signalling pathway 
at 10 vs 52 weeks. Integrin signalling regulates processes such as cell survival, 
growth, proliferation, motility, spreading, migration, and other44, and our finding 
suggests that they could be more active at 52 than 10 weeks of life.   
 
We also analysed the data for differential methylation of genes and DMRs of non-
immune pathways and how they change over time in the UK. Interestingly, we report 
an increase in hypermethylated DMGs in the thyrotropin and angiogenesis pathways 
over time.  Angiogenesis is a process of vessel formation, and it is particularly active 
within the first weeks of life23. Therefore an increase in methylation of genes involved 
in the angiogenesis pathway could be one of the mechanisms to regulate  this process 
later in life.  The thyrotropin pathway induces thyrotropin and prolactin release, and 
prolactin has been shown to both stimulate and inhibit angiogenesis45. We also found 
a decrease in a number of DMGs over time in the histamine and two G-protein 
signalling pathways. G proteins can act as molecular switches to control chemokines 
and their receptors; they also affect cell survival, proliferation and migration; and 
recent evidence suggests non-canonical GPCR signalling in immune cells46,47.  
Histamine signalling is known to regulate immune responses, particularly by 
regulating TH1 and TH2 cells48. Both G-protein and the histamine signalling pathways 
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could therefore contribute to vaccine-induced immune responses, and this research 
suggests that these pathways become more active over time.  
 
Other researchers have investigated longitudinal changes in DNA methylation in 
infants and early childhood. Two studies 49,50 observed dynamic changes in DNA 
methylation over the first 5 years of life. They report hypermethylation of genes 
involved in cell development and adhesion, DNA binding, and the formation of cellular 
components such as dendrite or axon, and hypomethylation of genes involved in the 
immune system such as regulation of T cell-mediated immunity, cellular response to 
interferon-gamma or regulation of cell killing. Similarly, we have also observed 
demethylation of immune genes involved in B cell activation or integrin signalling and 
observed methylation of development-related genes involved in angiogenesis, axon 
guidance, or synaptic vesicle trafficking. To our knowledge, no study has compared 
DNA methylation between a low and high-income country.   
 
Numerous environmental factors including infection, nutrition, radiation and 
xenobiotics, , have been shown to change the epigenetic profile51, and some of these 
factors could be driving differences in epigenetics between UK and Ugandan infants 
as well as over time in each country. BCG has been shown to change the epigenetic 
profile in adults13, and similarly, we might expect other vaccines to influence the 
epigenetic profile of infants. Thus, differences in immunisations could explain some 
disparate epigenetic profiles between both populations. Bacterial infections have 
been shown to mediate  epigenetic modifications52, and Mtb is known to control 
chromatin at interferon-stimulated gene (ISGs) complexes to inhibit IFNg production53. 
Additionally, there is evidence that maternal diet has an effect on the infant’s 
epigenome in the Gambia54.  In addition to exposure to environmental factors, infant 
development over the first year of life has a strong relationship with epigenetic 
profile49. Increased methylation of developmental genes and pathways over time is 
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associated with tissue morphogenesis and development. Conversely, decreased 
methylation of immune genes over time is associated with  development and 
activation of the immune system49.  
 
Our study has a number of limitations. Firstly, the DNA methylation was measured in 
whole blood, which is prone to fluctuations in cell composition. Changes in 
frequencies of cell populations could affect the DNA methylation readout. We argue, 
however, that in order to truly understand the immunological milieu it is informative to 
examine the DNA methylation profile of the full complement of venous blood immune 
cells. This approach has proved fruitful in whole blood gene expression studies55. 
Secondly, in Uganda, infants’ mothers were older, and there were more infants that 
were CMV or EBV infected, or born to LTBI mothers. CMV and EBV infection can 
affect the immune system by changing immune cell composition and function56,57, and 
maternal LTBI infection is associated with lower infant anti-mycobacterial T-cell 
responses after BCG immunisation58. Due to a small number of samples and no CMV, 
EBV or maternal LTBI infection detected in the UK, we could not adjust for these 
factors. Importantly, the prevalence of CMV, EBV and maternal LTBI is high in African 
populations and should be reflected in the analysis of the DNA methylation. Further 
studies could be conducted to analyse the role of these pathogens on the infant 
epigenetic profile.   
 
This is the first study that directly compares DNA methylation profiles of infant whole 
blood  between two distinct geographical locations. We aimed to answer whether 
differences in DNA methylation, specifically of immune pathways, could explain 
differences in vaccine immunogenicity observed between high and low-income 
countries. We report dynamic differences in DNA methylation between the UK and 
Uganda, and between 10 and 52 weeks of life. Specifically, we found that at 10 
weeks, the B cell activation pathway and key immune genes NFATC1 and SOCS5 
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are more methylated in Uganda than the UK. We also found that at 10 weeks, the 
integrin pathways, TGF-beta signalling and key interferon and T cell activation 
signalling genes JAK1 and JAK2 are hypermethylated in the UK. Over time, we report 
a decrease in methylation of B cell activation and integrin pathways in both countries. 
Future studies should involve in vitro models and explore how methylation of the 
aforementioned genes and pathways affects the immune responses to pathogens 
and vaccines.  
 
  
 263 
Acknowledgments 
 
We would like to thank all the infants and parents who participated in this study. We 
acknowledge the funding from: the European Commission within Horizon2020 
TBVAC2020 (Grant No. H2020 PHC-643381); Medical Research Council Vaccine 
Studentship; MRC Uganda. 
 
Author Contributions 
 
Conceptualization M.H.A, S.S, H.M.D.; Methodology M.H.A, J.V.T, J.L., P.M., D.A., 
J.S., E.W.; Investigation and Formal Analysis M.H.A., Resources D.A., A.E., S.C., 
H.D., S.S.; Writing-Original Draft M.H.A.; Writing- Review & Editing S.S.; Visualization 
M.H.A.; Supervision S.S.; Funding Acquisition A.E., H.D.  
 
Declaration of Interests 
None 
  
 264 
Figures  
 
  
 265 
Figure 1. Scatter plots of differentially methylated regions (DMRs). Samples used for analysis 
included UK infants at 10 weeks of age (n=31), Ugandan infants at 10 weeks of age (n=16), 
UK infants at 52 weeks of age (n=12), Ugandan infants at 52 weeks of age (n=46). The grey 
dots represent genomic regions that were not DMRs. The aqua dots represent DMRs of which 
the minimum difference in methylation between groups was 5%. The pink dots represent 
DMRs of which the minimum difference in methylation between groups was 10%. The 
following groups were compared: UK infants vs Ugandan infants (A), UK infants at 10 weeks 
vs. Ugandan infants at 10 weeks (B), Ugandan infants at 10 weeks vs. Ugandan infants at 52 
weeks (C), UK infants at 52 weeks vs. Ugandan infants at 52 weeks (D), UK infants at 10 
weeks vs. UK infants at 52 weeks (E). DMRs were analysed using logistic regression with a p 
value <0.05 considered significant after multiple testing adjustment. 
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Figure 2. A summary of hypermethylated differentially methylated regions across all 
comparisons. The number of DMRs informs that there were a number of DMRs 
hypermethylated in a given condition. DMRs were analysed using logistic regression with a p 
value <0.05 considered significant after multiple testing adjustment. 
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Figure 3. Heatmaps of differentially methylated regions (DMRs) over countries and by infants’ 
age. DMRs between all UK and Ugandan infants (A); Ugandan infants at 10 weeks and 52 
weeks of age (B); UK and Ugandan infants at 10 weeks of age (C); UK and Ugandan infants 
at 52 weeks of age (D); UK infants at 10 and 52 weeks of age (E). The aqua colour represents 
a 100% methylation whereas the pink colour represents 0% methylation. Each column 
represents an infant and each row represents 1 DMR. DMRs were analysed using logistic 
regression with a p value <0.05 considered significant after multiple testing adjustment. 
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Figure 4. The pathway analysis of differentially methylated regions. Each column represents 
two groups that were compared. Each row represents a pathway in which at least one DMR 
was found. The aqua colour indicates one, and pink colour five or more DMRs that are 
hypermethylated in the group in bold. The black colour indicates that no DMRs were found for 
a given comparison in the specific pathway. Pathways were classified into immune pathways, 
physiological pathways, metabolic pathways, disease and other pathways.   
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Figure 5. The analysis of cellular processes and signalling pathways of differentially 
methylated regions. Each column represents the two groups that were compared. Each row 
represents a pathway in which at least one DMR was found.  The aqua colour indicates one, 
and the pink colour five or more DMRs that are hypermethylated in the group in bold. The 
black colour indicates that no DMRs were found for a given comparison in the specific 
pathway. 
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Figure S1. The tSNE analysis of all samples. DNA methylation values for samples in all groups 
were analysed using the tSNE method. The groups in the analysis included Ugandan infants 
at 10 weeks (navy), Ugandan infants at 52 weeks (pink), UK infants at 10 weeks (aqua), and 
UK infants at 52 weeks (orange). tSNE was calculated with perplexity of 21 and 1000 
iterations.   
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Tables  
 
Characteristics UK Uganda P value 
Mother's Age (Median Years) 34 24 <0.001 
Birth Weight (kg) 3.31 3.135 0.095 
Proportion of Boys 22/43 30/62 0.780 
Proportion of Tuberculosis infected Mothers 0/43 7/62 0.023 
Proportion of CMV Infected Infants 0/37 14/59 0.001 
Proportion of EBV Infected Infants 1/37 16/43 0.002 
 
Table 1.Characteristics of all infant samples included in the DNA methylation analysis in 
Uganda (n=62) and in the UK (n=43). The p value ≤0.05 was considered significant and 
highlighted in bold. The Mann-Whitney test was used for continuous variables (mother’s 
median age and birth weight) and the Chi-square test for categorical variables (the proportion 
of tuberculosis-infected mothers, the proportion of CMV infected infants, the proportion of EBV 
infected infants). Due to a limited sample volume, not all infants were tested for CMV and EBV 
in Uganda and the UK.  
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Table S1: Primer/Probe sequences used for EBV and CMV detection  
 
Target gene Forward Primer Reverse Primer Probe 
EBV-
(BALF5) 
CGGAAGCCCTCTGGACTTC CCCTGTTTATCCGATGGAATG 6FAM-TGTACACGCACGAGAAATGCGCC-BHQ1 
CMV 
(UL55) 
TGGGCGAGGACAACGAA TGAGGCTGGGAAGCTGACAT HEX-TGGGCAACCACCGCACTGAGG-BHQ1 
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Table S2: A summary of all differentially methylated genes (DMGs) when following comparisons were made: UK 10 weeks vs Uganda 10 weeks (A); UK 10 
weeks vs Uganda 10 weeks (B); Uganda 10 weeks vs Uganda 52 weeks (C); Uganda 10 weeks vs Uganda 52 weeks (D); Uganda 52 weeks vs UK 52 weeks 
(E); Uganda 52 weeks vs UK 52 weeks (F); UK 10 weeks vs UK 52 weeks (G); UK 10 weeks vs UK 52 weeks (H); and the number of hypermethylated DMGs 
is relevant for the arm of comparison in bold.  
 
Comparison(s) 
Total Number of 
Hypermethylated 
Genes 
Differentially Hypermethylated Gene(s) 
E H G C D 1 PAX6 
E A H G 1 LHX5 
B A H G 1 MSLN 
F A G D 2 RP11-934B9.3 ADCY4 
F B G C 3 FADS1 IFFO1 FADS2 
E B H C 3 FAM219A DNAI1 MLNR 
E A H D 4 TNFAIP8L3 NTF3 SMAD3 RP11-108K3.1 
F E A 1 TYMP 
F E H 1 RP11-89K21.1 
F B H 1 HOXA13 
F A D 1 PAX7 
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F H G 1 PTPRN2 
E H D 1 HMX1 
B A C 1 CCDC106 
B A D 1 OSR1 
F B G 2 BAIAP2 BAIAP2-AS1 
F G D 2 B4GALNT1 CBX8 
E B H 2 NFATC1 SLC9B2 
E A H 2 BARX2 AUTS2 
A H D 2 GPR27 EIF4E3 
E H G 3 SPG7 ONECUT3 SKOR1 
E H C 3 HTRA1 GDF7 ARL6 
B H C 3 B3GNT2 AC007405.4 ERICH2 
F A G 4 SLC16A12 CATSPERG NR2E1 SLC35D3 
E B C 4 RPSAP52 RP11-572O17.1 SLBP HMGA2 
A G D 12 FNDC1 CAMTA1 RP11-268J15.5 PNMA2 SH3D21 FBXO16 DPYSL2 STEAP3 RP11-312B8.1 EVA1B GSX1 RP11-13P5.2 
F E 1 KDM2B 
F A 1 PLXNA2 
F C 1 ZNF398 
E C 1 RFC4 
G D 1 RCN1 
E A 2 TSPAN14 ODF3B 
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B A 2 GNAS EBF4 
H D 2 PDLIM1 GAS7 
G C 5 ARHGAP5-AS1 MFSD8 C4orf29 ARHGAP5 FOXO6 
F B 6 ZFAND2A KCNIP3 CLDN23 AC091729.9 RASSF2 PARP10 
F D 6 CPEB1 PHF21B RP11-752G15.3 YAF2 TRPC6 PPHLN1 
A H 11 RP11-111M22.2 NEU1 SPEG TCF7L1 FAM102A OTULIN CCDC78 SLC44A4 FAM173A PRKRIR CTD-2165H16.4 
B G 16 
STK25 ENTPD2 SPATA2 CDK18 ZCCHC6 SOGA3 PDGFRA BAALC-AS2 BAALC DNAJB14 RP11-229P13.15 FIP1L1 AMN SHISA2 SYT9 
PDE12 
B C 32 
RP11-95G6.1 NAT8L EMP2 ARHGEF7-AS2 FOXL1 TEX2 DUSP10 RP11-126L15.4 FLT1 U2AF2 NUDT8 SLC43A2 ESYT2 PQLC1 EPAS1 
KB-1732A1.1 ARHGEF7 TRMT112 FGF20 RP11-93B14.10 SUMO3 SLC12A9 PRDX5 NAGS SLCO4A1 HES6 HTR6 NTN1 FIGNL2 THBS2 
E2F6 AC096574.4 
A D 44 
PXYLP1 KLF3-AS1 RP11-343C2.9 EN1 ZNF395 ZNF747 LINC00682 TGIF2 SLC16A11 COG8 SEC61A1 TBC1D24 IQCJ-SCHIP1 GPRIN1 
PPP1R9B VWC2 RP11-343C2.7 ZNF768 IQCJ-SCHIP1-AS1 TUBB4B RNMT AC005256.1 VGF NTN3 ABTB1 KLF3 ST8SIA5 DLGAP4-AS1 
DACH1 RP11-158I9.8 PODXL2 TGIF2-C20orf24 EBF3 PLEKHA1 NIP7 DDX6 ELOVL6 FAM210A SOX11 RP11-742D12.2 FAM131B 
LINC01248 AC002310.14 USP1 
B H 55 
KCNA6 C20orf27 FEV AC093887.1 KIAA1211L THRB TPT1 PROSER3 AC002398.12 NR3C2 FLJ46906 DEGS1 RAX MAPK11 TPT1-AS1 
RP11-386G11.5 FLJ27354 SLC35F2 GALNT8 RAB39A HOXB7 MAPK4 KAZN EIF4EBP2 HSPB6 POU4F2 LRRC8C NTNG2 HOXB3 
FBRSL1 ISOC2 SUN1 KCNK17 SYNJ2 HOXB-AS4 CRLF1 TRIM9 THRB-AS1 RP11-413E1.4 DNAJC6 DALRD3 RP11-302M6.4 TMEM158 
FOXL2NB SYT3 DDN RP11-290D2.6 CELSR1 PRSS23 ABHD15-AS1 NHSL1 C19orf60 RP1-170O19.14 PDLIM3 HOXB-AS3 
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A G 59 
CREB3L1 NCOR2 FGF17 DMTN PRDM16 AAMDC NGFR UBE2D3 FAM160A2 CRAT ARPC1A PIP5K1C PRRX2 ARHGAP32 PPP2R4 
KMT2D TLN2 CSMD2 RP11-10L12.4 AC144831.3 APOLD1 DPP9 ARPC1B NAB1 ZNF512B LINC01006 GNB1 RSF1 MORF4L1 RP11-
680F8.1 ADAMTS7 NSUN4 RFX2 TMTC2 RP1-140A9.1 RAI14 EPB41L1 GRHL2 TOB1-AS1 CNRIP1 SHANK1 FGF4 SMAD4 RP11-81K2.2 
TCF24 CTB-66B24.1 OSGIN2 B3GAT2 RP11-729L2.2 CTD-2024P10.1 LAMB1 MSX1 SPTB CNGA4 PKN1 ATP12A ZMIZ1 HIVEP3 TOB1 
F G 66 
RP11-439L18.2 SMO USP6NL RIPK4 RING1 RP11-165N19.2 PXDN F7 AC005013.5 FLJ31306 RP11-545G3.1 TRIL HSPA2 GPRIN2 
PRCD RP11-973N13.4 NPAS2 INSM1 SPRY1 C14orf37 MIR219A1 GAS1 RNPS1 ABHD17B ZC3H4 GUK1 ELP2 BACH2 DIO3OS DIO3 
C9orf85 CMIP TEKT4P2 EFHD1 NACC2 RP11-138I18.1 SLC16A9 AC009065.1 IFNGR2 ZNF217 LINGO1 MEGF9 ITM2C TRIB1 KAT6A 
RP11-545G3.2 TNFSF12-TNFSF13 ISG15 TBC1D4 PTPRS HIVEP2 CYGB WNT7A CXCL12 FGF18 MIR940 FOXF1 ANK1 MIR1247 
ARID4A SMARCA2 SAE1 SP5 HES4 SUSD1 SLC39A6 
E H 68 
MSL1 REEP6 CHD9 KNDC1 TMEM132E UTF1 GEN1 CIAO1 OXTR SMC6 ECE1 RP5-940J5.3 NEDD4L CAV3 DCLK2 FLJ13224 TOX 
RAMP3 HUNK ADAMTS15 KCNJ12 CTD-2527I21.7 Six3os1_5 IFNLR1 NABP1 C17orf102 SP3 FAT1 UBALD2 ZNF503-AS2 GAPDH 
ZBTB25 CH25H ESPNP MCTP1 LBR KIF26B TLX3 CTD-2369P2.8 GRK6 TMEM127 ENAH RASEF RP11-25K19.1 GGPS1 LMO2 PTCHD2 
SLC7A10 Six3os1_6 GRAMD1A FAM60A ICAM4 PCSK4 ZBTB1 BCL2L1 MIR1199 NCAPD2 TDRP F12 ARID4B AGAP1 WNK1 NKX3-2 
HS3ST4 RP11-546B8.6 ICAM5 FMN2 KLHL24 
C 40 
CCDC177 LMNB2 LRRC48 TIAM1 ZNF425 SORCS2 CEP131 SVIL SHH VAV3-AS1 ZBTB4 SLC35G6 AP000251.3 BIRC6 POLR2A HNF1B 
HS3ST2 AJUBA PHF23 LIN54 CIB2 KCNA2 TMEM233 ETS2 TOM1L2 MAP3K10 RN7SL521P RP11-298I3.4 MTMR9 IDH3A RP11-
768F21.1 FOSL2 TMPRSS9 PCGF5 FLJ31356 TIMM13 AF131216.1 VAV3 NPTXR RP11-298I3.5 
D 46 
KCNMA1 PRKRA UFSP1 NRARP FOXA2 FRMD6-AS1 MFSD11 OGFR-AS1 ARPC4-TTLL3 MED18 ATP6V0A2 ANP32A WDR26 
ATP6V1E1 FAM19A5 LINC01276 ARPC4 VPS72 PLEKHG1 CPT1C ADM5 DFNB59 LDLRAD4 TADA3 NR5A1 INO80E FRMD6 HIRIP3 
BCL2L13 ACHE PVRL2 SPESP1 MIR636 FOXP4-AS1 CTB-33G10.6 RP11-136K14.1 OGFR SRSF2 MEST RP11-318A15.7 GMPS CNIH3 
RECQL4 PPP1R3G LRRC14 GATA4 
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F 62 
IRX5 DLX2 LAMP3 MMP15 PP14571 IRX3 EFNA2 LA16c-366D1.3 Six3os1_4 RAB11FIP4 CSRNP1 SENP3 HOTTIP_1 TNFSF13 SMOC2 
MAPKAPK3 RP11-434E6.4 LRP8 ZNRF3 RP11-982M15.5 RP11-47A8.5 TMEM200B RP4-784A16.5 MED12L SCO2 MNT ACOXL DOC2B 
ASTN1 CAPN15 SOBP CCNA1 PRTG Six3os1_2 DSCAML1 FRAT1 DHRS13 ZNF407 ZNF595 FLOT2 INF2 SMIM19 MRPS26 SENP3-
EIF4A1 FERMT2 BCL2L11 LHX3 FGF9 PPP2R1A SLC20A2 PLEC LINC00909 Six3os1_3 FAM84A PRR35 RP11-20B24.4 CDH4 CISH 
TRIM8 GPC1 HOTTIP TOP1 
E 69 
LRRC41 MIR3665 POU3F1 FBXO31 WNT3 MT-TP ABHD12 CCDC18 SLAIN1 RP11-615I2.2 PRRX1 RDX CPVL MAP1LC3B CD8A WNT9A 
CHN2 NFAT5 BAIAP3 PAX2 RP11-1008C21.2 PSMA5 FOXG1 CDH3 PDCD6 WNT1 MAF1 RP5-884C9.2 TIGD4 ARFIP1 TBX3 RP13-
582L3.4 RAB34 ENO3 PALD1 CCBE1 RPL23A MKX AC006486.9 SHOX2 UQCRH AP1G1 SNORD42B UAP1L1 MYO1C MGAT1 RP11-
2N1.2 PCP4L1 SFSWAP RRP9 MT-CYB STAC2 CCDC134 TMED5 MIR1538 KCNK2 MKX-AS1 CACNA1A PURG CASZ1 AC006486.10 
WRN WSB2 PARP3 SHARPIN MT-TT PFN1 SIX1 GSK3A 
B 231 
ELMO2 SAMD4A LCORL MYO9B IZUMO4 MAP3K3 RP11-298P3.4 NFIA NMNAT1 CDC25B LUZP1 UBE2E2-AS1 LEPREL2 MGAT4B 
C2CD3 GAS2L1 SYT12 HPCA SEC14L1 PPP2R5A SPTBN1 PHLDA1 DIDO1 RP11-274B21.1 IGDCC3 RP11-290L1.2 TPMT TP53I13 
C6orf58 TTC13 PHYKPL ASAP1 RP11-22P6.2 AP4M1 SH2B1 MAP7 SECTM1 RP11-53I6.3 NAV2 MICA SLC7A5P2 C19orf81 NARFL 
FAM107B NOL4L SNRPG ZBTB7C MAST4 SGSM3 RP11-482M8.3 MAGI1 RP11-84A14.4 RP11-123O10.3 RP11-293M10.6 RPS6KA2 
OLFM2 RASSF8-AS1 NDE1 UBASH3B FOXJ3 TSSC4 PPP3CB NAMPT RP1-261D10.2 UGGT2 EFHD2 MCM7 LGALS3 DCBLD1 SMG1P3 
SFI1 SHISA4 COMP LPCAT4 TUBA1C EIF4ENIF1 SRGAP1 DNAJC21 RP11-305P22.9 FOXB2 CTC-367J11.1 FBXL17 ZNF160 METTL24 
CROCCP2 KIF13A GRINA HERC5 TGIF1 EPS8L2 AC121334.1 UBE2E2 RP11-219B17.3 KCTD8 RP11-209D14.2 KDM1B LZIC RASSF8 
SOCS5 RP11-783K16.10 RIMKLA RBM15B AC019181.2 RP11-161H23.5 TSPAN4 TRAPPC3 N4BP2L1 JDP2 RP11-123O10.4 RP11-
429P3.3 XKR4 LBH RPRM BHLHE23 LENG8-AS1 MAP7D1 UTP15 ZNF697 RP5-875O13.1 PPP3CB-AS1 COBLL1 OTUD1 ANKRA2 ARV1 
HCP5 NDUFAF3 SLC22A4 NDST1 GALK1 IRF2BP2 RP11-410N8.1 GPR162 ST6GALNAC5 SOX21 RXRA ZNF704 TCHH SQSTM1 
NMRK1 OSTF1 CTIF AFG3L2 RP11-223A3.1 RP11-977B10.2 RP11-22N19.2 WTIP DSC2 MAPT CLDN7 ABHD15 MSX2 RP11-576D8.4 
FAM181B NDUFA4L2 FBXW4 AC131951.1 CHL1 SPON1 CGGBP1 SLC1A2 NGB KIF21A TTBK1 MYH10 SIPA1L1 NRG2 AGFG2 ZSWIM6 
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SPECC1 LENG8 C3orf80 GOPC HAUS8 RP5-1042K10.14 DRG1 RNF138 RP11-95O2.5 RP1-4G17.5 CAMK2G KCNK4 MVB12B CREB5 
RP4-781K5.2 FGFRL1 MOB3A MAPT-IT1 P4HA2 NPHP4 MIR3663HG RORA RP11-290L1.3 AC012501.2 MIR1908 AAMP KREMEN1 
TBC1D30 CDK2AP1 KCNAB2 PPME1 RP3-325F22.5 RP11-410N8.4 KCNQ2 LEMD1 RP11-359E10.1 DPH2 RP4-683L5.1 RP11-212P7.2 
DSCAS ZNF367 RP1-309F20.3 HOXB6 SOX21-AS1 KCNK13 PRKAR1B RP11-53I6.2 DEAF1 C6orf132 CHL1-AS2 IL12A-AS1 FSTL3 
TMTC4 RP11-219B17.1 PARD3B C3orf38 JPH3 HEATR3 CELF4 INPP5A chr22-38_28785274-29006793.1 PNKD ITPR3 
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MLC1 SLC4A8 RP11-156P1.2 DHRS11 TOPORS-AS1 CA11 CBX3P2 RP4-575N6.4 CTD-2012K14.6 RP11-783K16.5 RP11-656D10.3 
MAPK12 OTUD3 INTS1 ZNF284 P2RX5-TAX1BP3 EMILIN1 AC009501.4 CDC42EP3 PHF7 LIF CNTFR ITPRIPL2 SLC9A3 FKBP4 
PTGER1 GFI1 RTN4RL1 SERTAD2 PAQR4 SEMA3F-AS1 DENND5B-AS1 SNTG2 PAQR3 LINC01063 KIT AURKAIP1 RAB20 JAK2 
NKIRAS1 PEX26 NEGR1 FGF12 RP3-512B11.3 RP11-21J18.1 SMCHD1 RP11-65J3.3 CTD-2545H1.2 TRPC4 DLEU2 NR1D2 TRHDE 
PANO PARVB CTD-2228K2.7 CHST2 SLC37A1 ZNF223 BCL11B DACT3-AS1 RP11-146B14.1 RP4-591C20.10 EPHB1 MKKS WEE1 
HES2 COPS6 ADARB1 DBP UCKL1 FAM207A SLC27A6 RP11-685M7.3 UNCX AC073316.1 TUBB2B HECTD1 ZNF717 ATP9A APBB3 
PPP1R14B NKX2-3 MT-TS2 GALNT6 LRFN1 SIRPA FAM132A EML6 TAX1BP3 PRPF8 CTD-2012K14.7 ARHGEF4 PAOX DLEU2_6 
TMEM114 PPP1CB MT-TH GLDC AC116614.1 DLGAP3 CHST12 STAU1 TNIP1 DLG5-AS1 TAPT1-AS1 EMC6 CTD-2349B8.1 CRIP1 
VPS54 FBXL16 ZFAND5 SHANK2 RP5-858L17.1 TMEM41A ZNF496 RP11-776A13.1 CPB2-AS1 ARPC5L PIK3R1 AC083843.2 DLG5 
PER1 BMI1 GPR63 SEMA3F COMMD3-BMI1 PIDD1 PTPRU TIGD3 MRPL23 TTC9B NCOA7 LRRC37A17P RAPGEF4-AS1 RP11-
783K16.13 PYCARD MIR4488 OAT IQGAP2 MIR193B LINC01547 CHRNE RECQL RP5-1029K10.4 DSP RP11-144F15.1 RP11-510C10.2 
NXPH3 SLC44A2 DLEU1_1 DBNDD2 ZNF581 SLC2A13 RP11-65J21.3 FBN2 SSBP4 ALK DACT3 SYS1-DBNDD2 R3HDM4 RP11-
423C15.3 RP11-599B13.6 FLJ42351 RP11-586D19.1 EXO5 PP7080 RP11-65J3.2 PACS2 SKOR2 KHK ELOVL7 THBD ATHL1 SLC25A22 
C17orf107 MT-TL2 MAP3K8 EGR2 JAKMIP1 DGKZ LINC00092 PPP1R3B C14orf80 RSPO1 RP11-10A14.4 PPP2R5C MT-ND4 FAM168B 
LHX8 PDS5B RP11-363J20.2 LRFN2 KCNK1 NR6A1 NDUFV2-AS1 WBSCR17 PCGF2 DENND5B SSR4P1 CBX3P4 FAM118A ADCY8 
LRRC10B SOX9-AS1 RAPGEF4 CTCF AADAT DOT1L PBX3 LPAR2 PRLHR ETF1 TOPORS RNF213 CTB-58E17.5 SLC35A4 ZC3H13 
ARPC2 KLF1 ACSS1 EPB41 CARM1 RP1-102K2.8 TMEM51 ZNF580 WWTR1-AS1 AFAP1L2 TUBA8 BRAT1 S1PR1 CIC RP11-961A15.3 
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DAB2IP KDM4C SDK1 TEX22 PABPC4 PTH2R MDK SLC20A1 NR5A2 IQSEC1 PCDH10 AC008079.10 KIAA1456 RP11-326C3.2 RYR2 
PKMYT1 AP3D1 SLX4IP RP5-1148A21.3 BAP1 SALL4 AC011247.3 TSPAN9 KIAA1614 ANKRD12 RP11-849I19.1 RP11-316O14.1 
PYCARD-AS1 ZMYND11 WWTR1 COBL RP11-175D17.3 JAK1 QSER1 HNRNPLL EPHB6 ST8SIA2 TAPT1 PTP4A1 RFX4 LRRC16A 
RP11-510C10.3 ADPRHL2 EIF4G2 MAP4K4 PPP1R18 CHN1 SALL3 ADAMTS5 CAST DLEU1 TRHDE-AS1 GALNT16 AC053503.11 
GOLT1B DPYSL3 PHF21A RPRML RP11-390F4.6 TP53TG5 
G 530 
EIF2B5 DPY30 VPS33A RP11-512M8.5 SALL1 RMRP NHLRC3 NTRK1 FRAS1 UQCR11 DCAF5 TRIB3 ZNF131 TRIM33 AK7 GOT1 RP11-
201K10.3 CCDC166 UTRN CTC-359M8.1 CORO7-PAM16 RNF103-CHMP3 ZNF529 PLEKHO1 LINC01121 CNGA3 RP11-468E2.2 RP11-
347I19.7 IPO4 INSRR SHBG CTD-2265O21.7 OTUD4 GCC2 C1QL1 RP11-106M3.3 TIMM22 AC079790.2 TMEM200A RP5-906A24.1 
ZSCAN32 ARL16 PRRC2B UPF3A USP46-AS1 ZNF687 SDC2 QKI EZR FUT4 HGH1 ZNF655 HSPA8 PICALM ANKLE2 TLE2 VSIG8 
ADRA1A KISS1R IL5RA STON1 CDH24 DUSP18 TNFSF12 PLEKHM1P ARID5A LMO4 RP11-571L19.7 GOT2 UIMC1 PPP1R1B CLTCL1 
RP11-927P21.4 RP11-477I4.4 CASC4 SLC35F1 FHDC1 GPR158 RILPL1 SAMD10 GTF3C5 PARK7 CTC-435M10.3 BAI1 MEMO1 TBC1D8 
ASCL2 SYDE2 CTD-2089N3.2 NSMF DCAF11 RHPN1-AS1 BARD1 HS3ST6 CTD-2278I10.6 MIR6080 ZNF710 MCM10 H2AFY2 SAFB2 
AC072062.1 CHTF18 CTD-2562J17.4 RRAS ESR1 AC009236.2 GCH1 PEBP1P1 TNFRSF19 LRRC45 SLC19A1 KIF9 PITPNM2 TGFB1 
RAVER1 CAHM ADAMTS17 KLHDC2 RP11-353N14.1 B9D2 KRT86 LLNLR-304G9.1 MT-RNR1 PROCA1 NAP1L1 ZDHHC17 MTUS2 
CCDC107 COL4A2 RP3-510H16.3 RP11-95P2.3 EIF4E FAM200A RSPH14 LSM14B HMHA1 NGEF GFOD1 CTNNBIP1 AGRN PLCB4 
MRM1 IRX4 ADHFE1 USP46 GNAZ POU4F3 EIF3A YRDC FXR2 NRL PAPOLG SNX9 FAM134A Sep-08 PLCD1 CTD-2369P2.12 DBI 
LPIN2 CNTN1 LA16c-306E5.2 TENM3 ATP6V0C KCNG3 TMEM91 KIAA1257 LIPG CTD-2313J17.1 C2CD4D NEK8 RP11-347C18.3 
PPP2R2A C11orf80 JADE2 TRNT1 RP11-411B6.6 TNFRSF21 KLHL18 RP5-1059L7.1 CTD-3184A7.4 CABIN1 IER5 RHOT2 RP11-
417L19.4 ARL5C Mar-01 RP11-635N19.1 LINC01089 EZR-AS1 ANKLE1 NMRK2 TP53I11 XRN1 CTD-2186M15.3 CRMP1 GPR158-AS1 
SYBU AJ003147.8 COL4A1 RP11-755B10.4 LEKR1 VASP SETD1A CTB-180A7.3 LPP-AS2 PTGFRN ZMYM2 GUCD1 CTD-2089N3.3 
EFCC1 GTF2I SCAF1 SSPN GFOD1-AS1 FAM78B STRA13 DOK5 NOVA1 PNPLA7 MXD1 SOWAHA BOC ATP6C ELMOD3 ARMC4P1 
NEURL1B SP8 TRIM46 NSUN7 PIP5K1B KIAA1462 AC007040.6 PFKFB4 FUK KCNMB4 SBNO1 PRPF40B HIGD2A CNOT11 RRS1-AS1 
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RP6-65G23.3 STON1-GTF2A1L KDSR BHLHE41 PRCC BRAF PBX2 HGS ADARB2 LINC00472 GULP1 SATB1 PPM1D SDHA MAP3K9 
RHBDD1 STT3B SAFB FAM174B AC005391.2 LPP RGMB MPPED2 RP3-466P17.1 NUFIP2 AXIN1 RP11-1012A1.4 RP11-654A16.3 
TM9SF1 MIR1470 RNA5SP174 UCN RP5-1024C24.1 FBXL6 FAM20A CHID1 IKZF5 RHOF NRP1 SAMD3 AC010761.9 HRK EPHA2 RP11-
436D10.3 SLC18A3 DGKH LINC01424 AC009166.5 C5orf28 MIR8072 IKZF1 TBC1D5 SLC25A1 GAN EVC2 PRKCI FOXC1 WIZ ACBD5 
NLRP6 CKB MUC1 DYNLT1 AC019131.1 ARID3A GOLPH3 ARF4 CTD-2201E18.3 SEC31B SOS2 GPI AC007040.11 AGPAT3 ABO 
KCNH2 RP11-441O15.3 CELF6 TEX261 CCM2 ZNF707 ZNF382 NDUFAF6 ECE2 ARF1 POU4F1 CCNG2 ISL2 EVI5 PUS1 RNF103 
STOX2 RNF219-AS1 PPP3CC TPBGL PROSER1 RP11-97O12.2 FAM149A KAZALD1 RP11-685G9.2 AC010761.6 RP11-159F24.3 TTLL7 
ARL10 RP11-845M18.7 VEGFC ZFPM1 RGS7 RP11-276H7.2 C1orf122 CHAT RP11-410D17.2 NOP16 ANKRD11 BCAR1 ADO 
AC005481.5 FRAT2 UACA RRS1 KLF12 AMDHD2 KIAA2026 PPIB FAM155A CCDC127 LINC00982 TPRN TOM1 RP11-347I19.8 C2orf76 
RCAN3 ERI2 MANEAL LINC01397 PRKAG2 H2AFX TXLNA RAB31 SPATS2 ZNF696 SRSF4 GPR88 MKRN2 RP11-529K1.4 GMEB2 CTC-
308K20.1 STAG3 UBE2G2 PHLPP1 RP11-452K12.4 ACE SSSCA1-AS1 PTPRK WDR81 MFSD2B CTD-2369P2.10 ST3GAL2 RHPN1 
SEMA5B BDH1 LATS2 ZNF174 MKRN2OS LRP6 RBCK1 ZDHHC8 VCPKMT FDX1L MN1 LY75-CD302 CACNB4 SMURF1 FAM105A 
DNASE2 MT-TF EPN3 MTA3 EPB41L2 PIWIL4 NFIX RP11-402J6.1 LY75 HOXC12 CBL SLC35E4 CYB5R1 RTTN FADD ERBB3 HPCAL1 
PLD4 AGPAT2 TP53INP1 GNAQ IGDCC4 MMAA AC092675.3 TRAF4 CORO1A PPIL2 TRIM54 EPM2A EXD3 PAPL NEUROG2 PAX8 
TRRAP AC004381.6 ANPEP TBX20 GOLIM4 RP11-20I23.1 STK35 GS1-259H13.10 GPC2 RP4-753F5.1 MIR4665 TCERG1L TMEM163 
LHX5-AS1 SSSCA1 ALG3 BEND6 PLEKHH3 CDH23 CDC123 MLEC USHBP1 PPP1R16B AMOTL1 IER3IP1 CHD5 GPD2 RP11-455F5.5 
CORO7 RGMB-AS1 CDC42BPB CIRBP RP11-106M3.2 SNRPD3 CNP C1orf204 NOVA1-AS1 GATA6-AS1 CNPPD1 SYVN1 NUDT5 
PPP1R14C GNG13 HDGF PVRL3 CACNA2D4 MIR22HG LINC01482 PMEPA1 MFNG VTI1B RP11-449H3.3 RP11-283G6.3 SRSF5 ETV6 
AC092675.4 STK38 RETSAT UEVLD CLPP ESPN RNase_MRP MPG FAM132B GPR39 E2F3 RPL26L1 PVRL3-AS1 LRRC37A6P LHX9 
SLC52A2 C21orf58 AMD1 TRPC3 MBOAT2 CLIC6 VHL ATF7IP2 FAM49B RP11-867G2.8 PCNT CTD-2313J17.6 UBE2J2 PCIF1 
H 540 
FARP1 RP11-154J22.1 AHDC1 PAK1 GYS1 ERG ANKRD13B G2E3 FAT4 TMCC3 RP11-271C24.2 NR4A2 LRRN2 SNX33 RHOT1 EPT1 
ARL4A CCDC64 TAOK3 HSD11B2 ZNF48 AC097468.7 RELT ELANE TMEM240 ZNF32-AS3 WHSC1 RTF1 NEFH ALX1 CCNY MSH6 
 285 
IP6K1 PPP1R3D F2RL1 C1orf216 NTHL1 FAM163A HNRNPR PPM1A NKX6-1 RP11-14D22.2 CHST11 RALY-AS1 CTD-2269F5.1 NCDN 
PPFIA3 AL356020.1 TRIP12 ERO1L KDM2A SAPCD2 TFAP2B NEBL RP11-758P17.3 LYSMD2 RP11-610P16.1 IPO13 OSR2 Sep-01 
STAT5A SF3A3 NDNF FBXO36 ZFHX4-AS1 ATP10A PHACTR1 KLF4 ARHGEF16 SFRP2 STRIP1 GGN KCNK10 HOXB5 AC090616.2 
PIEZO2 GRWD1 CYHR1 PDSS1 SMG8 TMEM79 LINC00577 RIMBP2 Sep-05 AC005789.9 UBALD1 TMEM189 ZNF518B TSHZ1 
LRRC16B LRR1 MIR17HG RPS29 KIAA0319L TALDO1 CTNNB1 EME2 ATP6V1A AC093901.1 TPGS1 DNMT3A INCA1 NCK2 TRPM2 
CTD-2517M22.16 ZNF565 GLOD4 DVL1 PRMT1 TMOD2 ITGB8 NPNT PCBD2 XYLT2 MFAP3L CEP68 SCARF2 ENOPH1 MFI2 EVX1 
RNA5SP18 GPR124 MAPK8IP2 RUVBL2 EPN1 ZFAND6 VCP INTS12 RALB POU2F2 GFRA2 TSEN54 NCOA6 PPP4R1 TWSG1 UPF1 
TRIM47 SLC25A30 PTDSS1 GRIN3A FMNL1 STK24 C9orf116 CTB-147N14.6 HDDC2 RHOQP1 EGR4 MAP3K14-AS1 FOXD2 SOGA1 
PAM HAS3 EVX1-AS GOLGA7B SLC12A7 RP11-467D6.1 FLJ30679 C1orf229 RP11-647P12.1 CCR6 PLD2 TFAM PPP5D1 ENTPD6 
SLC31A1 HDAC4 CTNNA1 CTB-158D10.3 PGF RP11-14D22.1 DPM1 GP1BB RP11-54O7.16 PTBP3 RNA5SP492 BLVRA CASC15 
UNC5C CDK13 CAPN2 CTD-2006C1.2 ITPKB SLC22A31 TMEM50B FEZ1 DDIAS EIF3J FAM47E-STBD1 PHF2 MCHR2 LRRC26 SEMA6D 
MTHFD1L GPR113 NCL KCMF1 CTD-2330J20.2 BHLHE40 RNF111 SUSD4 TMEM189-UBE2V1 FKBP15 RP11-651L5.2 MAP3K4 
AC079779.4 LIN9 MAFB CYSRT1 TMEM14B MECOM RP11-428O18.6 RP11-350O14.18 DDHD1 ICA1 CTD-2020K17.4 SLC25A30-AS1 
SYPL1 ELOVL1 CDCA2 CASKIN2 RP11-1398P2.1 BAG4 ZNF32 MTERF3 ZNF746 SPSB1 JMJD8 RP3-400B16.4 ELAVL1 HRC CFLAR 
AC013460.1 RP11-81A22.5 WDR37 IMP3 AC062017.1 ZHX1 GDF1 ZNF789 RP11-739B23.1 RP11-348J12.5 SCMH1 IFNAR2 PITPNC1 
GPX1 DOCK7 LIN28A AP000708.1 KCNJ11 RP11-230B22.1 THUMPD3-AS1 RP11-297D21.2 MGRN1 HAP1 RP11-428C19.4 SETD4 
MAP2K3 RP11-480I12.10 RHOBTB1 CHPF LPCAT1 RP3-400B16.1 LINC00404 GINS2 DCAF17 CCDC24 CERS4 CKAP4 ANKRD37 
B3GNT5 AC005775.2 E2F8 PRCP RP11-1103G16.1 STK24-AS1 SLTM TRIO NUBP2 KIF7 AC013394.2 RP4-555D20.4 NRM RP11-
135A24.4 TMEM9B-AS1 LINC00866 NR2F1 FASN METTL8 EIF3J-AS1 ABCG1 AL391839.1 RP11-324I22.4 RNF208 RALY RP11-662M24.2 
FAM150B FBLIM1 AC034243.1 SOCS2-AS1 CACHD1 TMEM223 RP11-649E7.5 AKIRIN2 DDAH1 RP11-73M18.2 WDR43 MTHFSD KIF5B 
RP11-483H20.4 SND1 RP5-942I16.1 AP000688.11 SNRPA PRKD3 LRRC4 TSC2 AC007009.1 PNMAL2 CNN3 JAG1 MCHR2-AS1 SLC1A5 
GET4 GRIK4 TP53INP2 ALX3 ALDH1A2 RP11-637O19.3 FAM208B CD58 LITAF TRIM37 TMEM165 CTD-2369P2.5 EGFL7 ATP5J2-
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PTCD1 NEK7 ARNTL2 CPA2 MAP4K1 PPM1M PDE9A STUB1 SIM1 NHP2 CDK6 HMX2 ZFHX4 MOCS3 ANO1 AKTIP HTT-AS PLEKHG3 
SENP6 RIF1 FHL2 PCAT6 NCAPG2 NAA50 RP3-428L16.2 CERS1 GPATCH4 PTK7 CSNK1G2 RAD52 B4GALT2 KIAA1147 HELZ2 
CACUL1 HR TFAP2D ROBO1 TMEM9B RP11-727F15.12 DRAM1 SETD5 CTB-113I20.2 NOC2L CDK5R2 NDFIP2-AS1 NDFIP2 CD9 
VDAC1 ASRGL1 SCGB3A1 AC007128.1 SEMA3B CXXC5 RP4-639F20.1 TFRC EPC1 CTA-293F17.1 RQCD1 RP11-399E6.1 KCTD9 
PRNP TRIP13 LINC00237 RPL36AL TAF6L RP11-135A24.2 ECI2 USP37 PRICKLE2 NEBL-AS1 RP11-758P17.2 SPRED3 UBE2D1 MLK4 
ZNF461 WDR47 PHLDB1 C16orf74 RP11-888D10.3 PRKCE MIR126 AC073343.13 NDUFB10 BRD9 GIT1 MSL2 DPF3 bP-21264C1.2 
NIPSNAP3A EDIL3 CNNM1 TSPAN15 SHISA6 TPM4 PPP4R1-AS1 INPP4B RP11-103J8.1 B3GALNT1 MGAT2 RAI1 C17orf104 RPL21 
SYT6 ADAMTS1 CYP20A1 HTT BRI3 HNRNPDL RP1-167A14.2 GRIN2D GALNTL6 KIFC2 GRIN1 NAT16 ZKSCAN5 TUBB6 RHOB IDI1 
WNT10A ASB6 Sep-11 ICAM1 SIX4 LHX6 RBM22 SHISA9 MICAL3 SMG5 DCP2 SRD5A3-AS1 GTDC1 PDZRN4 SH2B3 KIF1C NR2F1-
AS1 DUT RP11-522B15.3 MIR3621 FGFR1OP C19orf54 CTD-2510F5.6 SLC12A5 AC099850.1 MRPS2 RP13-16H11.8 SPSB3 TMEM198 
BAI2 C18orf25 NEUROG1 SOCS2 INSR KLC1 MIR6872 HTRA2 PPFIA1 VSX2 SLC39A11 AUP1 LSM1 QSOX1 CDC34 FAM217B RNMTL1 
SLC6A9 PTCD1 CRTAC1 SCN8A PPP1R35 KLHL17 TMEM179B CITED4 PSMD7 EIF3K CPSF4 GPR156 MAK STC2 GAREM RP11-
7O11.3 AC009120.4 RP11-12M5.1 LA16c-313D11.9 ZHX1-C8orf76 CTD-3224K15.2 WNT5B AC007391.2 ZNF12 NMD3 MCF2L2 DNER 
HMGA1 CTD-2231E14.2 KDM3A NRG1 SESN2 RP11-552F3.9 ITPRIP RP11-371M22.1 FAM160A1 RASSF1 BHLHE40-AS1 AC006077.3 
N4BP3 AMZ1 
  
 287 
Table S3: A summary of all pathways and the number of hypermethylated DMGs in each arm of the comparison (highlighted in red). The number 
in brackets next to the pathway name refers to Panther Pathway Analysis pathway ID.  
 
UK10/ 
UG10 
UK10/ 
UG10 
UG10/ 
UG52 
UG10/ 
UG52 
UK52/ 
UG52 
UK52/ 
UG52 
UK10/ 
UK52 
UK10/ 
UK52 
Pathway Type  
2 5 1  1  3 2 B cell activation (P00010) Immune Pathways 
5 5   1 3 2 8 7 
Inflammation mediated by chemokine and cytokine 
signalling pathway (P00031) 
Immune Pathways 
8 3  1  1 13 4 Integrin signalling pathway (P00034) Immune Pathways 
3 2       2 1 2 Interferon-gamma signalling pathway (P00035) Immune Pathways 
 1     3 2 Interleukin signalling pathway (P00036) Immune Pathways 
2             1 JAK/STAT signalling pathway (P00038) Immune Pathways 
1 2 1  1  3 3 T cell activation (P00053) Immune Pathways 
3 1 1 1 2   4 5 TGF-beta signalling pathway (P00052) Immune Pathways 
1       2 Toll receptor signalling pathway (P00054) Immune Pathways 
    1   1   1 1 FAS signalling pathway (P00020) Immune Pathways 
1 1   1 1 1 3 Blood coagulation (P00011) Physiological Pathways 
1               Circadian clock system (P00015) Physiological Pathways 
5 1  2 2  3 4 Cytoskeletal regulation by Rho GTPase (P00016) Physiological Pathways 
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1           1   Hypoxia response via HIF activation (P00030) Physiological Pathways 
1 2 1    1 3 Oxidative stress response (P00046) Physiological Pathways 
1           1 2 Vasopressin synthesis (P04395) Physiological Pathways 
4 1   1 3 7 12 Angiogenesis (P00005) Physiological Pathways 
5       2   4 7 CCKR signalling map (P06959) Physiological Pathways 
3 5 2  3  4 6 PDGF signalling pathway (P00047) Physiological Pathways 
  2           2 Synaptic vesicle trafficking (P05734) Physiological Pathways 
2     1 2 2 VEGF signalling pathway (P00056) Physiological Pathways 
17 8 1 3 2   10 10 
Gonadotropin-releasing hormone receptor pathway 
(P06664) 
Physiological Pathways 
2 1     2  
Cortocotropin releasing factor receptor signalling pathway 
(P04380) 
Physiological Pathways 
1       1   1   Endogenous cannabinoid signalling (P05730) Physiological Pathways 
2 1     1  Enkephalin release (P05913) Physiological Pathways 
2 2     1   1 4 Ionotropic glutamate receptor pathway (P00037) Physiological Pathways 
 2     2 3 
Metabotropic glutamate receptor group I pathway 
(P00041) 
Physiological Pathways 
1 1     1   1   
Metabotropic glutamate receptor group II pathway 
(P00040) 
Physiological Pathways 
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1 2   1  1 4 
Metabotropic glutamate receptor group III pathway 
(P00039) 
Physiological Pathways 
2       1   6 2 Oxytocin receptor-mediated signalling pathway (P04391) Physiological Pathways 
2    1  6 1 
Thyrotropin-releasing hormone receptor signalling 
pathway (P04394) 
Physiological Pathways 
3 2     1   2 6 Alzheimer disease-amyloid secretase pathway (P00003) Disease Pathways 
3   1 5 3 3 8 Alzheimer disease-presenilin pathway (P00004) Disease Pathways 
6   1 1 1   6 10 Huntington disease (P00029) Disease Pathways 
1    1 1 4 3 Parkinson disease (P00049) Disease Pathways 
2 2   1 1 2 3 7 Apoptosis signalling pathway (P00006) Cellular Pathways and Signalling 
2 1   6 2 4 7 Cadherin signalling pathway (P00012) Cellular Pathways and Signalling 
            1 1 Cell cycle (P00013) Cellular Pathways and Signalling 
    1   3 Cholesterol biosynthesis (P00014) Cellular Pathways and Signalling 
    1   1 1 1   DNA replication (P00017) Cellular Pathways and Signalling 
4 1 1    6  Dopamine receptor-mediated signalling pathway (P05912) Cellular Pathways and Signalling 
4 4       1 8 7 EGF receptor signalling pathway (P00018) Cellular Pathways and Signalling 
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3 1  1 1 1 2  GABA-B receptor II signalling (P05731) Cellular Pathways and Signalling 
        1   1 1 Glycolysis (P00024) Cellular Pathways and Signalling 
 1 1   1 1 1 Hedgehog signalling pathway (P00025) Cellular Pathways and Signalling 
5 4 1 1 3 2 9 2 
Heterotrimeric G-protein signalling pathway-Gi alpha and 
Gs alpha mediated pathway (P00026) 
Cellular Pathways and Signalling 
2 2 1  2  7 3 
Heterotrimeric G-protein signalling pathway-Gq alpha and 
Go alpha mediated pathway (P00027) 
Cellular Pathways and Signalling 
1           3   
Heterotrimeric G-protein signalling pathway-rod outer 
segment phototransduction (P00028) 
Cellular Pathways and Signalling 
       1 mRNA splicing (P00058) Cellular Pathways and Signalling 
3 2   1     7 5 
Muscarinic acetylcholine receptor 1 and 3 signalling 
pathway (P00042) 
Cellular Pathways and Signalling 
1 1  1   3  
Muscarinic acetylcholine receptor 2 and 4 signalling 
pathway (P00043) 
Cellular Pathways and Signalling 
2         1 3 1 Notch signalling pathway (P00045) Cellular Pathways and Signalling 
1 2 2   1 1 3 p38 MAPK pathway (P05918) Cellular Pathways and Signalling 
1 1 1   1   3 1 p53 pathway (P00059) Cellular Pathways and Signalling 
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       1 p53 pathway by glucose deprivation (P04397) Cellular Pathways and Signalling 
2 1       1 2 2 p53 pathway feedback loops 2 (P04398) Cellular Pathways and Signalling 
4 1     3 1 PI3 kinase pathway (P00048) Cellular Pathways and Signalling 
1 1       1 4 3 Ubiquitin proteasome pathway (P00060) Cellular Pathways and Signalling 
7 6  1 7 3 14 13 Wnt signalling pathway (P00057) Cellular Pathways and Signalling 
1           1 1 5HT1 type receptor-mediated signalling pathway (P04373) Cellular Pathways and Signalling 
2      6 2 5HT2 type receptor-mediated signalling pathway (P04374) Cellular Pathways and Signalling 
              1 5HT3 type receptor-mediated signalling pathway (P04375) Cellular Pathways and Signalling 
2 1     1 1 5HT4 type receptor-mediated signalling pathway (P04376) Cellular Pathways and Signalling 
            1   Adrenaline and noradrenaline biosynthesis (P00001) Cellular Pathways and Signalling 
1      3 1 Alpha adrenergic receptor signalling pathway (P00002) Cellular Pathways and Signalling 
1 1     1   2 1 
Angiotensin II-stimulated signalling through G proteins and 
beta-arrestin (P05911) 
Cellular Pathways and Signalling 
2 2 1 1 1  1 3 Axon guidance mediated by netrin (P00009) Cellular Pathways and Signalling 
2     1     3 1 Axon guidance mediated by semaphorins (P00007) Cellular Pathways and Signalling 
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1 3 1 1 1 1 1 4 Axon guidance mediated by Slit/Robo (P00008) Cellular Pathways and Signalling 
3 1         2   Beta1 adrenergic receptor signalling pathway (P04377) Cellular Pathways and Signalling 
3 1     2  Beta2 adrenergic receptor signalling pathway (P04378) Cellular Pathways and Signalling 
2 1         1   Beta3 adrenergic receptor signalling pathway (P04379) Cellular Pathways and Signalling 
   1  2 1  De novo purine biosynthesis (P02738) Cellular Pathways and Signalling 
          1   1 
De novo pyrimidine deoxyribonucleotide biosynthesis 
(P02739) 
Cellular Pathways and Signalling 
     1   De novo pyrimidine ribonucleotides biosythesis (P02740) Cellular Pathways and Signalling 
5 3   1 1 1 5 2 Endothelin signalling pathway (P00019) Cellular Pathways and Signalling 
6 4 1   4 7 5 FGF signalling pathway (P00021) Cellular Pathways and Signalling 
  1 1         1 Gamma-aminobutyric acid synthesis (P04384) Cellular Pathways and Signalling 
       1 General transcription regulation (P00023) Cellular Pathways and Signalling 
2 1         5 1 
Histamine H1 receptor-mediated signalling pathway 
(P04385) 
Cellular Pathways and Signalling 
2 1     1  
Histamine H2 receptor-mediated signalling pathway 
(P04386) 
Cellular Pathways and Signalling 
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  1         2 2 
Insulin/IGF pathway-mitogen activated protein kinase 
kinase/MAP kinase cascade (P00032) 
Cellular Pathways and Signalling 
1    2  1 2 
Insulin/IGF pathway-protein kinase B signalling cascade 
(P00033) 
Cellular Pathways and Signalling 
4           5   Nicotine pharmacodynamics pathway (P06587) Cellular Pathways and Signalling 
1 2  2 2  3  
Nicotinic acetylcholine receptor signalling pathway 
(P00044) 
Cellular Pathways and Signalling 
2           1 1 Opioid prodynorphin pathway (P05916) Cellular Pathways and Signalling 
1      1  Opioid proenkephalin pathway (P05915) Cellular Pathways and Signalling 
1           1   Opioid proopiomelanocortin pathway (P05917) Cellular Pathways and Signalling 
1 2 1  2 1 2 7 Ras Pathway (P04393) Cellular Pathways and Signalling 
1 2       1 2 1 
Transcription regulation by bZIP transcription factor 
(P00055) 
Cellular Pathways and Signalling 
1        Histidine biosynthesis (P02747) Cellular Pathways and Signalling 
1           1   MYO signalling pathway (P06215) Cellular Pathways and Signalling 
1        Salvage pyrimidine ribonucleotides (P02775) Cellular Pathways and Signalling 
              1 5-Hydroxytryptamine degredation (P04372) Metabolic Pathways 
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1        Acetate utilization (P02722) Metabolic Pathways 
            2   Asparagine and aspartate biosynthesis (P02730) Metabolic Pathways 
      1  N-acetylglucosamine metabolism (P02756) Metabolic Pathways 
            1 1 Pentose phosphate pathway (P02762) Metabolic Pathways 
2   1   1  Pyrimidine Metabolism (P02771) Metabolic Pathways 
            1   Tetrahydrofolate biosynthesis (P02742) Metabolic Pathways 
1 1     1  Vitamin D metabolism and pathway (P04396) Metabolic Pathways 
  1 1           Arginine biosynthesis (P02728) Metabolic Pathways 
       1 Formyltetrahydroformate biosynthesis (P02743) Metabolic Pathways 
1 1             Fructose galactose metabolism (P02744) Metabolic Pathways 
1      1  Activin beta signalling pathway (P06210) Other Pathways 
1           1   ALP23B signalling pathway (P06209) Other Pathways 
1      1  BMP/activin signalling pathway-drosophila (P06211) Other Pathways 
1           1   DPP signalling pathway (P06213) Other Pathways 
1      1  DPP-SCW signalling pathway (P06212) Other Pathways 
1           1   GBB signalling pathway (P06214) Other Pathways 
1           1   SCW signalling pathway (P06216) Other Pathways 
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7. Discussion 
7.1 Final Discussion and Summary 
 
This PhD describes an international and longitudinal study that aimed to achieve a 
better understanding of the varying efficacy of the BCG vaccine. The immunogenicity 
of BCG in the UK and Uganda was investigated using multiple assays. I explored 
immune pathways that could explain immunogenicity profiles in both countries, as 
well as novel, innovative molecular approaches such as epigenetic profiling, that 
could drive the immune changes. 
 
In the third chapter, a pilot study was conducted to investigate whether DNA 
methylation patterns differ between low and high BCG-responding South African 
infants. The aim was to test the feasibility of combining assays for DNA methylation 
and for measuring cellular immunity parameters, as well as to establish a DNA 
methylation data analysis pipeline to be used in future experiments. I found differential 
methylation of 318 genes between low and high respondents to the BCG vaccine, as 
measured by BCG-specific cytokine response. I discovered that KCNN4 and ERICH1 
genes were differentially methylated between 8/10 cytokine groups.  Both genes 
encode for proteins that mediate calcium influx into the cell and by doing so could 
directly affect the immune response to the BCG vaccine. After analysing differentially 
methylated genes, I found 67 pathways in which these genes were involved. 
Expectedly, I found pathways of the immune system in which genes were differentially 
methylated between low and high BCG responding infants and could directly affect 
the BCG-induced immune responses. Unexpectedly, I also discovered  the differential 
methylation of genes that are part of pathways that could indirectly affect the BCG-
induced immune responses. These pathways included calcium signalling or WNT 
pathways, both known to be important in T cell development1 and proliferation2. One 
might, therefore, conclude that there is scope for DNA methylation to play a role in 
 302 
the modulation of vaccine immunity. Further studies should investigate the 
methylation of highlighted pathways and genes and how they affect the overall 
vaccine-induced immune responses in vitro. The differences in DNA methylation of 
both immunity-related and genes of other pathways were small between low and high 
responding BCG infants. One could, therefore, conclude that DNA methylation is 
unlikely to be the only or main molecular mechanism to drive sustained differences 
of BCG induced immune responses. This study confirmed the robustness of immune 
and DNA methylation assays and allowed the establishment of a DNA methylation 
data analysis pipeline. Having observed different immune responses in South African 
infants, and established immune protocols, I investigated the immune profile of UK 
and Ugandan infants after BCG vaccination.   
 
In the fourth chapter, I analysed the cytokine immune response to  BCG vaccination 
in  UK and Ugandan infants at 10 and 52 weeks post-BCG. I also examined immune 
parameters such as T cell phenotype to investigate the cellular source of cytokines 
produced. Surprisingly, no differences were found in TH1 or TH2 cytokines between 
UK and Uganda when measured by the Luminex assay. Our group has previously 
reported significant differences in BCG immune responses between Malawian, 
Gambian and UK infants3. We suggest that differences observed in these cohorts 
might have been accentuated by different timing of vaccination, different vaccine 
strains, and rural vs urban cohorts. In contrast, UK and Ugandan infants were both 
from urban settings, had the same time of BCG administration, and both groups 
received the BCG Danish strain.  
 
Interestingly, I observed an inflammatory profile in Ugandan infant samples in 
response to the BCG vaccine, but also without stimulation, and when stimulated with 
the PHA antigen. Ugandan infants produced higher amounts of IL1b and TNFa at 10 
and 52 weeks post BCG vaccination when measured by the Luminex assay. The 
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increased inflammatory profile could indicate underlying inflammation or higher 
responsiveness of the immune system to pathogens in Ugandan infants. Increased 
inflammatory cytokine production by macrophages and monocytes have been 
observed before in people of African descent4,5. Interestingly, whereas the direct 
recognition of PAMPS activates DCs into fully immunogenic cells, the recognition of 
inflammatory signals from epithelial, hematopoietic, and non-hematopoietic tissue 
activates DCs to non-immunogenic phenotype6. This non-immunogenic but mature 
DC phenotype has been shown to induce the clonal expansion of CD4 T cells but 
failed to produce IL12 and subsequently resulted in impaired TH differentiation6,7. This 
has important implications for BCG immunogenicity and efficacy as the fully functional 
TH1 response was shown to be important to elicit a sufficient BCG response and 
subsequent TB protection8. The analysis of dendritic cell phenotypes did not directly 
compare UK and Ugandan infants and did not measure the capacity of DC-mediated 
TH differentiation. However,  a small increase was found in a frequency of IFNg or IL2 
producing CD4 or CD8 T cells at 52 weeks in the UK. The difference at 10 weeks was 
not significant, although the sample size was much smaller. A slight increase in the 
frequency of IL4/5/13 producing CD8 T cells at 52 weeks in Uganda was also 
reported. The observed differences in frequencies of cytokine-producing T cells 
somehow reflect the immune profile of Malawian and Gambian infants as they also 
produced lower levels of IFNg, IL2 and higher levels of IL4, IL5, and IL13 cytokines. 
However, these differences were very small and diminished when the overall whole 
blood immune response was measured with the Luminex assay. It is therefore 
plausible that high inflammatory signals such as TNFa and IL1b derived from 
epithelial, hematopoietic (including monocytes and macrophages) cells, and non-
hematopoietic tissue could activate DCs into a mature but non-immunogenic 
phenotype that induces clonal T cell expansion but impairs TH1 and favours TH2 
differentiation. Interestingly, the increased levels of TNFa and IL1b could be indirectly 
 304 
mediated by DNA methylation as observed in chapter six. I reported a higher number 
of hypermethylated genes in the UK than Uganda that regulate integrin-mediated 
processes. Integrins play a strategic role in the recruitment of leukocytes to sites of 
inflammation9. Thus, higher DNA methylation could lead to reduced integrin-mediated 
leukocyte recruitment and lower levels of proinflammatory cytokines as observed in 
the UK. To complement this, I examined the differential DNA methylation between 
BCG-specific low and high TNFa producers in South African infants in chapter three. 
I have found 146 differentially methylated regions and 128 genes between low and 
high TNFa producers.  One of the genes, ITGAX, had lower DNA methylation in high 
TNFa producers. ITGAX encodes the X chain of the integrin protein (CD11b)10, which 
regulates leukocyte adhesion and subsequently affects leukocyte-mediated 
inflammatory responses11. Thus, low methylation of ITGAX could result in higher 
levels of CD11b, increased leukocyte recruitment and elevated levels of 
proinflammatory cytokines, including TNFa, as observed in South African and 
Ugandan infants. Taken together, I propose that low DNA methylation of genes that 
are associated with TNFa production, such as ITGAX, could increase levels of 
CD11b. The increased levels of CD11b would drive leukocyte recruitment and 
increase the production of proinflammatory cytokines as observed in Uganda. 
Inflammatory signals could induce mature but non-immunogenic profile of DCs, 
leading to impaired TH1 differentiation, with important implications for BCG 
immunogenicity. This cascade of events should be further explored with in vitro 
models as well by using novel technologies that allow for a precise edition of DNA 
methylation such as CRISPR and Cas912.    
 
Lastly, I found that at 52 weeks there is a higher frequency of naïve CD4 or CD8 T 
cells in the UK, whereas, in Uganda, CD4 and CD8 T cells have an increased 
terminally differentiated phenotype. Naïve T cells differentiate into their mature 
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phenotype after antigen exposure in the periphery13, and this process is mediated by 
epigenetic mechanisms13–15. One would expect for Ugandan infants to have a higher 
exposure to environmental mycobacterial and increased antigen exposure, and these 
factors could drive the differentiation of T cells from their naïve to mature and 
terminally differentiated phenotypes. Interestingly, when I compared DNA methylation 
between UK and Ugandan infants in chapter six, I found that UK infants had higher 
methylation of JAK1 and JAK2 genes. JAK proteins play a central role in cell growth, 
survival, development and differentiation of immune cells. There is growing evidence 
that JAK1 and JAK2 are essential for an effective function of CD4 T cells, as JAK1/2 
inhibition impairs T cell functions in vitro16,17, and JAK proteins are vital for the 
expansion of CD4 T cells18 and their differentiation from the naïve phenotype19. Thus, 
it could be plausible that higher methylation of JAK1 and JAK2 proteins in the UK 
results in their lower levels and delayed or impaired differentiation of naïve T cells to 
their memory and terminally differentiated phenotypes, as observed in the UK. 
However, this novel pathway of T cell differentiation should be investigated further.  
 
I was not able to directly compare immune responses between UK, Ugandan and the 
South African infant cohort described in chapter three. South African samples were 
stimulated with BCG for 12 hours (including 5 hours with Brefeldin A), whereas UK 
and Ugandan samples were stimulated with PPD for 24 hours (including 24 hours 
with Brefeldin A). I conclude that the immune response to the BCG vaccine between 
UK and Uganda is similar, and perhaps this can be explained by the fact that both 
cohorts of infants live in urban areas, although this needs further investigation. I 
highlight the need to conduct an international trial to examine the immunogenicity of 
the BCG vaccine, spanning more than two countries, and including infants from both 
rural and urban backgrounds while controlling for BCG timeliness and strain 
administered. 
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Having investigated the immune response to the BCG vaccine in Uganda and the UK, 
I examined immune pathways that may contribute to BCG immunogenicity. In chapter 
four I explored T cell phenotypes, and in chapter five I investigated the phenotypes 
of dendritic cells in Uganda.  The Ugandan study collected samples at multiple time 
points throughout the first year of life, including cord blood. This gave us an excellent 
opportunity to investigate the dynamics of dendritic cell phenotype in the first year of 
life. I employed state-of-the-art techniques for flow cytometry data analysis such as 
viSNE and SPADE. Surprisingly, I found that observed dendritic cell phenotypes are 
absent in blood at birth but appear within the first month of life. Previous studies have 
observed decreased frequencies of DCs in blood at birth but our study is the first 
longitudinal and comprehensive analysis to observe dynamic changes in DC 
phenotypes in the first year of life of African infants. The appearance of DCs in the 
first month of life could be due to a natural development of the immune system and 
differentiation of hematopoietic stem cells to dendritic cell progenitors and dendritic 
cells. However, this appearance could also be accentuated by the exposure to 
multiple environmental pathogens in the first month of life; or repeated vaccinations, 
including BCG. It would be beneficial to conduct a similar study that compares the 
phenotype of dendritic cells in infants with the standard vaccination schedule and with 
a delayed vaccination scheduled within the first month of life. This would inform us of 
the contribution that vaccines have on the development of DCs phenotypes. The 
finding that known DCs are mostly absent at birth has significant implications for 
vaccine efficacy. Although except for polysaccharide vaccines20, there is no evidence 
that vaccines given at birth have a limited efficacy21. For logistical reasons, infants’ 
samples were not collected in the early weeks of life in the UK, therefore, a 
comparison between countries cannot be made.   
 
Interestingly, I found that maternal latent TB infection is associated with an increase 
in the frequency of cDC1, cDC2 and MDDC populations in infants. The increased 
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number of DC populations may be detrimental to BCG efficacy as it has been shown 
that elevated DC numbers impair protective immunity to intracellular bacteria22. The 
exposure to TB antigens in utero could also mask the subsequent BCG mediated 
immune response and result in a lower production of IFNg and TNFa as observed 
previously23. Besides, I have found that infant EBV infection decreases numbers of 
known DC phenotypes, including plasmacytoid DCs, which mediate viral induced 
immunity by producing type I IFNs. Thus, an EBV driven decrease in DC populations, 
specifically pDCs, might be one of the mechanisms to regulate host-mediated 
immune responses against EBV. Surprisingly, I found limited evidence of the effect 
of infant CMV infection on the phenotype of dendritic cells. I have observed a 
moderate delay in the development of crucial DC populations but no changes in 
marker expression in CMV infected infants. I conclude that maternal LTBI, infant EBV 
and to a lesser extent CMV affect the phenotype of dendritic cells. I highlight the 
importance of the development of vaccines or new treatments for these pathogens 
and also urge to include these pathogens and infections in clinical efficacy trials of 
new vaccines. I was not able to analyse the dendritic cell profile in South Africa, as I 
was limited by sample availability. I examined the dendritic cell phenotype in a limited 
subset of UK infants, however, when I compared findings from both countries I 
discovered technical issues that prevented me from a direct comparison of UK and 
Ugandan DC phenotypes. I also realised that the isolated analysis of UK infants was 
not sufficient to complement an understanding of the dendritic cell story.  
 
Lastly, in chapter six I continued the investigation of DNA methylation between UK 
and Ugandan infants at 10 and 52 weeks of life. I observed dynamic differences in 
DNA methylation between the UK and Uganda. Interestingly, at 10 weeks, genes from 
the B cell activation pathway as well as vital immune genes NFATC1 and SOCS5 
have higher methylation in Uganda than in the UK. In contrast, in the UK, integrin 
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pathways, JAK1 and JAK2, as well as TGFb signalling pathways were more 
methylated at 10 weeks of age. These findings suggest that B cell activation might be 
impaired in Ugandan infants when compared to the UK. NFATC1 is a ubiquitous 
immune modulator, and its increased methylation might indirectly affect numerous 
immune pathways including T cell activation. Lastly, increased methylation of TGFb 
signalling pathways could indicate that TGFb regulation of immune responses in the 
UK is limited and other regulatory mechanisms such as IL10 of Tregs might be more 
important. Interestingly, I did not find any differences in DNA methylation patterns for 
cytokine genes, reflecting the Luminex findings for most cytokines, as observed in 
chapter four. However, I report that DNA methylation patterns do not mirror the 
proinflammatory profile of the BCG vaccine in Ugandan infants. As found in chapter 
four, Ugandan infants produced more IL1b and TNFa at 10 and 52 weeks post-BCG 
vaccination, however, the DNA methylation of these genes was not decreased in 
Uganda, nor increased in the UK (an increase in DNA methylation of a gene would 
limit the protein transcription of that gene). These findings indicate that DNA 
methylation plays a moderate role in the regulation of immune responses, although 
well-controlled, in vitro studies are needed to confirm this. Highlighted genes and 
pathways and what effect they have on the overall vaccine response should be 
examined.  Alternatively and similarly to chapter three, I could stratify immune 
responses to low and high vaccine responders and compare the DNA methylation 
between two groups and whether these findings support findings from chapter three. 
I decided however, not to proceed with this comparison as the racial background of 
samples differs; the origin of samples is different (PBMCs in South Africa and whole 
blood in the UK and Uganda); and samples were stimulated according to different 
protocols. This analysis could be conducted in future.  
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7.2 Conclusions  
 
This study was conducted to investigate the spectrum of immune responses to the 
BCG vaccine in the UK and Uganda and examine the molecular mechanisms that 
drive them. To address that I analysed BCG immune responses and DNA methylation 
of samples from South Africa, Uganda and the UK. I hypothesised that that DNA 
methylation patterns or dendritic cells phenotypes and composition are underlying 
mechanisms that can explain the spectrum of BCG immunogenicity and in this study, 
are associated with the immune response to the BCG vaccine. I found that the 
contribution of DNA methylation to the overall BCG response is modest, as limited 
number of immune pathways was associated with the immune response to the BCG 
vaccine. In addition I found that phenotypes of dendritic cells change change over 
time. Specifically, known DC phenotypes are missing at birth and appear within the 
first month of life, and the relationship between marker expression and age is 
dynamic. In summary, DNA methylation is an unlikely mechanisms to largely 
influence the immunogenicity of BCG and further studies need to be conducted to 
measure the impact of DC development dynamics on BCG immune responses.  
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LSHTM
11 May 2015 
Dear 
Study Title: The impact of maternal infection with Mycobacterium tuberculosis on the infant response to BCG immunisation 
LSHTM Ethics Ref: 8720 
Thank you for responding to the Observational Committee’s request for further information on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation
as revised, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Covering Letter response letter ethics 17/04/2015 1
Protocol / Proposal UgUK BCG study Protocol ver2 17/04/2015 2
Information Sheet UgUK BCG study Consent form ver3_150415_1 17/04/2015 3
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Study Title: The impact of maternal infection with Mycobacterium tuberculosis on the infant response to BCG immunisation 
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Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above amendment to research on the basis described in the application form, protocol and supporting
documentation as revised, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval for the amendment having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
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Covering Letter Answer letter to ethical committee_2 27/11/2015 1
Covering Letter Answer letter to ethical committee_3 16/02/2016 3
Other UgUK BCG study Protocol ver3 16/02/2016 3
Other SKMBT_28316020309470 (1) 16/02/2016 1
Other UCT LSHTM MTA Draft v3 8 February 2016 16/02/2016 1
     
After ethical review
The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the Committee for review
using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.  
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project
by submitting a SUSAR/protocol violation form. 
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk
Additional information is available at: www.lshtm.ac.uk/ethics
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Room 001 
Jarrow Business Centre 
Rolling Mill Road 
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Professor of Immunology 
London School of Hygiene and Tropical Medicine 
Keppel Street, London 
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Dear Professor Dockrell 
 
Study title: The impact of maternal infection with Mycobacterium 
tuberculosis on the infant response to BCG 
immunisation 
REC reference: 15/LO/0048 
IRAS project ID: 162186 
 
Thank you for your letter of 25 February 2015, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this favourable opinion letter.  The expectation is that this information will be published 
for all studies that receive an ethical opinion but should you wish to provide a substitute 
contact point, wish to make a request to defer, or require further information, please contact 
the REC Manager, Hayley Henderson, nrescommittee.london-camdenandislington@nhs.net. 
Under very limited circumstances (e.g. for student research which has received an 
unfavourable opinion), it may be possible to grant an exemption to the publication of the study.  
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On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
 316 
 
 
 
  
 317 
 
 
 
 
 
 
